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ABSTRACT 
As the name indicates, T-helper cells are shown to help in primary and secondary cellular 
and humoral immune responses. They behave as conductors of immune responses. Conferring 
immunity to various kinds of antigens, the immune system has evolved different cell types. 
There are different terminally differentiated helper cells such as Th1, Th2, TFh, Th17, Treg, Th9, 
and Th22 cells tailored to combat different pathogens. Production of any subtype of cells 
depends on the type of antigen, dose of antigen, mode of entry, and cytokine milieu in the 
microenvironment. An infection or an aberrant growth of tumor cells or an autoimmunity occurs 
when there is an imbalance in immune responses. Since CD4
+
 T cells are the conductors 
controlling different arms of immune-responses, the most frequent imbalances of immune 
response in the above conditions occur from deregulated CD4
+
 T cell responses. Because of the 
importance associated with CD4
+
 T cells, understanding the patho-physiology and biology 
associated with CD4
+
 T cells is crucial. Our study addresses the role of CD4
+
 Th17 cells in 
tumor immunity, in autoimmune type 1 diabetes (T1D), and in experimental autoimmune 
encephalitis (EAE). We have also considered the biology associated with CD4
+
 Th2 cells. 
In tumor immunity, it was demonstrated by various studies that CD4
+
 Th17 cells induce 
antitumor immunity, leading to the eradication of established tumors. However, the mechanism 
of CD8
+
 CTL activation by CD4
+ 
Th17 cells and the distinct role of CD4
+ 
Th17 and CD4
+ 
Th17 
activated CD8
+
 CTLs in antitumor immunity were still elusive. In this study we have 
demonstrated that CD4
+ 
Th17 cells acquired pMHC-I and expressed RORγt, IL-17 and IL-2.  
CD4
+ 
Th17 cells did not have any direct in vitro tumor cell killing activity, but still were able to 
stimulate CD8
+
 CTL responses via IL-2 and pMHC-I, but not IL-17 signalling. The therapeutic 
effect of CD4
+ 
Th17 cells was shown to be associated with IL-17, but not IFN-γ, and was 
mediated by CD4
+ 
Th17-stimulated CD8
+
 CTLs via the perforin pathway, which were recruited 
into B16 melanoma via CD4
+ 
Th17-stimulated CCL20 chemoattraction. These results elucidated 
distinct roles of CD4
+ 
Th17 and CD4
+ 
Th17-stimulated CD8
+
 CTLs in the induction of 
preventive and therapeutic antitumor immunity, which may greatly impact the development of 
CD4
+ 
Th17-based cancer immunotherapy. 
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In autoimmunity, earlier studies showed that both CD4
+
 Th17 cells and CD8
+
 CTLs were 
involved in T1D and EAE. However, their relationship in pathogenesis of autoimmune diseases 
was still elusive.  In this study, we found that CD4
+ 
Th17 cells stimulated OVA- and MOG-
specific CD8
+
 CTL responses, respectively, in mice. When CD4
+
 Th17 cells were transferred 
into (i) transgenic RIP-mOVA or (ii) RIP-mOVA mice treated with anti-CD8 antibody to 
eliminate Th17-stimulated CD8
+ 
T cells, we found that OVA-specific CD4
+
 Th17-stimulated 
CD8
+
 CTLs, but not CD4
+
 Th17 cells themselves, induced diabetes in RIP-mOVA. In cases of 
mice injected with MOG-specific CD4
+
Th17 lymphocytes, CD4
+
 Th17 but not CD4
+
 Th17-
activated CD8
+
 CTL induced EAE in C57BL/6 mice. These results demonstrate the distinct roles 
of CD4
+
 Th17 and CD4
+
 Th17-stimulated CD8
+
 CTLs in the pathogenesis of autoimmune 
diseases, which may have great impact on the overall understanding of CD4
+
 Th17 cells in the 
pathogenesis of autoimmune diseases. 
To study the functional conversion of naive CD4
+
 T-helper cells into Th1 or Tr1 cells 
under Th2 differentiation culture conditions, we generated OVA-specific wild-type (WT) Th2, 
and Th2(IL-5 KO), or Th2(IL-5 KO), or Th2(IL-6 KO), or Th2(IL-10 KO) cells, and assessed 
their capacity in modulating DCOVA-induced CD8
+
 cytotoxic T lymphocyte (CTL) responses and 
antitumor immunity in WT C57BL/6 mice. We demonstrated that GATA-3-expressing Th2 cells 
enhanced DCOVA-induced CTL responses via IL-6 secretion. We also showed that IL-6 and IL-
10 gene deficient Th2(IL-6 KO) and Th2(IL-10 KO) cells, but not IL-4 and IL-5 gene deficient  
Th2(IL-4 KO) and Th2(IL-5 KO) cells, behaved like functional Tr1 and Th1 cells by inhibiting 
and enhancing DCOVA-induced OVA-specific CD8
+
 CTL responses and antitumor immunity, 
respectively. We further demonstrated that inhibition and enhancement of DCOVA-induced OVA-
specific CTL responses by Th2(IL-6 KO) and Th2(IL-10 KO) cells were mediated by their 
immune suppressive IL-10 and pro-inflammatory IL-6 secretions, respectively. Taken together, 
our results suggest that deletion of a single cytokine gene IL-6 and IL-10 converts CD4
+
 Th2 
cells into functional CD4
+
 Tr1 and Th1 cells under Th2 differentiation condition. Our data thus 
not only provide new evidence for another type of CD4
+
 T cell plasticity, but also have a 
potential to impact the  development of a new direction in immunotherapy of allergic diseases. 
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CHAPTER 1 
REVIEW OF LITERATURE, INTRODUCTION AND OBJECTIVES 
Review of Literature and Introduction 
1.1 General overview 
All the chapters of this thesis are presented as either published manuscripts or manuscript 
in press, so the relevant reviews of literature and introductions are provided within each chapter. 
The purpose of this general review of literature, introduction, and objectives is to give a brief 
overview of the subject matter that will be covered in the context of the thesis as whole. Mainly 
CD4
+
 T helper cell subsets comprise the subject matter of this thesis; therefore, all available 
information on different currently identified subsets of CD4
+
 T helper cells is discussed. We 
have also discussed different disease models with reference to CD4
+
 T helper cell involvement. 
Dendritic cells (DCs) being central antigen presenting cells, we have compared DCOVA induced 
immune response with Th17 induced response and evaluated Th2 cell influence on DCOVA 
induced immune response. To understand the biology associated with DCs we have discussed 
briefly the DC and DC subsets. 
 
1.2 Dendritic cells  
Pathogen recognition, activation of primary and memory immune responses, and 
preservation of tolerance to self-antigens are central to maintaining health. These important 
functions are performed by DCs. DCs are central to the immune system; they are the potent 
professional antigen presenting cells (APCs) of the immune system. They up take antigens by 
sensor receptors expressed on DCs and process the antigens on to MHC complexes. Through 
chemokine-guided mechanisms, they migrate to the T-cell areas of lymph nodes to present 
processed antigen for inducing T- cell activation.  There are extensive studies showing that DCs 
are critical APCs for priming immune responses and also crucial in the regulation of T- cell 
mediated immune reposes (1). In addition to their role in adaptive immune responses, they also 
play an important role in innate immune responses by serving as sentinels in identifying the 
invading pathogens through pattern recognition receptors (PPRs). When they sense dangers, they 
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secrete host defence peptides and proinflammatory cytokines, eliciting the host defence by 
linking both innate and adaptive immune responses (2). 
Initially, the presence of DCs was discovered by Paul Langerhans in 1868; he discovered 
DCs in skin (Langerhans cells). Later, in 1973 Steinman and Cohn identified a morphologically 
distinct cell type with dendrites from peripheral lymphoid organs; they named these cells as DCs 
and showed that they are potent stimulators of primary immune responses (3). Similar kinds of 
leukocytes were observed both in humans and rodents in lymphoid and non-lymphoid organs (4). 
There was a lack of information on DCs until the last decade because of the low frequency of 
these cells in the body (1-2% of total leukocytes) (3), the lack of distinct markers for DCs, and 
deficiency in protocols to purify DCs (5). From the last decade, with the invention of various 
cocktails of cytokines for in vitro culture of DCs along with monoclonal antibody development, 
research has led to extensive study of phenotypic and functional characterization of DCs. It has 
been shown that DCs follow various haematopoietic pathways of differentiation and maturation 
into multiple heterogeneous subsets of DCs with different marker expression (1, 6). They play 
both stimulatory and suppressor roles on immune responses. Upon sensing the danger signals, 
DCs produce various proinflammatory cytokines, stimulating innate and adaptive immune 
responses. On the other hand, DCs also induce immunological tolerance, as in cases of clonal 
deletion of self-reactive T cells in thymus (central tolerance), or of clonal deletion and active 
suppression by inducing T regulatory cells (peripheral tolerance) (7). These diverse functions of 
DCs reflect the presence of various subsets of DCs. 
A proper understanding of developmental lineages, precursors and inducing factors of 
each subset of DCs would help in generating or activating specific DC subsets in in vitro or in 
vivo to potentially target various disease conditions and cancers for favourable immune 
responses. Because of DCs’ functional similarities with macrophages and also as many in vitro 
studies used monocytes or GM-CSF (important myeloid growth factor) for the culture of DCs, 
DCs were originally thought to be myeloid in lineage. However, there is a considerable evidence 
showing the development of DCs by lymphoid lineage (8).  
 
1.2.1 Dendritic cell subsets 
3 
 
There are two categories of DCs based on their origin namely blood derived and tissue 
derived. Blood derived DCs are derived from bone marrow and are delivered via peripheral 
blood, so they are named as myeloid DCs. These blood derived DC subsets appear to develop in 
lymphoid organs from precursors of DCs (pre-DCs) generated in bone marrow (9). Tissue 
derived forms are the DCs arrive by migration via lymphatic afferent vessels, once they uptake 
antigens. Blood derived DCs can be divided into two sub-populations, conventional DCs (cDCs) 
and plasmacytoid DCs (pDCs) (9).  
Various DC subsets have been defined in mouse lymphoid organs on the basis of cell 
surface markers expression. Mouse DCs are basically differentiated based on their expression of 
CD11c and MHC class II in combination with CD4, CD8α, CD11b, and CD205 (DEC 205). The 
T cell markers CD4 and CD8 are useful in differentiating DC subsets. CD8 on the DC is in the 
form of αα-homodimer rather then αβ-heterodimer which is typically seen in CD8+ T cells. Other 
markers that are useful for segregating mouse DC subsets include myeloid cell marker CD11b 
and interdigitating DC marker CD205 (DEC205)(5).  
The CD4
−CD8αhighCD205+CD11b− DCs are lymphoid in origin, and they constitute 20% 
of the DCs in spleens. They are present in the T cell areas of spleens and are also found at 
moderate levels in lymphnodes. They constitute a dominant subset amongst thymic DCs (10-12). 
They express equal B7-1(CD80), B7-2(CD86), and CD40 compared to 
CD4
+CD8α−CD205−CD11b+ DCs. They exhibit higher Toll-like receptor 3 (TLR3) expression, 
interleukin-12 (IL-12) production, MHC class I presentation, and cross-presentation activities 
than the other splenic DC subsets (13). Freshly isolated CD4
−CD8αhighCD205+CD11b− lymphoid 
DCs have a regulatory effect on T cells, in which they activate both CD4
+
 and CD8
+
T cells. 
However, they can induce apoptosis in CD4
+
T cells and a limited CD8
+
T cell responses as they 
produce reduced level of IL-2 (14).  Moreover, they are responsible for maintaining peripheral 
tolerance under steady-state conditions through induction of cross-tolerance (15). These DCs 
may function to maintain T-cell tolerance in lymphoid organs in the absence of infection. In 
presence of danger signals, CD4
−CD8αhighCD205+CD11b− lymphoid DCs can not only activate 
CD8
+
T cells, but also cross present for the stimulation of cytotoxic T cells (16). 
CD4
−CD8αhighCD205+CD11b− lymphoid DCs can trigger the development of Th1 cells in vivo. 
Th1 response is shown to be dependent on interleukin-12 production by these DCs (17), and they 
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induced IgG2a antibody responses (18). Some studies have shown that disruption of CD40-
CD154 interactions inhibited the induction of the Th1 response by CD8
+
 DCs in vivo. CD40-
CD154 interactions were not required for the proliferation of antigen specific naive T-helper 
cells stimulated by either DC subset, but were indispensable in the production of IL-12 from 
CD8
+ 
DCs and their induction of Th1 cells in vitro (18) 
The CD4
+CD8α−CD205−CD11b+ DCs are myeloid in origin, and they constitute 40% of 
the DCs in spleen. CD4
+CD8α−CD205−CD11b+ DCs express B7-1(CD80), B7-2(CD86), and 
CD40 (10). They show stronger MHC II presentation activity compared to that of other DC 
subsets (13). These CD4
+CD8α−CD205−CD11b+DCs stimulate both CD4+ and CD8+ T cells in in 
vitro conditions, but in in vivo they are known to stimulate Th2 responses and IgE antibody 
responses (18). Inhibition of CD40-CD40L interactions will not affect the T cell response 
stimulated by this DC subset (18). 
In addition, CD4
−CD8α−CD205−CD11b+ DCs are double negative (CD4 and CD8) DCs 
and are myeloid in origin; they constitute 15% of total DCs in the spleen. Similar to CD4
+
 DCs, 
these DCs also express B7-1(CD80), B7-2(CD86), CD40. These DCs are located in marginal 
zone in between white and red pulp; upon stimulation, they will move to a T-cell area to activate 
T cells (10). In in vitro condition they are efficient stimulators of both CD4
+
 and CD8
+
 T cells. In 
in vivo conditions they are shown to stimulate Th2 responses inducing IgE antibody responses 
(18) or immune tolerance responses (19).  
CD4
−CD8α−CD205+CD11b+ and CD4−CD8αlowCD205+CD11b−  DCs both are myeloid in 
origin and normally found in lymph nodes and not normally found in spleens. They are also 
named as interstitial DCs. They both showed a relatively low expression of CD8, but a moderate 
or high expression of DEC-205. Both appeared among the DCs migrating out of skin into 
lymphnode, but  CD4
−CD8αlowCD205+CD11b− DC  was restricted to skin draining lymphnodes 
and was identified as the mature form of epidermal Langerhans cells. 
CD4
−CD8α−CD205+CD11b+ DCs may induce a Th1 or a Th2 kind of response. They are large in 
size and have high levels of MHC class II, DEC-205, CD40 and express many myeloid surface 
markers (20). Langerhans cell migration experiments indicate that Langerhans cells upregulated 
CD8 and LFA-1 upon stimulation and migration to the lymphnodes (11, 21). They express 
chemokine receptors CCR6 and CCR7, facilitating their recruitment in the periphery and their 
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migration to the T-cell zones of secondary lymphoid organs. Some studies have also shown that 
Langerhans cells in lymphnodes produce MDC and TARC chemokines involved in T-cell 
attraction. The expression of CCR7 and T cell attracting chemokines by Langerhans cells may 
explain their exclusive localization in T cell areas of lymphnodes. Langerhans cells may play a 
fundamental role in the induction of immunity by priming Th1 responses (21). When there is 
migration of DCs from peripheral tissues in absence of any danger signals, which occurs in 
steady state conditions, they will help in maintaining peripheral tolerance by inducing T cell 
anergy (22). 
Plasmacytoid DCs are a cell type, displaying a unique set of surface antigens. Having 
been identified from their expression of lymphoid or myeloid related antigens these obscure cells 
were named plasmacytoid T cells or plasmacytoid monocytes (23). In 1997, Grouard et al. (24) 
and Olweus et al. (25) reported finding plasmacytoid T cells/monocytes with characteristics of 
precursor DCs; later, they were therefore renamed plasmacytoid DCs. They contribute 25% of 
total spleen DCs. Plasmacytoid DCs characteristics were different from other conventional DCs. 
Plasmacytoid DCs enter lymphnodes from blood through high endothelial venules with CD62L, 
whereas conventional DCs gain access from peripheral tissues (26). Plasmacytoid DCs reside in 
bone marrow, blood, thymus, and T cell rich areas of lymphoid organs in a steady-state condition 
and can localize to skin and other tissue areas in inflammation and autoimmunity. Freshly 
isolated plasmacytoid DCs display typical morphology of large round cells with diffused 
nucleus, few dendrites; they express Gr-1, B220, CD8, CD11c, CD205 and MHC class I, and 
lack co-stimulatory molecules (5). Some recent evidence has shown that they express some 
plasmacytoid DC markers, such as mPDCA-1, 120G8, 440c. Plasmacytoid DCs are specifically 
responsible for IFN-α production, which is dependent on toll like receptors TLR7 and TLR9 (27, 
28). TLR ligation in plasmacytoid DCs activates IkB kinase-α leading to IFN-α production (29). 
Because of their specific role in IFN-α production they may play important role in viral 
infections. Plasmacytoid DCs play a regulatory role in peripheral tolerance in steady state 
condition and they are poor stimulators of T cells (30). In vitro activation of plasmacytoid DCs 
moderately up regulates their expression of CD8, MHC class II and co-stimulatory molecules. 
Plasmacytoid DC derived IFN-α induces IFN-γ production by NK cells and improves their 
cytotoxicity. In co-operation with IL-12, plasmacytoid DC derived IFN-α also induces Th1 
differentiation and cytotoxic T cell production (31). 
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For efficient stimulation of naive T cells, they should interact with mature DCs. DCs 
must mature by the time they arrive at lymphnodes after seeing the antigen. It is well known that 
DC maturation is mediated by pro-inflammatory cytokines such as TNF-α, TLR stimulation, and 
CD40L co-stimulation signals (32). Mature DCs are DCs which should efficiently activate T 
cells through signals 1, 2, and 3. Signal 1 is delivered through the T-cell receptor (TCR) 
engagement with the MHC antigenic peptide complex (pMHC). Signal 2 is referred to as co-
stimulation through CD80, CD86, and CD40L. Signal 3 is conducted through various cytokines 
produced by DCs, which will dictate the fate of T cell differentiation (7). For example, IL-12 is 
one of the signal 3 mediators. IL-12 in cooperation with IFN-α, induces naive T-cell 
differentiation into Th1 cells and induces cytotoxic activity and IFN-γ production by NK cells 
and cytotoxic T lymphocytes (33). Another example is the expression of notch family member 
Delta-1 on DCs, which induces differentiation of Th1 (34). Expression of jagged-2 initiates Th2 
differentiation (34). Molecules like T-bet and semaphorin 4A are also involved in Th1 
differentiation (35).  Some studies have shown that regulatory T cells (Treg) are essential for the 
maintenance of peripheral immune tolerance. DC-derived cytokines TGF-β and IL-2 induce Treg 
differentiation, and Treg differentiation is suppressed in the presence of IL-6 (36). 
 
1.3 CD4
+ 
T-helper cells 
Immune response is the body’s ability to defend against invading pathogens or 
pathogenic self antigens; it differs with different invaders or antigens with its specificity, 
memory, versatility and tolerance. Basically immune response is divided into two types, namely 
cellular immune response and humoral immune response. There are various cell types involved 
in maintaining the immune system’s complexity in protecting specificity, versatility, memory, 
and tolerance to antigens. In T cells grossly, there are two types of cells classified according to 
their surface markers, CD4 and CD8 expression. CD4
+
 T-cells are also known as T-helper cells 
as they have their function in regulation of both cellular and humoral immune responses. T-
helper cells are classified into different subtypes based on various cytokines and signalling 
pathways controlling their differentiation and development. Mosmann and Coffman had 
proposed a model with two types of T-helper cells; of late there are number of other cell types 
added to the list of T-helper cells (37).  
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T-helper cells, as named, are shown to help in primary and secondary cellular, and 
humoral immune responses. The Mosmann and Coffman model had two types of T-helper cells, 
there are other cell types added to the list of T-helper cells (38). Naive CD4
+
 T cells are 
maintained in pluripotent state and are quiescent in their effector function. They continuously 
circulate through blood and lymphoid organs surveying for specific MHC-peptide complexes on 
antigen presenting cells. Through activation by antigen presenting cells, in the presence of 
different cytokine milieu, they differentiate into different effector CD4
+
 T cell subsets.  To 
confer immunity to various kinds of antigens, the immune system has evolved different cell 
types. There are different terminally differentiated helper cells such as Th1, Th2, TFh, Th17, 
Treg, Th9 and Th22 cells tailored to combat different pathogens (Figure 1.1). Production of any 
subtype of cells depends on the type of antigen, dose of antigen, mode of entry and cytokine 
milieu at the microenvironment. They tailor their response to the character of the threat 
encountered, providing B cells and cytotoxic T cell stimulation, and activating immune cells of 
innate immune system. Different subsets of CD4
+
 T cells are characterized by different sets of 
cytokines. These specific cytokine secretions are co-related with epigenetic changes in the 
cytokine genes, reflecting their competent or silent state (39). These CD4
+
 T cells’ importance is 
very much evident with the range of infections in HIV infected persons due to loss of CD4
+
 T 
cells (40). The production of different subtypes will lead to antigen specific solid immunity (in 
various infections and cancer) or might lead to immunopathology (viz; autoimmunity, asthma, 
allergy) (40). Involvement of CD4
+
 T cells in cancer is considered in chapter 2 and their 
involvement in autoimmunity in chapter 3. 
 
1.3.1 CD4
+ 
T-helper-1 (Th1) cells  
The evidence shows that Th1 cells participate in cell mediated immunity. They are 
essential for controlling intracellular pathogens such as viruses, certain bacteria, (e.g., Listeria 
and Mycobacterium tuberculosis), and anti-cancer immunity. They provide cytokine mediated 
help to cytotoxic T lymphocytes (CTL). Th1 cells are characterized by cell specific cytokine 
IFN-γ and transcription factor T-bet.  Th1 cells are differentiated from naive CD4+ T cells in 
presence of cytokines IL-2, IL-12 and anti-IL-4 antibody. They secrete high levels of IFN-γ 
(Figure 1.1). Th1 cells induce the production of IgG2a antibodies in mice and IgM, IgA, IgG1, 
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IgG2 and IgG3 antibodies in humans. IL-12 is a key cytokine for Th1 development. IL-12 and 
IFN-α produced by dendritic cells, stimulate Th1 development. Upon a danger signal received by 
dendritic cells, they produce IL-12, which activates STAT 1 in naive CD4
+
 T cells. Activated 
STAT1 up regulates T-bet, which in turn induces IFN-γ production and IL-12Rβ2 expression. 
Those IL-12Rβ2 expressing T cells can directly respond to IL-12 in inducing IFN-γ production 
through STAT4 activation (41). It was also evident as knockdown of STAT4 expression resulted 
in reduced IL-12Rβ2 expression, leading to reduced Th1 development. T bet is the key regulator 
of Th1 development as T-bet deficient mice have shown impaired production of IFN-γ producing 
Th1 cells (42). T-bet appears to directly activate IFN-γ gene by binding to several of its 
regulatory elements, by inducing chromatin remodelling of the IFN-γ locus, and the expression 
of Hlx, a downstream target of T-bet required for stabilization of the Th1 phenotype (43). Upon 
IL-12 and STAT4 stimulation, IL-18Rα expression increases, leading to a further increase in 
IFN-γ production (44). Th1 cells preferentially express chemokine receptors CXCR3, CCR5, and 
CCR7 (45). Th1 cells play major roles in cell-mediated immunity, inducing immune-responses in 
intra-cytoplasmic parasitic infestations, viral infections and tumor immunity. Historically, Th1-
associated autoimmune diseases, experimental autoimmune encephalitis (EAE) and collagen 
induced arthritis (CIA) were ablated with neutralizing antibodies to IL-12p40 subunit, which is 
also shared with newly discovered cytokine IL-23 (46, 47). Later, it was shown that IL-23 
deficient mice ablated autoimmune diseases, but not the IL-12 deficient, showing that Th17 is 
main factor responsible for autoimmunity (48, 49). Th1 cells are shown to play a major 
pathogenic role in type-1 autoimmune diabetes (50, 51). In support of the very new novel 
concept of T-APC, Dr. Jim Xiang’s lab has demonstrated that Th1 cells acquire pMHC I 
complexes and co-stimulatory molecules from DCOVA upon DCOVA activation, and become 
capable of stimulating OVA-specific CD8
+
 CTL responses via IL-2 and pMHC I signaling and 
induce efficient antitumor immunity (52, 53) 
 
1.3.2 CD4
+ 
T-helper-2 (Th2) cells  
Th2 cells are characterized with production of cytokines IL-4, IL-5, IL-13 and IL-10 and 
transcription factor GATA binding protein-3 (GATA-3) (Figure 1.1). Th2 cells lead to tissue 
damage and fibrosis in parasitic infections like helmenths (54), and the persistence of Th2 cells 
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leads to allergic disorders (55, 56). Th2 cells play a major role in humoral immunity in 
modulating antibody responses, Th2 cytokines IL-4 and IL-13 induce IgE class switching in B 
cells (57). IL-5 influence the eosinophil function with increased production and release of 
eosinophils (58). Th2 cells induce IgG1 and IgE antibodies in mice whereas IgM, IgG4 and IgE 
are induced in humans. IL-4 (endogenous or exogenous) interacts with its receptor and induces 
the activation of STAT6, which in turn up-regulates the expression of GATA-3 and c-maf (59). 
GATA-3 is known to auto-stimulate itself, but GATA-3 alone is not sufficient to induce IL-4. 
IL-2 mediated stimulation of STAT5 is required for IL-4 production and maintenance (60). Th2 
cells preferentially express chemokine factors CCR3, CCR4, and CCR8 (45). CD8
-
 DCs were 
shown to induce Th2 response, leading to IgE antibody production in mice (61). IL-25 cytokine, 
which is structurally related to IL-17 is shown to induce Th2 cells (62). IL-25 is also shown to 
enhance allergic airway inflammation by inducing a Th2 cell dependent pathway (63) but 
absence of IL-25 has not impaired the ability of T cells to differentiate into Th1 and Th2 cells. 
IL-1α and IL-1β are shown to regulate the Th2 response in nematode infections (64). Th1 and 
Th2 cells mutually regulate one another through their cytokines and transcription factors.  
Moreover, Th2 cells play major roles in allergic diseases. (65). In the sensitization phase 
of allergic diseases there will be differentiation and clonal expansion of allergen specific Th2 
cells. Th2 produced IL-4 and IL-13 leads to the induction of B cell class switch to the ε-
immunoglobulin heavy chain and to the production of allergen-specific IgE Ab. Allergen 
specific IgE binds to the high affinity FcεRI on the surface of mast cells and basophils, thus 
leading to the patient’s sensitization to an allergen. During this phase, a pool of memory allergen 
specific T and B cells will be generated. In the effector phase, when there is a new encounter 
with the allergen, it will lead to cross linking of the IgE-FcRI complexes on sensitized basophils 
and mast cells, thus triggering their activation and subsequent release of anaphylactogenic 
mediators responsible for the classical symptoms of the immediate phase (type 1 
hypersensitivity).  In the later phase, when there is continuous presence of an allergen, it leads to 
T cell activation. Activated allergen-specific Th2 cells produce IL-4, IL-5, IL-10 and IL-13, 
which play a key role in the maintenance of allergen-specific IgE levels, eosinophilia, 
recruitment of inflammatory cells to inflamed tissues, production of mucus, and decreased 
threshold of contraction of smooth muscles (66). As a consequence of these events, the more 
severe clinical manifestations of allergy, such as chronic persistent asthma, allergic rhinitis, 
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atopic dermatitis, and in extreme cases, systemic anaphylactic reactions appear. To alleviate 
these pathogenic effects of Th2 cells, it is important to understand the biology of Th2 cells 
(chapter 4).  
There are various studies showing the counter balance of Th1 and Th2 cells through their 
cytokines (67-71). An increase in activation induced cell death of Th1 cells in atopic diseases 
contributes to the predominant Th2 cells (72). In shistasomiasis Th2 cells and Tregs inhibit Th1 
response through inhibition of IL-12 produced by dendritic cells. This inhibitory effect is 
mediated through IL-10 produced by them (73). When T-cells were co-stimulated by CD3/CD28 
under Th1 and Th2 conditions they show high polarized secretion of cytokines. Th2-cells co-
stimulation induces Th2 cytokines leading to abrogation of Th1 mediated bone marrow 
transplant rejection (74). Dendritic cells secreting Th1 cytokines like IL-12, IFN-γ along with 
expression of peptide specific MHC and intracellular adhesion molecule-1 (ICAM-1), converts 
established Th2 polarized CD4
+
 T cells to Th1 in recall response (75). CD8
-
 DCs were shown to 
induce Th2 response leading to IgE antibody production in vivo even in the presence of a pre-
existing antigen specific Th1 environment (61)  Th2 clones specific to alloantigen regulate 
alloimmune response are shown to promote allograft survival (38), but the mechanism of this 
response is not shown. On the contrary, some studies also show that antitumor CTL activity is 
not affected by the presence of Th2 cells (76, 77). Antigen-specific Th2 cells eradicated an 
established visceral and lung metastasis of a CTL-resistant melanoma (78). Similarly, injection 
of OVA-specific CD4
+
 T cells expressing either Th1 or Th2 phenotype cleared an established 
A20-OVA B-cell lymphoma (79). IL-4 is shown to induce infiltration of macrophages, 
eosinophils and in some cases neutrophils and lymphocytes to a tumor site, leading to tumor 
clearance (80-82). Similar to IL-4, IL-13 over-expression also showed antitumor immune 
response through recruitment of neutrophils and macrophages (83, 84). Treg cells are shown to 
directly inhibit the activation of allergen specific Th2 cells, thus minimizing the production of 
IL-4, IL-5, IL-13 and IL-10, which are essential cytokines during the effector phase of allergic 
reactions (85).   
 
1.3.3 CD4
+ 
T-Follecular helper (TFh) cell  
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T follicular helper (TFh) cells were first identified in humans, possessing a cytokine 
profile different from Th1 and Th2 cells. TFh cells have emerged as a subset of T-helper cells 
with unique transcriptional and cytokine production properties, providing help to B cells in 
maintaining a long-lived antibody response. They provide help to B cells in eliciting a long-lived 
antibody response in secondary lymphoid organs. Antigen-specific T cells interact with B cells at 
the border of the T-B cell area in the secondary lymphoid organs. At that stage, isotype switching 
will be initiated, and B cells migrate to the germinal centre. In the germinal centre, rare TFh cells 
help mutated B cells to differentiate into high affinity plasmacytes or memory B cells, which 
produce long lasting high affinity antibodies (86). Defining the TFh cell has become difficult 
because of the  heterogeneity of T cells present in B cell follicles and the heterogeneity of 
various known markers for identifying these cells (87).  TFh cells are characterized by 
transcription factor Bcl-6 and chemokine receptor CXCR5. CXCR5 is required for TFh 
migration into lymphoid follicles, which are attracted by chemokine receptor ligand CXCL13 
expressed at B cell follicles (88). CXCR5
+
CCR7
low
 cells migrate into the germinal centres after 
exposure to antigen (89). CXCR5 is most widely used as a marker for TFh cells. TFh cells also 
express CXCR4, PD-1, and ICOS. There are studies showing the importance of Bcl6 in inducing 
CXCR5 expression (90, 91). Over expression of Bcl6 up-regulates the expression of CXCR5, 
CXCR4, PD-1, ICOS, IL-21R, and IL-6R, and down-regulates CCR7 both in vitro and in vivo 
(90-92). Over expression of Blimp-1, transcriptional repressor of Bcl6 will down-regulate these 
molecules (92). TFh cells produce high levels of IL-21 and low moderate levels of IL-4 and low 
levels of IFN-γ and IL-17 (93, 94). IL-21 has an autocrine effect on FTh cells and acts as a 
germinal centre B cell survival and differentiation factor (93). 
 
 
1.3.4 CD4
+ 
T-helper-17 (Th17) cell  
Th17 cells are the new subset of T-helper cells added in 2005, through the cell-specific 
cytokine IL-17, which was identified a decade back. Th17 cells produce IL-17 and express 
transcription factor RORγt through activation of STAT3 by IL-6 and IL-23 in mice (Figure 1.1) 
(95). STAT3 regulates IL-6 induced expression of RORγt and IL-17 production (96). IL-6 
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activates both STAT3 and STAT1. STAT1 being inhibitory on Th17 cells, SATA1 will be 
inhibited by Th17 cells whereas STAT3 expression is maintained (97). IL-27 and IFN-γ inhibits 
the development of Th17 cells through a STAT1 dependent mechanism (98). There is a small 
difference between mouse and human Th17 cells with regard to their origin. Human Th17 cells 
require cytokines IL-1β and IL-23 for their differentiation. Meanwhile the involvement of TGF-β 
in human Th17 cell differentiation is controversial (99). It has been recently shown that TGF-β is 
not essential for Th17 development in mice and humans and it has been demonstrated that TGF-
β plays an indirect role in inhibiting Th1 and Th2 development (100, 101). Prostaglandin E2 is 
shown to play an important role in the development of human Th17 cells. Though Th17 cells 
secrete small amount of IL-2, cytokine IL-2 has been shown to constrain Th17 generation from 
CD4
+
 T cell precursors via STAT5 (102, 103). Transcription factors interferon regulatory factor 
4 (IRF-4) and T-bet are shown to inhibit Th17 cell differentiation (104, 105). Aryl hydrocarbon 
receptor (Ahr) promotes Th17 development through STAT1 inhibition and STAT5 activation 
(106).  
Additional research demonstrates that Th17 cytokines are strongly pro-inflammatory, and 
Th17 cells have been shown to play critical role in immune-mediated inflammation (107). 
Historically, Th1 cells were associated with autoimmune diseases, experimental autoimmune 
encephalitis (EAE) and collagen induced arthritis (CIA), and they were ablated with neutralizing 
antibodies to the IL12p40 subunit, which is also shared with newly discovered cytokine IL-23 
(46, 47). Later it was shown that IL-23 deficient mice ablated autoimmune diseases but not the 
IL-12 deficient showing that Th17 is a main pathogenic cell responsible for autoimmunity (48, 
49). There is not much difference between Th17 and Th1 cells compared to Th17 and Th2 cells 
(108). Th1 cell cytokines IL-12 and IFN-γ are shown to inhibit Th17 cell differentiation (108). 
Th17 cells resemble Th1 cells in most of the surface marker expressions compared to Th2 cells, 
but Th17 cells are differentiated with Th1 cells by their expression of IL-17, TNF, and absence 
of transcription factor T-bet expression (108). With the invention of Th17 cells as a new subset 
of CD4
+
 T helper cells, Th17 cell has replaced Th1 cell in autoimmune and allergic disorders as 
a pathogenic subset of T-helper cells. Th1 cytokine IFN-γ knockout is shown to have an 
increased susceptibility to EAE (109), and EAE is suppressed in mice deficient in IL-23, a Th17 
expansion cytokine (48), suggesting that the Th1 cell type is replaced with the Th17 cell as a 
pathogenic cell type in EAE. This was also proved by adoptive transfer of Th17 cells, showing a 
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more efficient induction of EAE than Th1 cells (110). Absence of P19 receptor subunit which is 
specific to IL-23 makes mice resistant to EAE with a defect in Th17 production (48, 110). 
Recently, both Th17 and CD8
+
 T cells have been identified in active lesions in brains of multiple 
sclerosis (MS) patients (111).   
With Th-17 cytokines being strongly pro-inflammatory, Th17 cells have been shown to 
play a critical role in immune-mediated inflammation (95, 107, 112). Involvement of Th17 cells 
in antitumor immunity has recently been reported. Th17 cells and IL-17 expression have been 
found in various human tumors (113, 114). Transgenic IL-17 expression either induced tumor 
regression through enhanced antitumor immunity in immune competent mice (115, 116) or 
promoted tumor progression through an increase in inflammatory angiogenesis in immune 
deficient mice (117, 118). It has been demonstrated that Th17 cells secreting both IL-17 and IL-
21 were indirectly linked to antitumor immunity(119). In addition, autoimmunity-inducing Th17 
cells were found to eradicate established prostate tumors (120). More recently, tumor growth and 
lung metastasis were enhanced in IL-17 deficient mice associated with decreased IFN-γ+ NK and 
T cells (121), and tumor-specific Th17-polarized cells were found to inhibit growth of well-
established melanoma via INF-γ production (53). Th17 cell cytokines recruit various 
inflammatory cells. Pathogen specific cells produced during mycobacterial infection induced 
expression of chemokine ligands CXCL9, CXCL10 and CXCL11, which attract Th17 cells to the 
lung, helping in the control of infection (122).  
 
1.3.5 CD4
+ 
T-regulatory (Treg) cell  
In maintaining the immune homeostasis, immune tolerance is very important to keep 
hyperimmune-mediated damage at bay. Treg cells play a major role in maintaining tolerance, 
preventing autoimmune diseases and limiting chronic inflammatory diseases. Apart from that, 
Tregs are shown to have an immune suppressor mechanism with a suppressor effect on T cell 
responses in tumors, helping tumors evade the antitumor immune responses (123, 124). Some 
experiments have shown that depletion of Tregs has led to effective antitumor immune responses 
with reduced tumor growth in mice (125, 126). Moreover, a number of studies demonstrate that 
Tregs control self-reactive Th1, Th2, and Th17 cells (127, 128). Tregs are CD4
+
 T cells with 
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high expression of CD25 and transcription factor Foxp3 (forkhead/winged helix transcription 
factor) (129). There are two categories of Treg cells. One category naturally occurring in the 
thymus is identified as (natural Treg) nTreg and the other, which differentiates in the periphery, 
is inducible by some cytokines and identified as iTreg. Tregs are characterized by the expression 
of forkhead transcription factor Foxp3 and cytokines TGF-β, IL-10, and IL-35 secretion (Figure 
1.1) (130). The nTregs are generated during the early stages of foetal and neonatal T cell 
development (131). These cells are generated in the thymus and then they are exported to 
peripheral tissues, where they normally function. The thymus-induced regulatory T cells 
(nTregs) are CD4
+
, and they typically express high levels of CD25 as well as the co-stimulatory 
molecule cytotoxic T-lymphocyte antigen 4 (CTLA-4), the tumor-necrosis factor (TNF) 
superfamily member GITR (glucocorticoid-induced TNF receptor family related protein, 
TNFRSF18), and the Foxp3 (129, 132). Foxp3 has been demonstrated to be an essential factor 
for the suppressive phenotype of nTregs, as mutations in the Foxp3 gene led to autoimmune 
disease (133). In addition, iTregs are generated from naive CD4
+
 T cell populations under certain 
conditions of antigenic stimulation and they can be induced ex vivo by culturing naive CD4
+
 T 
cells with an antigen or polyclonal activators in the presence of immunosuppressive cytokines 
(Figure 1.1) (134)  Tr1 cells are part of iTregs producing IL-10, differentiated in the presence of 
TGF-β and IL-10 (135) (chapter 4). Studies from Dr. Jim Xiang`s laboratory had shown that 
double negative CD4
-
8
-
 DC subset induce IL-10 secreting Tr1 cells (19). Studies in mice and 
humans have shown the developmental link between Treg and Th17 cells. TGF-β is shown to be 
important for the production of Th17 cells, as TGF-β is essential for inducing Rorγt, a Th17 cell 
specific transcription factor (136, 137). Interestingly TGF- β is also shown to induce the Treg-
specific transcription factor Foxp3 (138).  
 
 
1.3.6 CD4
+ 
T-helper-9 (Th9) cells  
Th9 is a very recently added new CD4
+
 effector T cell subset which is characterized by 
IL-9 production (139). Earlier, IL-9 was known to be a Th2-derived cytokine (140). IL-9 was 
found to increase in an allergen challenge and was important in inducing the mucus 
hypersecretion in asthmatic subjects (141, 142). IL-9 also contributes to the development of 
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tuberculosis by reducing IFN-γ production in peripheral blood mononuclear cells stimulated with 
M. tuberculosis antigens (143). Murine Th2 cells cultured in the presence of IL-4 and TGF-β lost 
the capacity to produce IL-4, IL-5 and IL-13, but they maintained the ability to produce IL-9 in 
addition to IL-10 (144). Th9 does not express the transcription factors T-bet, GATA-3, RORγt, 
and FoxP3 which are specific to Th1, Th2, Th17, and Tregs, respectively, but they express the 
transcription factor PU.1 in both human and mouse T cells (139, 144, 145).  The IL-9
+
IL-10
+
 T 
cells demonstrated no immune regulatory properties despite producing abundant IL-10. On the 
other hand, their adoptive transfer into recombination-activating gene 1-deficient mice (RAG-1) 
induced colitis and peripheral neuritis. This novel Th subset therefore lacks the suppressive 
function and constitutes a distinct population of effector T cells that promote tissue inflammation 
(139). More recently, it was found that IL-9 is produced in high amounts by Th17 apart from 
Th2 and Th9 cells (146). IL-9 synergized with TGF-β to differentiate naïve CD4+ T cells into 
Th17 cells, while IL-9 secretion by Th17 cells was regulated by IL-23. IL-9 enhanced the 
suppressive function of Tregs in vitro, and the absence of IL-9 signalling weakened the 
suppressive activity of Tregs in vivo, leading to an increase in effector cells and a worsening of 
EAE. These findings suggest a novel role of IL-9 as a regulator of pathogenic and protective 
mechanisms of immune responses (147). 
 
1.3.7 CD4
+
T-helper-22 (Th22) cells  
IL-22 was originally described in mice and humans as a cytokine produced by mature 
Th17 cells (148). IL-22 belongs to IL-10 cytokine family with an overall sequence identity of 
22% in mice and 25% in humans with IL-10 gene (149). Very recently, distinct subsets of human 
skin homing memory T cells have been shown to produce IL-22, IL-26 and IL-13, but they do 
not secrete IL-17, and/or IFN-γ (150, 151). IL-22 is also produced by Th1, Th17, NK and NKT 
cells, where in IL-22 is shown to play a protective role in infections or pathogenic role in chronic 
inflammatory conditions (152). Th22 cells are characterized with the expression of chemokine 
receptors CCR6, CCR4, CCR10 and the transcription factor aryl hydrocarbon receptor (Ahr). 
Cytokines IL-23 and IL-6 can directly induce the production of IL-22 from naive T cells both in 
mice and humans. Ahr agonists also induce the production of IL-22 both in mice and humans 
(153, 154). Differentiation of Th22 could be promoted by stimulation of naive T cells in the 
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presence of IL-6 and TNF-α or by the presence of plasmacytoid dendritic cells; it appears to be 
independent of Rorc but dependent upon the Ahr (151). Dermal DCs and Langerhans cells were 
shown to be very efficient in inducing the generation of Th22 cells. On the other hand, 
monocyte-derived DCs were shown to induce the development of Th17 cells that produced both 
IL-17 and IL-22 together (155). The human Th22 cell population co-expresses the chemokine 
receptor CCR6 and the skin-homing receptors CCR4 and CCR10, which led to hypotheses that 
these cells may be important in skin homeostasis and pathology (150, 151). Th22, along with 
Th17 and Th1 cells are increased in peripheral blood of psoriatic patients (156). Levels of IL-22 
co-related with the disease severity in psoriatic patients (157). In rheumatoid arthritis, some 
studies have shown the possibility of Th22 playing the pathogenic role. IL-22 is shown to 
increase the proliferation of synovial fibroblasts and CCL-2 production by them (158). There 
was an increase in IL-22 and collagen-specific antibodies in the serum of collagen induced 
arthritis mice (159).  
 
1.4 Plasticity of CD4
+
 T cells 
For decades, researchers have been looking for different regulators of immune responses 
in order to understand the immune system. In 1986, Robert Coffman and Timothy Mossman 
showed that the immune system is regulated by different kinds of T-helper cells. Later, there 
were various effector T-helper cells added to the list, based on their cytokine secretion.  The 
cytokine milieu is very important in deciding the fate of an undifferentiated T-helper cell. 
Historically, T helper cells are deemed terminally differentiated cell lineages committed to their 
path. With the discovery of various new T-helper cells, there is also evidence that some T-helper 
cells are plastic in nature; a mature effector cell will be converted into a different effector T-
helper cell in certain microenvironments. Most in vitro differentiation models suggest that such 
commitment of T-helper cells provide simplified experimental models that allow us to 
understand how they are regulated. Recent emerging evidence suggests that under certain 
conditions, seemingly committed T cells possess plasticity and may convert into other types of 
effector cells. However, how CD4
+
 T-helper cells achieve such plasticity is not fully understood, 
but it is very well understood that under different microenvironments, even well-differentiated T-
helper cells are ready to re-differentiate into different T helper subsets. However, the biological 
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significance of this plasticity remains unclear. It would be fruitful to harvest this phenomenon to 
treat immune-mediated disease conditions by designing effective immune-balancing strategies. 
Various models of the plasticity of T cell subsets have been described. Long-lived Th1 
effector/memory cells are able to turn off IFN-γ expression in vivo, appearing to be ready to re-
differentiate (160). Th1 cell promoting lymphocytic choriomeningitis virus (LCMV) converted 
stably committed Th2 cells into Th2/Th1 phenotypes with GATA3 and T-bet expression through 
concerted action of TCR, interferon I and II, interleukin-12, and T-bet (161). However, the 
plasticity of Th1/Th2 cells seems to depend on their differentiation state (162). In addition, it is 
difficult to redirect Th1 or Th2 cells to become either Th17 or Tr cells, consistent with 
suppressive genomic modification at Rorc and Foxp3 loci in Th1 and Th2 cells (163). It is shown 
that in vitro generated Th17 cells are not stable in maintaining their cytokine expression 
capacities in vivo and can be converted into Th1 cells in lymphopenic environments (164, 165). 
However, they maintained their cytokine expression in normal mice and tumor-bearing mice 
(166, 167). The research shows that Treg cells known for their suppressor function are shown to 
become immune-stimulatory T-helper cells (168). Reduced expression of Foxp3 in Tr cells by 
genetic means resulted in the acquisition of Th2 phenotype (169). Tr cells can also be self-
induced to become IL-17-producing cells in the absence of TGF-β when IL-6 is present (170), 
and the fully differentiated Tr cells can reverse into Th17 cells (171). Transferring Tr cells into 
lymphopenic mice also resulted in down-regulation and up-regulation of Foxp3 and IL-17, 
respectively (172). In addition, the existence of Th17 cells producing Foxp3 and IL-17/IFN-γ 
CD4
+
 T cells has been shown (173, 174). Th17 cells have also been shown to convert into Th1 
cells in the absence of TGF-β (50, 164, 165).   
There are various mechanisms underlying this plasticity associated with CD4
+
 T cells. 
These mechanisms could be divided into two categories. 1) Microenvironment: including 
cytokines and co-stimulation, with these two being the primary factors in differentiation, they 
also play roles in the plasticity associated with T-helper cells. Different antigen-presenting cells 
are shown to induce different kinds of T-helper subsets. For example, neutrophils are shown to 
promote Th17 cell response (175). NK cells are shown to promote Th1 response through IFN-γ 
secretion (176). As explained earlier, even well differentiated T-helper cells re-differentiate in 
different microenvironments. 2) Transcription factors: interaction between different cell specific 
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transcription factors is important in driving different T-helper subsets. For example mutual 
transcriptional repression of Th1 and Th2 cell specific transcription factors T-bet and GATA-3 
plays a major role in deciding about the lineage (177). Treg specific transcription factor Foxp3 
can inhibit the transcriptional activity of Th17 cell specific transcription factor Rorγt (178). 
These studies indicate that understanding the regulation of T-helper subsets by transcription 
factors has to be looked upon as a gradient of their expression rather than just as absence or 
presence, as they are shown to change during the course of infection. 
 
1.5 Trogocytosis 
In maintaining immune homeostasis and eliciting effective immune responses against any 
foreign antigens there should be a concerted activation of the immune system, where cellular 
communications mediated by either soluble or cell surface molecules amongst immune cells is 
certainly essential. The advent of the latest analytical and imaging tools has allowed researchers 
to enhance their understanding of the cellular communication through the intercellular exchanges 
of molecules. To explain transfer of membrane patches in intercellular communication the term 
trogocytosis was coined by Hudrisier in 2003; the term is derived from the ancient Greek word 
trogo, meaning gnaw or nibble. Trogocytosis is a phenomenon characterized by a transfer of 
membrane molecules from cell to cell (179). Trogocytosis is a common phenomenon affecting 
different stages of immune responses involving different immune cells (180). T cells have been 
shown to acquire MHC class I and class II proteins (102, 181), co-stimulatory molecules (182) 
from APCs and other proteins from endothelial cells (183). Dr. Jim Xiang’s lab has shown 
bidirectional membrane molecule transfer between dendritic and T cells in murine system (184). 
NK cells are shown to capture the target cell-MHC class I protein both in vitro and in vivo (185) 
as well as the virus receptor (CD155) (186) and the membrane fragments (187). B cells, which 
are part of humoral immunity, are also shown to capture membrane-associated antigens from 
target cells, and the amount of antigen captured correlates with the affinity of the B-cell receptor 
for the antigen (188). In Burkitt’s lymphoma, γδ T cells have been shown to capture the 
membrane fragments from the tumor cells (189).  
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Proteins are tagged to the cell surface by hydrophobic interactions, and the disruption of 
this hydrophobic bond is necessary to initiate the intercellular transfer of proteins (180). 
Trogocytosis of various immune-stimulatory or suppressor molecules will happen through 
various mechanisms, viz., internalization and recycling of membrane molecules, Dissociation-
associated, Exosome uptake pathways or membrane nanotube formation (190).  
Internalization and recycling: effective T cell responses are elicited by TCR recognition 
of peptide-MHC (pMHC) on APCs along with co-stimulatory and cytokine signalling (191). 
When there is a specific interaction of T cells with APCs, within minutes TCR and MHC 
molecules are assembled at the centre to form supramolecular activation clusters at the site of T 
cell contact or synapse (192, 193). Subsequent to synapse formation, TCR down regulation 
occurs and T cell-APC interactions cause transfer of APC derived surface molecules to the 
surface of T cells (194). These transferred clusters are internalized through TCR-mediated 
endocytosis and localized in endosomes and lysosomes, followed by recycling and expression of 
these molecules on T cell surfaces within 30 minutes (181). There are various studies endorsing 
this phenomenon wherein T cells acquire both MHC class I and class II proteins from APCs 
(195, 196). 
Dissociation associated pathway: This phenomenon of torgocytosis was first 
demonstrated by Wetzel et al by using live cell imaging technology (197). They observed that 
when T cells come off from immune synapse from APCs they directly capture peptide-MHC 
complexes. Another study in macrophages showed repeated association and dissociation of CD4
+
 
T cells with macrophages (198).  By using in vitro imaging, dendritic cells were shown to 
possess dissociation-association with CD4
+
 T cells in three-dimensional collagen matrix (199).  
Exosome uptake pathway: Exsosomes are membrane bodies or vesicles measuring 
approximately 50-90 nm, released by variety of cells. This phenomenon of vesicle secretion acts 
to lose potentially harmful components, as shown in case of the recovery of human neutrophils 
from complement attack by shedding membrane attack complex (200). Exosome-mediated 
intercellular membrane transfer is mediated by the secretion and uptake of exosome by a 
different cell. Various studies have shown that APCs shed MHC class II glycoproteins which are 
acquired by T cells (201, 202).  
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Membrane nanotubes: Advances in cell imaging technology have led to demonstrating 
the intercellular exchange of proteins through membrane tubes, long membrane tethers between 
cells. Nanotubes are reported to connect a wide range of immune cells, such as T cells, B cells, 
NK cells, and monocytes (203, 204). Nanotubes were also observed between B cells and NK 
cells (205). There is a study demonstrating the T cell with T cell nanotube formation which 
might have important consequences in allowing rapid spread of HIV-1(206). 
Intercellular communication through trogocytosis is very important in maintaining the 
homeostasis of the complex immune system in order to elicit effective immune responses. When 
we look at the functional consequence of trogocytosis, these acquired molecules appear to have 
immune stimulatory or suppressive impact. In our study, we speculate that DC molecules are 
acquired by T cells (chapters 2&3). 
 
1.6 Cytokines 
 Cytokines are small proteins/peptides/glycoproteins released by cells which have specific 
roles in the immune system by autocrine and paracrine mechanisms. Lymphocytes being the 
primary source of cytokines, other cells also produce cytokines. Cytokines include a number of 
groups: interleukins, lymphokines, and cell signal molecules, such as the tumor necrosis factor 
and the interferons. Cytokines are usually pleotrophic with diverse activity on different cells. 
They act through binding specific receptors. They are shown to regulate cell activation, 
hematopoiesis, apoptosis, cell migration, and cell proliferation. With various functions, they are 
involved in both innate and adaptive immune responses. There are various cytokines and 
cytokine families, of which I will be discussing those cytokines relevant to our study. 
 
 
1.6.1 Interleukin-4 (IL-4) 
 IL-4 is multifunctional pleiotorpic cytokine that plays a critical role in Th2-mediated 
immune regulation. It is produced by Th2 cells, basophils and mast cells (207). IL-4 was also 
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produced by NK cells upon in vivo challenge with anti-CD3 (208). Upon Th2 pathogen 
stimulation, γδ T cells are shown to produce IL-4 (209). Clones of CD8+ T cells produce IL-4-
helping B cells (210). Addition of IL-4 in the secondary culture period of DCs induces strong 
antigen presenting capacity (211).  IL-4 binds to IL-4Rα and recruits a common gamma chain 
(γc) for its downstream effects, this heterodimerization is necessary for physiological function 
(212). IL-4 promotes Th2 responses through GATA3. IL-4 upregulates the GATA3 expression 
which is expressed in low levels in naïve T cells. GATA3 is upregulated through STAT6 
activation by IL-4 cytokine (213). The IL-4-mediated STAT6 signalling pathway leads to 
silencing of IFN-γ expression and, inhibition of a Th1 kind of response (214). On the contrary, 
Th1 cytokine, IL-12 inhibits Th2 cells through suppression of GATA3 (215).  Th1 cytokine IFN-
γ acts as a key activator of IL-12 and IL-12R, further suppressing a Th2 response (41).  IFN-γ is 
also shown to directly suppress the IL-4 gene through interferon regulatory factors IRF1 and 
IRF2 (216). IL-4 plays an important physiological function through immunoglobulin class 
switching. In mice, IL-4 induces the secretion of IgE and IgG1 from B cells (217, 218) and in 
humans, induces IgE and IgG4 secretion (219). These antibody-switching functions of IL-4 
demonstrate its role in allergic conditions. Through Th2 responses, IL-4 promotes protective 
immunity in helminth and extracellular parasitic infestation. IL-4 is shown to act as a co-mitogen 
along with IL-2 in B cells (220). Apart from that, it increases the expression of MHC class II 
molecules in B cells (221). IL-4 as well as TNF are shown to induce the expression of vascular 
cell adhesion molecule-1 (VCAM-1) in vascular endothelial cells along with down-regulation of 
E-selectin (222, 223). This shift in adhesion molecules will help in recruiting T cells and 
eosinophils than granulocytes to the site of inflammation.  
 
1.6.2 Interleukin-6 (IL-6) 
 IL-6 is a pleiotropic cytokine with its receptors in various cell types, showing a wide 
range of biological activities, immune regulation, haematopoiesis, inflammation, and 
oncogenesis (224). IL-6 was first identified as B-cell stimulating factor-2, and later named as IL-
6 (225). Many cell types produce this cytokine, including T cells, dendritic cells, macrophages, 
fibroblasts, synovial cells, endothelial cells, glial cells, and keratinocytes (224). IL-6 being a pro-
inflammatory cytokine, overproduction of IL-6 has been associated with various inflammatory 
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diseases. Synovial cells from rheumatoid arthritis patients showed increased production of IL-6 
(226). Physiologically, this cytokine functions through IL-6R, and the binding of this receptor 
also induces the interaction of gp130 (227, 228). The cell surface polypeptide gp130 is expressed 
in almost all tissues and cells, endorsing the pleiotropic nature of IL-6 (229). Several studies 
have shown that gp130 acts as a receptor component for several other cytokines such as CNTF in 
brain, LIF, oncostatin M, IL-11, IL-27, neuropoetin, and cardiotrophin (230). IL-6 is shown to be 
induced by various stimuli including bacterial and viral infections, microbial components like 
lipopolysaccharide, and by cytokines like IL-1, TNF-α and PDGF (224). IL-6 acts as an 
important link between innate and adaptive immune responses with its effects on T and B cells 
(231). Cytokine IL-6 acts through the JAK-STAT pathway, through STAT3 activation (232). 
STAT3 regulates IL-6-induced expression of RORγt and IL-17 production, indicating the 
primary role of IL-6 in Th17 cell differentiation (96). Through up-regulation of NFATc2 and c-
maf, IL-6 influences T cell effector functions by promoting Th2 cell differentiation (233, 234). 
IL-6 is shown to be an important factor in antibody production because it induces plasma cell 
development from B cells (235). IL-6 deficient mice show reduced antigen specific IgG1, IgG2a, 
and IgG3 levels upon immunization with T cell-dependent antigen (236). Humanized antibody 
Tocilizumab is approved for clinical use in treating IL-6 induced pathologies (230, 237). 
 
1.6.3 Interleukin-10 (IL-10) 
 IL-10 is an anti-inflammatory cytokine. It was initially identified as the cytokine 
synthesis inhibitory factor (CSIF) produced by Th2 cells in response to antigen presentation  by 
APC,  and it was shown to inhibit Th1 cells (238). IL-10 is produced by macrophages, dendritic 
cells, B cells, and various subsets of CD4
+
 and CD8
+
 T cells (239). IL-10 signals through IL-
10R1 and IL-10R2 receptor complexes, inducing Jak1 and Tyk2 kinases, which phosphorylates 
SATA3 to drive STAT3 responsive genes (240). IL-10 being an anti-inflammatory cytokine will 
inhibit MHC class II and co-stimulatory molecule B7-1/B7-2 expression on macrophages and 
monocytes, and will also inhibit the production of pro-inflammatory cytokines and chemokines 
(241). In dendritic cells, autocrine signalling has led to inhibited IL-12 local production in 
mycobacterial infection (242). IL-10 also induced the differentiation of regulatory DCs secreting 
IL-10, thus leading to stimulation of Tr1 cells (243). Moreover, IL-10 is shown to play role in B 
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cell survival through Bcl2 up-regulation, showing its importance role in humoral response (244). 
Endorsing the anti-inflammatory role of IL-10, IL-10 deficient mice showed spontaneous 
enterocolitis (245). IL-10 deficient mice also showed increased Th1 responses with protection 
from granuloma formation with Chlamydia trachomatis lung infection (246). 
 
1.6.4 Interleukin-17 (IL-17) 
IL-17 plays host-defensive role in many infectious diseases, but promotes host-
destructive inflammatory pathology in autoimmune disorders. IL-17 is essential for host defence 
against many microbes such as bacteria and fungi (247). Originally, IL-17 was thought to be 
produced only by T cells, but is currently shown to be produced by various other cells: dendritic 
cells, macrophages, smooth-muscle cells, NK cells, NKT cells, and γδ T cells  are some known 
sources (248). The IL-17 family of cytokines are composed of IL-17A, IL-17B, IL-17C, IL-17D, 
IL-17E (IL-25), and IL-17F (249). IL-17 has five receptors IL-17RA, IL-17RB/IL-25R, IL-
17RC, IL-17RD and IL-17RE (250). IL-17 receptors are expressed ubiquitously by most of the 
cell types, hence most of them can respond to IL-17 (251). IL-17 cytokines are strongly pro-
inflammatory, and they induce the expression of several chemokines such as CCL2, CCL7 and 
CCL20, as well as pro-inflammatory cytokines like IL-6 and TNF-α (249, 252). Transgenic over-
expression of IL-17A in the lungs provokes pro-inflammatory gene expression and tissue 
infiltration of leukocytes. In contrast, inhibition of IL-17A expression impairs host defenses 
against bacterial infection (253) and resistance to autoimmune diseases (110, 171). IL-17E (IL-
25) induces Th2 type of cytokines and chemokines RANTES and Eotoxin-1, and it plays role in 
allergic responses (249). IL-17 acts as an angiogenic factor stimulating migration and chord 
formation of vascular endothelial cells in vitro and also leads to vessel formation in vivo (118, 
254). IL-17 plays distinct roles in lymphopenic and immune-competent mice with reference to 
tumor immunity. Transgenic expression of IL-17 either induced tumor regression through 
enhanced antitumor immunity in immune-competent mice (115, 116) or promoted tumor 
progression through an increase in inflammatory angiogenesis in immune-deficient mice. 
 
1.7 T-APC model 
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 Antigen presenting cells (APCs) play critical roles in eliciting adaptive immune 
responses and keeping memory. APCs will acquire foreign protein or self-protein and process 
that antigen to present it on MHC molecules. T cells lack the ability to recognize the free 
antigen, where as they can recognize the antigen presented on MHC molecules through specific 
TCRs present on T cells.   APCs are classified into professional APCs and non-professional 
APCs. APCs which have MHC class II on them are termed professional APCs. Expression of co-
stimulatory molecules like CD80, CD86, CD40, etc. is a characteristic feature of professional 
APCs. Originally, dendritic cells, B cells, and macrophages fall under this category.  There are 
various subsets of each cell type which are involved in immune responses. Recently, Dr. Jim 
Xiang’s group has shown that CD4+ T cells themselves act as APCs, inventing the new concept 
of a dynamic model of two cell interactions by CD4
+
 Th-APC (255). 
 To generate effective CTL responses for minor histo-compatibility antigens and tumor 
antigens, which lack danger signals, DCs and CD8
+
 T cells need help form CD4
+
 T cells (256). 
There are three models explaining the help provided by CD4
+
 T cells to CD8
+
 T cells in 
generating effective CTL response. The first model is the passive model of three-cell interaction, 
wherein antigen-specific CD4 and CD8
+
 T cells simultaneously come in contact with specific 
antigen-carrying APCs (257). One difficulty associated with this model is the chance of all these 
cells coming together at the same time. In the sequential two-cell interaction model, APCs 
activate CD4
+
 T cells and gets reciprocally activated through CD40-CD40L signalling. 
Reciprocally activated APC will then directly stimulate CD8
+
 T cells (258). There was a caveat 
in this model because of the temporal nature of antigen presentation and CTL production. To 
address the drawbacks associated with these two models, a novel concept of Th-APC was 
proposed by Dr. Jim Xian’s group (255). Trogocytosis (intercellular transfer of membrane 
proteins) is a common phenomenon that occurs between immune cells, which play an important 
role in immune modulation (259). As a sequel to antigen-specific T cell-APC interactions an 
immunological synapse is formed, comprising a central cluster of TCR-MHC-peptide complexes 
and outer ring of CD28-CD80 interactions and other accessory molecular interactions (192, 193). 
When these cells come off the synapse, APCs-derived surface molecules are transferred to the T 
helper cells; later, they are recycled back to the surface by TCR internalization and recycling 
(181, 260). Dr. Jim Xinag’s lab has shown that during the membrane molecule transfer from 
APCs to CD4
+
 T cells by APC stimulation, CD4
+ 
T cells acquire the synapse-composed MHC 
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class II and co-stimulatory molecules (CD54 and CD80) along with the bystander peptide-MHC 
class I complexes. The CD4
+
 T cells carrying acquired APC antigen-presenting machinery were 
shown to act as CD4
+
 Th-APCs by stimulating in vitro and in vivo antigen-specific CTL 
responses (255).  
 Further endorsing the dynamic model of two cell interactions by CD4
+
 Th-APC, by using 
confocal imaging technology, it was demonstrated that peptide-MHC class II and bystander 
peptide-MHC class I co-localize within the synapse formed between CD4
+
 T cells and antigen-
presenting DCs. Co-stimulatory molecules CD54, CD80, CD40, OX40L and 41BBL also co-
localized in the same synapse. Recycling of acquired peptide-MHC class I molecules was also 
demonstrated (184, 261). It was also shown in human T cells that they acquire MHC molecules 
and co-stimulatory molecules from APCs and act as T-APCs to other T cells. These acquired 
molecules were also shown to persist on T cells for 72 hours (262). As a different mechanism of 
antigen presenting machinery transfer from APCs to T cells, exosomes containing peptide-MHC 
class I and co-stimulatory CD40 and CD80 molecules released by DCs were transferred to T 
cells, making them effective T-APCs in  inducing antigen-specific CTL response and long term 
memory (263, 264). In vitro DCOVA activated T-helper cells, acting as T-APCs, stimulated OVA-
specific memory response with the involvement of IL-2 secreted by T-APCs (265). CD4
+
 Th1 
cells with acquired peptide-MHC I by DCOVA stimulation were able to reduce the apoptosis and 
to prolong the survival of active CD8
+
 Tc1 cells in vitro, and to promote CD8
+
 Tc1 cell tumor 
localization and memory responses in vivo (266). DC-activated T-APCs were shown to elicit 
antigen specific CTL response in MHC class II knockout mice and were able to overcome the 
self tolerance in the transgenic RIPmOVA diabetic model (267, 268). Th-APC with acquired 
peptide MHC class I and II could also stimulate Th1 and central memory CD8
+
44
+
CD62L
high
IL-
7R
+
 T cell responses, leading to effective antitumor immunity (52). As a part of this thesis, Th17 
cells induced by DC activation were shown to behave as T-APCs to induce antigen-specific CTL 
responses in EAE and T1D autoimmune models (269). Th17 cells were also shown to induce 
both preventive and therapeutic antitumor immune responses through the acquired peptide MHC 
class I molecule from DCs (102). 
 
1.8 Disease models 
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 In our study, we have dealt with cancer immunotherapy and with the pathophysiology of 
autoimmune diseases with reference to T-helper cells. The autoimmune diseases addressed in our 
study are type 1 diabetis, experimental autoimmune encephalitis (animal model for human 
multiple sclerosis). 
 
1.8.1 Cancer 
Cancer is an uncontrolled growth of abnormal cells in the body. Cancer could be benign 
with localized growth or malignant with disseminating behaviour to other locations. Cancer cells 
are self cells, so there are only certain minimal differences between normal cells and cancerous 
cells. Because of this minor difference in antigen profile, cancer cells grow very well even in the 
presence of a strong intact immune system. Apart from that, tumors secrete immunosuppressive 
cytokines such as TGF-β and IL-10 that have negative effects on the immune system, letting 
tumors off the immune-scanner (270, 271). Another immunosuppressive molecule found in 
tumors is indoleamine 2, 3-dioxygenase, an inducible enzyme involved in tryptophan catabolism. 
Tryptophan depletion in tumors by this enzyme decreases the functionality of effector T cells and 
causes dendritic cells to become immunosuppressive (272). In addition, tumors often harbour 
immunosuppressive cells such as regulatory T cells, myeloid-derived suppressor cells, and 
immature dendritic cells, making the tumor microenvironment  even more immunosuppressive 
(19). This phenomenon of evading immune response is referred to as immunoediting (273). To 
fight an immunosuppressive tumor environment, we can harness the immune system by 
stimulating the body’s own immune system and/or by adaptive transfer of active humoral or 
cellular immune system. There are various studies showing the role of functionally differentiated 
T-helper cells in induction of antitumor immune response (274).  Th1 cells are shown to 
counteract immune suppressive regulatory cells by stimulating efficient CD8
+
 T cell and NK cell 
responses (264) and Th17 cells are shown to induce effective antitumor immune response 
through antigen-specific CD8
+
 T cell induction (102). 
 
1.8.2 Type 1 diabetes (T1D) 
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Type 1 diabetes (T1D) is a chronic autoimmune disease, wherein the pancreatic β-cells 
which secrete insulin are selectively destroyed. It is thought to be a Th1 cell-mediated disease 
that involves CD8
+
 T cells and innate immune cells (275). CD4
+
 and CD8
+
 T cells, as well as 
macrophages, have been shown to have a role in β-cell death. The recurrence of T1D in 
recipients of segmental pancreas grafts from HLA-identical donors showed a clear role for T 
cells, particularly CD8
+
 T cells and monocytes, with little evidence for a humoral immune 
response, in β-cell destruction (276). CD8+ cytotoxic T cells could kill pancreatic β-cells through 
MHC class I-mediated cytotoxicity. As well, both CD4
+
 Th1 and CD8
+
 CTL cells produce 
cytokines, such as interferon-γ (IFN-γ) that induce expression of the death receptor FAS (CD95) 
and chemokine production by β-cells. Activation of FAS by FAS ligand (FASL)-expressing 
activated T cells could initiate β-cell apoptosis (275). IFN-γ can also activate macrophages and 
induce increased pro-inflammatory cytokine production, including IL-1β and tumor necrosis 
factor (TNF). In addition, IFN-γ, IL-1β, and TNF also induce the expression of reactive oxygen 
species (ROS), including nitric oxide by β-cells; ROS also have the potential to mediate 
apoptosis (275).  Th17 cells are considered as contributing factor in the pathogenic process of 
T1D. For example, it has been found that IL-17 is expressed in the pancreas during the course of 
T1D in the mouse model (277); reducing the number of Th17 cells with induction of IFN- γ 
inhibited IL-17 production and restored normoglycemia at the prediabetic stage (278). Dr. Jim 
Xiang’s lab has shown that Th17-stimulated CD8+ CTL, but not Th17 cells, play a major 
pathogenic role in the induction of diabetes in RIP-mOVA mice (chapter 3) (51). 
Although CD4
+ 
Th1 and Th17 cells have a pathological role in T1D onset, there is also 
evidence supporting a role for T cells in the prevention of β-cell destruction. Patients with IPEX 
(immunodysregulation, polyendocrinopathy, enteropathy, X-linked) syndrome have mutations in 
FoxP3 and can develop T1D, which highlights the importance of Treg cells in controlling the 
onset of this autoimmune disease (279). Studies in NOD mice have shown the importance of 
Treg cells in preventing T1D: CD28-deficient NOD mice, which lack Treg cells, develop 
accelerated disease (280). In addition, it is also evident from strategies such as injection of IL-2 
to increase Treg cell numbers, is as potential therapeutic approach for T1D (281). 
 
1.8.3 Multiple sclerosis (MS) 
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Multiple sclerosis (MS) is a chronic inflammatory demyelinating disease affecting the 
central nervous system. Both environmental and autoimmune causes have been attributed to MS. 
There is little evidence to support the complete environmental trigger for MS, whereas the 
autoimmune cause has been well established (282). Aberrantly high precursor frequencies of 
autoreactive T cells due to a failure of central (thymic) tolerance mechanisms or an aberrant 
activation or skewing of autoreactive T cells in the peripheral immune compartment by a failure 
of peripheral tolerance mechanisms, can potentially lead to T cell triggered autoimmune tissue 
inflammation. Myelin-specific T cells become activated in the peripheral immune system and 
overcome the blood brain barrier, causing disease. To understand the T cell biology in MS 
pathophysiology, mouse model of EAE has been used extensively. 
In earlier studies, Th1 responses have been attributed for organ-specific autoimmunity 
including MS; they found IFN-γ in MS lesions, which peaked at the peak of the disease and 
declined with recovery (283).  This concept of Th1 cell involvement was seriously challenged, 
when mice which were genetically deficient for IFN-γ showed serious disease than protection 
(283). IL-23 deficient mice were totally protected from EAE, endorsing the importance of IL-23 
in EAE pathology (48). IL-23 is a member of the IL-12 family of heterodimeric cytokines and 
shares the p40 subunit with IL-12, but has a unique p19 subunit. IL-23 KO mice, which are 
completely resistant to EAE, were found to be devoid of a particular subset of CD4
+
 T cells that 
produced IL-17 (110). Whereas IL-12 is an essential differentiation factor for Th1 cells, IL-23 is 
shown to be an important cytokine of Th17 cells. It has been shown that adoptive transfer of 
sensitized CD4
+
 Th17 cells can induce EAE in wild-type C57BL/6 mice (284) (chapter 3).  Not 
surprisingly, Th17 cells are associated with a series of autoimmune or chronic inflammatory 
disorders such as MS (285), rheumatoid arthritis (286), psoriaisis (287), and inflammatory bowel 
disease (288). Some studies have argued that both Th1 and Th17 cells are involved in CNS 
autoimmunity (289). 
 
1.8.4 Experimental Autoimmune Encephalitis (EAE) 
EAE is a demyelinating disease, a rodent model that has been valuable for 
characterization of the immunopathogenic process of human multiple sclerosis (MS). EAE is 
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induced in susceptible animals by immunizing them with one of the various number of myelin-
specific antigens emulsified in complete freund’s adjuvant (CFA) along with intra-peritoneal 
pertusis toxin (290, 291). Attention has originally been focused on the role of CD4
+
 T cells in the 
induction of EAE because susceptibility to MS is associated with MHC class II genes (292). 
Earlier, it was canonically accepted that Th1 cells are pathogenic in EAE and Th2 are protective 
(293). With the invention of Th17 cells, there are various studies showing the role of both Th1 
and Th17 cells in the pathogenesis of EAE (283, 294). Though there were differences in relative 
proportion of Th1 and Th17 cells in different mice models of EAE, both cell types were present 
in EAE lesions (110, 295).  It has also been shown that MOG-specific CD8
+
 T cell responses are 
involved prior to and after the onset of EAE (296); the adoptive transfer of MOG-specific CD8
+
 
T cells is also shown to induce EAE (291, 297) (chapter 3). As various studies have shown, the 
importance of both CD4
+
 and CD8
+
 T cells, it is important to understand the relationship of those 
cells.  
 
1.9 General hypothesis and objectives 
Specific hypothesis and objectives are described in introduction to each chapter. 
Hypothesis and objectives for each chapter were designed in order to understand different 
aspects of CD4
+
 T cell biology.  
First hypothesis: there were studies suggesting the involment of Th17 cells in antitumor 
immunity. However, the mechanism of antitumor immunity and CD8
+
 T cell activation by Th17 
cells was still elusive. To understand the mechanism we hypothesized that Th17 cells can 
directly stimulate CD8
+
 T cell response, themselves acting as antigen-presenting cells, inducing 
effective antitumor immune response. The objective of this hypothesis was to decipher the roles 
of molecular signals in preventive and therapeutic antitumor immunity (chapter 2). 
Second hypothesis: it had been documented that both CD4
+
 and CD8
+
 T cells are 
involved in T1D and EAE, but the relationship of these two cells in the pathogenesis of these 
autoimmune diseases was not addressed. To understand the relationship and pathogenic 
involvement of CD4
+
 and CD8
+
 T cells, we hypothesized that (i) CD4
+
 Th17 cells directly 
stimulate CD8
+
 T cells. (ii) both Th17 and Th17-induced CD8
+
 T cells differentially regulate 
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T1D and EAE. There were two main objectives for this hypothesis: (i) to demonstrate that CD4
+
 
Th17 cells act as antigen-presenting cells in inducing antigen-specific CD8
+
 T cell response, and 
(ii) to show that CD4
+
 and CD8
+
 T cells play distinct roles in T1D and EAE pathogenesis 
(chapter 3). 
Third hypothesis: there was evidence showing overlapping cytokine expression by CD4
+
 
T helper cells, indicating the plasticity of these cells; based on that evidence, we hypothesized 
that the deletion of cytokine genes would lead to functional conversion of these cells. There were 
two main objectives for this hypothesis: (i) to show that CD4
+
 Th2 cells are not inhibitory on 
DCOVA induced CD8
+
 T cell response, and (ii) to document that single cytokine gene deleted 
naive CD4
+
 T cells differentiated under Th2 culture conditions are functionally converted to a 
different subset of CD4
+
 T helper cell (Chapter 4). 
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Figure 1.1 Differentiation of naive CD4
+
 T cells into different CD4
+
 T cell subsets. This 
figure illustrates the cytokines that play roles in differentiation and maintenance of different 
CD4
+
 T cell subsets, and CD4
+
 T cell subset-specific cytokines. 
 
32 
 
1.10 References 
1. Liu, Y. J. 2001. Dendritic cell subsets and lineages, and their functions in innate and 
adaptive immunity. Cell 106:259-262. 
2. Iwasaki, A., and R. Medzhitov. 2004. Toll-like receptor control of the adaptive immune 
responses. Nat Immunol 5:987-995. 
3. Steinman, R. M., and Z. A. Cohn. 1973. Identification of a novel cell type in peripheral 
lymphoid organs of mice. I. Morphology, quantitation, tissue distribution. J Exp Med 
137:1142-1162. 
4. Hart, D. N. 1997. Dendritic cells: unique leukocyte populations which control the 
primary immune response. Blood 90:3245-3287. 
5. Sato, K., and S. Fujita. 2007. Dendritic cells: nature and classification. Allergol Int 
56:183-191. 
6. Shortman, K., and Y. J. Liu. 2002. Mouse and human dendritic cell subtypes. Nat Rev 
Immunol 2:151-161. 
7. Hao, S., J. Yuan, S. Xu, M. A. Munegowda, Y. Deng, J. Gordon, Z. Xing, and J. Xiang. 
2008. Antigen specificity acquisition of adoptive CD4+ regulatory T cells via acquired 
peptide-MHC class I complexes. J Immunol 181:2428-2437. 
8. Takeuchi, S., and M. Furue. 2007. Dendritic cells: ontogeny. Allergol Int 56:215-223. 
9. Ohteki, T. 2007. The dynamics of dendritic cell: mediated innate immune regulation. 
Allergol Int 56:209-214. 
10. Vremec, D., J. Pooley, H. Hochrein, L. Wu, and K. Shortman. 2000. CD4 and CD8 
expression by dendritic cell subtypes in mouse thymus and spleen. J Immunol 164:2978-
2986. 
11. Anjuere, F., P. Martin, I. Ferrero, M. L. Fraga, G. M. del Hoyo, N. Wright, and C. 
Ardavin. 1999. Definition of dendritic cell subpopulations present in the spleen, Peyer's 
patches, lymph nodes, and skin of the mouse. Blood 93:590-598. 
12. Vremec, D., and K. Shortman. 1997. Dendritic cell subtypes in mouse lymphoid organs: 
cross-correlation of surface markers, changes with incubation, and differences among 
thymus, spleen, and lymph nodes. J Immunol 159:565-573. 
13. Watowich, S. S., and Y. J. Liu. 2010. Mechanisms regulating dendritic cell specification 
and development. Immunol Rev 238:76-92. 
33 
 
14. Kronin, V., D. Vremec, K. Winkel, B. J. Classon, R. G. Miller, T. W. Mak, K. Shortman, 
and G. Suss. 1997. Are CD8+ dendritic cells (DC) veto cells? The role of CD8 on DC in 
DC development and in the regulation of CD4 and CD8 T cell responses. Int Immunol 
9:1061-1064. 
15. Belz, G. T., G. M. Behrens, C. M. Smith, J. F. Miller, C. Jones, K. Lejon, C. G. Fathman, 
S. N. Mueller, K. Shortman, F. R. Carbone, and W. R. Heath. 2002. The CD8alpha(+) 
dendritic cell is responsible for inducing peripheral self-tolerance to tissue-associated 
antigens. J Exp Med 196:1099-1104. 
16. den Haan, J. M., S. M. Lehar, and M. J. Bevan. 2000. CD8(+) but not CD8(-) dendritic 
cells cross-prime cytotoxic T cells in vivo. J Exp Med 192:1685-1696. 
17. Maldonado-Lopez, R., T. De Smedt, P. Michel, J. Godfroid, B. Pajak, C. Heirman, K. 
Thielemans, O. Leo, J. Urbain, and M. Moser. 1999. CD8alpha+ and CD8alpha- 
subclasses of dendritic cells direct the development of distinct T helper cells in vivo. J 
Exp Med 189:587-592. 
18. Yasumi, T., K. Katamura, T. Yoshioka, T. A. Meguro, R. Nishikomori, T. Heike, M. 
Inobe, S. Kon, T. Uede, and T. Nakahata. 2004. Differential requirement for the CD40-
CD154 costimulatory pathway during Th cell priming by CD8 alpha+ and CD8 alpha- 
murine dendritic cell subsets. J Immunol 172:4826-4833. 
19. Zhang, X., H. Huang, J. Yuan, D. Sun, W. S. Hou, J. Gordon, and J. Xiang. 2005. CD4-8- 
dendritic cells prime CD4+ T regulatory 1 cells to suppress antitumor immunity. J 
Immunol 175:2931-2937. 
20. Henri, S., D. Vremec, A. Kamath, J. Waithman, S. Williams, C. Benoist, K. Burnham, S. 
Saeland, E. Handman, and K. Shortman. 2001. The dendritic cell populations of mouse 
lymph nodes. J Immunol 167:741-748. 
21. Merad, M., L. Fong, J. Bogenberger, and E. G. Engleman. 2000. Differentiation of 
myeloid dendritic cells into CD8alpha-positive dendritic cells in vivo. Blood 96:1865-
1872. 
22. Lutz, M. B., and G. Schuler. 2002. Immature, semi-mature and fully mature dendritic 
cells: which signals induce tolerance or immunity? Trends Immunol 23:445-449. 
23. Galibert, L., C. R. Maliszewski, and S. Vandenabeele. 2001. Plasmacytoid monocytes/T 
cells: a dendritic cell lineage? Semin Immunol 13:283-289. 
34 
 
24. Grouard, G., M. C. Rissoan, L. Filgueira, I. Durand, J. Banchereau, and Y. J. Liu. 1997. 
The enigmatic plasmacytoid T cells develop into dendritic cells with interleukin (IL)-3 
and CD40-ligand. J Exp Med 185:1101-1111. 
25. Olweus, J., A. BitMansour, R. Warnke, P. A. Thompson, J. Carballido, L. J. Picker, and 
F. Lund-Johansen. 1997. Dendritic cell ontogeny: a human dendritic cell lineage of 
myeloid origin. Proc Natl Acad Sci U S A 94:12551-12556. 
26. Nakano, H., M. Yanagita, and M. D. Gunn. 2001. CD11c(+)B220(+)Gr-1(+) cells in 
mouse lymph nodes and spleen display characteristics of plasmacytoid dendritic cells. J 
Exp Med 194:1171-1178. 
27. Heil, F., H. Hemmi, H. Hochrein, F. Ampenberger, C. Kirschning, S. Akira, G. Lipford, 
H. Wagner, and S. Bauer. 2004. Species-specific recognition of single-stranded RNA via 
toll-like receptor 7 and 8. Science 303:1526-1529. 
28. Hemmi, H., O. Takeuchi, T. Kawai, T. Kaisho, S. Sato, H. Sanjo, M. Matsumoto, K. 
Hoshino, H. Wagner, K. Takeda, and S. Akira. 2000. A Toll-like receptor recognizes 
bacterial DNA. Nature 408:740-745. 
29. Uematsu, S., S. Sato, M. Yamamoto, T. Hirotani, H. Kato, F. Takeshita, M. Matsuda, C. 
Coban, K. J. Ishii, T. Kawai, O. Takeuchi, and S. Akira. 2005. Interleukin-1 receptor-
associated kinase-1 plays an essential role for Toll-like receptor (TLR)7- and TLR9-
mediated interferon-{alpha} induction. J Exp Med 201:915-923. 
30. Martin, P., G. M. Del Hoyo, F. Anjuere, C. F. Arias, H. H. Vargas, L. A. Fernandez, V. 
Parrillas, and C. Ardavin. 2002. Characterization of a new subpopulation of mouse 
CD8alpha+ B220+ dendritic cells endowed with type 1 interferon production capacity 
and tolerogenic potential. Blood 100:383-390. 
31. Brawand, P., D. R. Fitzpatrick, B. W. Greenfield, K. Brasel, C. R. Maliszewski, and T. 
De Smedt. 2002. Murine plasmacytoid pre-dendritic cells generated from Flt3 ligand-
supplemented bone marrow cultures are immature APCs. J Immunol 169:6711-6719. 
32. Winzler, C., P. Rovere, M. Rescigno, F. Granucci, G. Penna, L. Adorini, V. S. 
Zimmermann, J. Davoust, and P. Ricciardi-Castagnoli. 1997. Maturation stages of mouse 
dendritic cells in growth factor-dependent long-term cultures. J Exp Med 185:317-328. 
33. Reis e Sousa, C. 2006. Dendritic cells in a mature age. Nat Rev Immunol 6:476-483. 
35 
 
34. Amsen, D., J. M. Blander, G. R. Lee, K. Tanigaki, T. Honjo, and R. A. Flavell. 2004. 
Instruction of distinct CD4 T helper cell fates by different notch ligands on antigen-
presenting cells. Cell 117:515-526. 
35. Kumanogoh, A., T. Shikina, K. Suzuki, S. Uematsu, K. Yukawa, S. Kashiwamura, H. 
Tsutsui, M. Yamamoto, H. Takamatsu, E. P. Ko-Mitamura, N. Takegahara, S. 
Marukawa, I. Ishida, H. Morishita, D. V. Prasad, M. Tamura, M. Mizui, T. Toyofuku, S. 
Akira, K. Takeda, M. Okabe, and H. Kikutani. 2005. Nonredundant roles of Sema4A in 
the immune system: defective T cell priming and Th1/Th2 regulation in Sema4A-
deficient mice. Immunity 22:305-316. 
36. Wahl, S. M. 2007. Transforming growth factor-beta: innately bipolar. Curr Opin 
Immunol 19:55-62. 
37. Mosmann, T. R., and R. L. Coffman. 1989. TH1 and TH2 cells: different patterns of 
lymphokine secretion lead to different functional properties. Annu Rev Immunol 7:145-
173. 
38. Waaga, A. M., M. Gasser, J. E. Kist-van Holthe, N. Najafian, A. Muller, J. P. Vella, K. L. 
Womer, A. Chandraker, S. J. Khoury, and M. H. Sayegh. 2001. Regulatory functions of 
self-restricted MHC class II allopeptide-specific Th2 clones in vivo. J Clin Invest 
107:909-916. 
39. Ansel, K. M., D. U. Lee, and A. Rao. 2003. An epigenetic view of helper T cell 
differentiation. Nat Immunol 4:616-623. 
40. O'Shea, J. J., and W. E. Paul. 2010. Mechanisms underlying lineage commitment and 
plasticity of helper CD4+ T cells. Science 327:1098-1102. 
41. Szabo, S. J., A. S. Dighe, U. Gubler, and K. M. Murphy. 1997. Regulation of the 
interleukin (IL)-12R beta 2 subunit expression in developing T helper 1 (Th1) and Th2 
cells. J Exp Med 185:817-824. 
42. Szabo, S. J., B. M. Sullivan, C. Stemmann, A. R. Satoskar, B. P. Sleckman, and L. H. 
Glimcher. 2002. Distinct effects of T-bet in TH1 lineage commitment and IFN-gamma 
production in CD4 and CD8 T cells. Science 295:338-342. 
43. Mullen, A. C., A. S. Hutchins, F. A. High, H. W. Lee, K. J. Sykes, L. A. Chodosh, and S. 
L. Reiner. 2002. Hlx is induced by and genetically interacts with T-bet to promote 
heritable T(H)1 gene induction. Nat Immunol 3:652-658. 
36 
 
44. Smeltz, R. B., J. Chen, R. Ehrhardt, and E. M. Shevach. 2002. Role of IFN-gamma in 
Th1 differentiation: IFN-gamma regulates IL-18R alpha expression by preventing the 
negative effects of IL-4 and by inducing/maintaining IL-12 receptor beta 2 expression. J 
Immunol 168:6165-6172. 
45. Sallusto, F., D. Lenig, C. R. Mackay, and A. Lanzavecchia. 1998. Flexible programs of 
chemokine receptor expression on human polarized T helper 1 and 2 lymphocytes. J Exp 
Med 187:875-883. 
46. Gran, B., G. X. Zhang, S. Yu, J. Li, X. H. Chen, E. S. Ventura, M. Kamoun, and A. 
Rostami. 2002. IL-12p35-deficient mice are susceptible to experimental autoimmune 
encephalomyelitis: evidence for redundancy in the IL-12 system in the induction of 
central nervous system autoimmune demyelination. J Immunol 169:7104-7110. 
47. Constantinescu, C. S., M. Wysocka, B. Hilliard, E. S. Ventura, E. Lavi, G. Trinchieri, and 
A. Rostami. 1998. Antibodies against IL-12 prevent superantigen-induced and 
spontaneous relapses of experimental autoimmune encephalomyelitis. J Immunol 
161:5097-5104. 
48. Cua, D. J., J. Sherlock, Y. Chen, C. A. Murphy, B. Joyce, B. Seymour, L. Lucian, W. To, 
S. Kwan, T. Churakova, S. Zurawski, M. Wiekowski, S. A. Lira, D. Gorman, R. A. 
Kastelein, and J. D. Sedgwick. 2003. Interleukin-23 rather than interleukin-12 is the 
critical cytokine for autoimmune inflammation of the brain. Nature 421:744-748. 
49. Murphy, C. A., C. L. Langrish, Y. Chen, W. Blumenschein, T. McClanahan, R. A. 
Kastelein, J. D. Sedgwick, and D. J. Cua. 2003. Divergent pro- and antiinflammatory 
roles for IL-23 and IL-12 in joint autoimmune inflammation. J Exp Med 198:1951-1957. 
50. Bending, D., H. De la Pena, M. Veldhoen, J. M. Phillips, C. Uyttenhove, B. Stockinger, 
and A. Cooke. 2009. Highly purified Th17 cells from BDC2.5NOD mice convert into 
Th1-like cells in NOD/SCID recipient mice. J Clin Invest 119:565-572. 
51. Ankathatti Munegowda, M., Y. Deng, R. Chibbar, Q. Xu, A. Freywald, S. J. Mulligan, S. 
van Drunen Littel-van den Hurk, D. Sun, S. Xiong, and J. Xiang. 2011. A Distinct Role 
of CD4(+) Th17- and Th17-Stimulated CD8(+) CTL in the Pathogenesis of Type 1 
Diabetes and Experimental Autoimmune Encephalomyelitis. J Clin Immunol 31:811-826. 
37 
 
52. Umeshappa, C. S., H. Huang, Y. Xie, Y. Wei, S. J. Mulligan, Y. Deng, and J. Xiang. 
2009. CD4+ Th-APC with acquired peptide/MHC class I and II complexes stimulate type 
1 helper CD4+ and central memory CD8+ T cell responses. J Immunol 182:193-206. 
53. Muranski, P., A. Boni, P. A. Antony, L. Cassard, K. R. Irvine, A. Kaiser, C. M. Paulos, 
D. C. Palmer, C. E. Touloukian, K. Ptak, L. Gattinoni, C. Wrzesinski, C. S. Hinrichs, K. 
W. Kerstann, L. Feigenbaum, C. C. Chan, and N. P. Restifo. 2008. Tumor-specific Th17-
polarized cells eradicate large established melanoma. Blood 112:362-373. 
54. Romagnani, S. 1995. Biology of human TH1 and TH2 cells. J Clin Immunol 15:121-129. 
55. Fallon, P. G., and N. E. Mangan. 2007. Suppression of TH2-type allergic reactions by 
helminth infection. Nat Rev Immunol 7:220-230. 
56. Gordon, J. R., F. Li, A. Nayyar, J. Xiang, and X. Zhang. 2005. CD8 alpha+, but not CD8 
alpha-, dendritic cells tolerize Th2 responses via contact-dependent and -independent 
mechanisms, and reverse airway hyperresponsiveness, Th2, and eosinophil responses in a 
mouse model of asthma. J Immunol 175:1516-1522. 
57. Kopf, M., G. Le Gros, M. Bachmann, M. C. Lamers, H. Bluethmann, and G. Kohler. 
1993. Disruption of the murine IL-4 gene blocks Th2 cytokine responses. Nature 
362:245-248. 
58. Coffman, R. L., B. W. Seymour, S. Hudak, J. Jackson, and D. Rennick. 1989. Antibody 
to interleukin-5 inhibits helminth-induced eosinophilia in mice. Science 245:308-310. 
59. Zhu, J., B. Min, J. Hu-Li, C. J. Watson, A. Grinberg, Q. Wang, N. Killeen, J. F. Urban, 
Jr., L. Guo, and W. E. Paul. 2004. Conditional deletion of Gata3 shows its essential 
function in T(H)1-T(H)2 responses. Nat Immunol 5:1157-1165. 
60. Zhu, J., J. Cote-Sierra, L. Guo, and W. E. Paul. 2003. Stat5 activation plays a critical role 
in Th2 differentiation. Immunity 19:739-748. 
61. Yasumi, T., K. Katamura, I. Okafuji, T. Yoshioka, T. A. Meguro, R. Nishikomori, T. 
Kusunoki, T. Heike, and T. Nakahata. 2005. Limited ability of antigen-specific Th1 
responses to inhibit Th2 cell development in vivo. J Immunol 174:1325-1331. 
62. Fort, M. M., J. Cheung, D. Yen, J. Li, S. M. Zurawski, S. Lo, S. Menon, T. Clifford, B. 
Hunte, R. Lesley, T. Muchamuel, S. D. Hurst, G. Zurawski, M. W. Leach, D. M. 
Gorman, and D. M. Rennick. 2001. IL-25 induces IL-4, IL-5, and IL-13 and Th2-
associated pathologies in vivo. Immunity 15:985-995. 
38 
 
63. Tamachi, T., Y. Maezawa, K. Ikeda, S. Kagami, M. Hatano, Y. Seto, A. Suto, K. Suzuki, 
N. Watanabe, Y. Saito, T. Tokuhisa, I. Iwamoto, and H. Nakajima. 2006. IL-25 enhances 
allergic airway inflammation by amplifying a TH2 cell-dependent pathway in mice. J 
Allergy Clin Immunol 118:606-614. 
64. Helmby, H., and R. K. Grencis. 2004. Interleukin 1 plays a major role in the development 
of Th2-mediated immunity. Eur J Immunol 34:3674-3681. 
65. Larche, M., C. A. Akdis, and R. Valenta. 2006. Immunological mechanisms of allergen-
specific immunotherapy. Nat Rev Immunol 6:761-771. 
66. Akdis, M., and C. A. Akdis. 2009. Therapeutic manipulation of immune tolerance in 
allergic disease. Nat Rev Drug Discov 8:645-660. 
67. Lukacs, N. W., and D. L. Boros. 1993. Lymphokine regulation of granuloma formation in 
murine schistosomiasis mansoni. Clin Immunol Immunopathol 68:57-63. 
68. Oswald, I. P., P. Caspar, D. Jankovic, T. A. Wynn, E. J. Pearce, and A. Sher. 1994. IL-12 
inhibits Th2 cytokine responses induced by eggs of Schistosoma mansoni. J Immunol 
153:1707-1713. 
69. Boros, D. L., and J. R. Whitfield. 1999. Enhanced Th1 and dampened Th2 responses 
synergize to inhibit acute granulomatous and fibrotic responses in murine schistosomiasis 
mansoni. Infect Immun 67:1187-1193. 
70. Chensue, S. W., K. S. Warmington, J. Ruth, P. M. Lincoln, and S. L. Kunkel. 1994. 
Cross-regulatory role of interferon-gamma (IFN-gamma), IL-4 and IL-10 in schistosome 
egg granuloma formation: in vivo regulation of Th activity and inflammation. Clin Exp 
Immunol 98:395-400. 
71. Sher, A., D. Fiorentino, P. Caspar, E. Pearce, and T. Mosmann. 1991. Production of IL-
10 by CD4+ T lymphocytes correlates with down-regulation of Th1 cytokine synthesis in 
helminth infection. J Immunol 147:2713-2716. 
72. Akkoc, T., P. J. de Koning, B. Ruckert, I. Barlan, M. Akdis, and C. A. Akdis. 2008. 
Increased activation-induced cell death of high IFN-gamma-producing T(H)1 cells as a 
mechanism of T(H)2 predominance in atopic diseases. J Allergy Clin Immunol 121:652-
658 e651. 
39 
 
73. McKee, A. S., and E. J. Pearce. 2004. CD25+CD4+ cells contribute to Th2 polarization 
during helminth infection by suppressing Th1 response development. J Immunol 
173:1224-1231. 
74. Erdmann, A. A., U. Jung, J. E. Foley, Y. Toda, and D. H. Fowler. 2004. Co-
stimulated/Tc2 cells abrogate murine marrow graft rejection. Biol Blood Marrow 
Transplant 10:604-613. 
75. Radhakrishnan, S., K. R. Wiehagen, V. Pulko, V. Van Keulen, W. A. Faubion, K. L. 
Knutson, and L. R. Pease. 2007. Induction of a Th1 Response from Th2-Polarized T 
Cells by Activated Dendritic Cells: Dependence on TCR:Peptide-MHC Interaction, 
ICAM-1, IL-12, and IFN-{gamma}. J Immunol 178:3583-3592. 
76. Fernando, G. J., T. J. Stewart, R. W. Tindle, and I. H. Frazer. 1998. Th2-type CD4+ cells 
neither enhance nor suppress antitumor CTL activity in a mouse tumor model. J Immunol 
161:2421-2427. 
77. Doan, T., K. A. Herd, P. F. Lambert, G. J. Fernando, M. D. Street, and R. W. Tindle. 
2000. Peripheral tolerance to human papillomavirus E7 oncoprotein occurs by cross-
tolerization, is largely Th-2-independent, and is broken by dendritic cell immunization. 
Cancer Res 60:2810-2815. 
78. Mattes, J., M. Hulett, W. Xie, S. Hogan, M. E. Rothenberg, P. Foster, and C. Parish. 
2003. Immunotherapy of cytotoxic T cell-resistant tumors by T helper 2 cells: an eotaxin 
and STAT6-dependent process. J Exp Med 197:387-393. 
79. Nishimura, T., K. Iwakabe, M. Sekimoto, Y. Ohmi, T. Yahata, M. Nakui, T. Sato, S. 
Habu, H. Tashiro, M. Sato, and A. Ohta. 1999. Distinct role of antigen-specific T helper 
type 1 (Th1) and Th2 cells in tumor eradication in vivo. J Exp Med 190:617-627. 
80. Modesti, A., L. Masuelli, A. Modica, G. D'Orazi, S. Scarpa, M. C. Bosco, and G. Forni. 
1993. Ultrastructural evidence of the mechanisms responsible for interleukin-4-activated 
rejection of a spontaneous murine adenocarcinoma. Int J Cancer 53:988-993. 
81. Tepper, R. I., R. L. Coffman, and P. Leder. 1992. An eosinophil-dependent mechanism 
for the antitumor effect of interleukin-4. Science 257:548-551. 
82. Pericle, F., M. Giovarelli, M. P. Colombo, G. Ferrari, P. Musiani, A. Modesti, F. Cavallo, 
F. Di Pierro, F. Novelli, and G. Forni. 1994. An efficient Th2-type memory follows 
40 
 
CD8+ lymphocyte-driven and eosinophil-mediated rejection of a spontaneous mouse 
mammary adenocarcinoma engineered to release IL-4. J Immunol 153:5659-5673. 
83. Lebel-Binay, S., B. Laguerre, F. Quintin-Colonna, H. Conjeaud, M. Magazin, B. Miloux, 
F. Pecceu, D. Caput, P. Ferrara, and D. Fradelizi. 1995. Experimental gene therapy of 
cancer using tumor cells engineered to secrete interleukin-13. Eur J Immunol 25:2340-
2348. 
84. Ma, H. L., M. J. Whitters, B. A. Jacobson, D. D. Donaldson, M. Collins, and K. Dunussi-
Joannopoulos. 2004. Tumor cells secreting IL-13 but not IL-13Ralpha2 fusion protein 
have reduced tumorigenicity in vivo. Int Immunol 16:1009-1017. 
85. Akdis, M., J. Verhagen, A. Taylor, F. Karamloo, C. Karagiannidis, R. Crameri, S. 
Thunberg, G. Deniz, R. Valenta, H. Fiebig, C. Kegel, R. Disch, C. B. Schmidt-Weber, K. 
Blaser, and C. A. Akdis. 2004. Immune responses in healthy and allergic individuals are 
characterized by a fine balance between allergen-specific T regulatory 1 and T helper 2 
cells. J Exp Med 199:1567-1575. 
86. Duffy, D., C. P. Yang, A. Heath, P. Garside, and E. B. Bell. 2006. Naive T-cell receptor 
transgenic T cells help memory B cells produce antibody. Immunology 119:376-384. 
87. Yu, D., and C. G. Vinuesa. 2010. The elusive identity of T follicular helper cells. Trends 
Immunol 31:377-383. 
88. Vinuesa, C. G., S. G. Tangye, B. Moser, and C. R. Mackay. 2005. Follicular B helper T 
cells in antibody responses and autoimmunity. Nat Rev Immunol 5:853-865. 
89. Ansel, K. M., L. J. McHeyzer-Williams, V. N. Ngo, M. G. McHeyzer-Williams, and J. G. 
Cyster. 1999. In vivo-activated CD4 T cells upregulate CXC chemokine receptor 5 and 
reprogram their response to lymphoid chemokines. J Exp Med 190:1123-1134. 
90. Nurieva, R. I., Y. Chung, G. J. Martinez, X. O. Yang, S. Tanaka, T. D. Matskevitch, Y. 
H. Wang, and C. Dong. 2009. Bcl6 mediates the development of T follicular helper cells. 
Science 325:1001-1005. 
91. Yu, D., S. Rao, L. M. Tsai, S. K. Lee, Y. He, E. L. Sutcliffe, M. Srivastava, M. 
Linterman, L. Zheng, N. Simpson, J. I. Ellyard, I. A. Parish, C. S. Ma, Q. J. Li, C. R. 
Parish, C. R. Mackay, and C. G. Vinuesa. 2009. The transcriptional repressor Bcl-6 
directs T follicular helper cell lineage commitment. Immunity 31:457-468. 
41 
 
92. Johnston, R. J., A. C. Poholek, D. DiToro, I. Yusuf, D. Eto, B. Barnett, A. L. Dent, J. 
Craft, and S. Crotty. 2009. Bcl6 and Blimp-1 are reciprocal and antagonistic regulators of 
T follicular helper cell differentiation. Science 325:1006-1010. 
93. Linterman, M. A., L. Beaton, D. Yu, R. R. Ramiscal, M. Srivastava, J. J. Hogan, N. K. 
Verma, M. J. Smyth, R. J. Rigby, and C. G. Vinuesa. 2010. IL-21 acts directly on B cells 
to regulate Bcl-6 expression and germinal center responses. J Exp Med 207:353-363. 
94. Yusuf, I., R. Kageyama, L. Monticelli, R. J. Johnston, D. Ditoro, K. Hansen, B. Barnett, 
and S. Crotty. 2010. Germinal center T follicular helper cell IL-4 production is dependent 
on signaling lymphocytic activation molecule receptor (CD150). J Immunol 185:190-202. 
95. Bettelli, E., M. Oukka, and V. K. Kuchroo. 2007. T(H)-17 cells in the circle of immunity 
and autoimmunity. Nat Immunol 8:345-350. 
96. Mathur, A. N., H. C. Chang, D. G. Zisoulis, G. L. Stritesky, Q. Yu, J. T. O'Malley, R. 
Kapur, D. E. Levy, G. S. Kansas, and M. H. Kaplan. 2007. Stat3 and Stat4 direct 
development of IL-17-secreting Th cells. J Immunol 178:4901-4907. 
97. Kimura, A., T. Naka, and T. Kishimoto. 2007. IL-6-dependent and -independent 
pathways in the development of interleukin 17-producing T helper cells. Proc Natl Acad 
Sci U S A 104:12099-12104. 
98. Batten, M., J. Li, S. Yi, N. M. Kljavin, D. M. Danilenko, S. Lucas, J. Lee, F. J. de 
Sauvage, and N. Ghilardi. 2006. Interleukin 27 limits autoimmune encephalomyelitis by 
suppressing the development of interleukin 17-producing T cells. Nat Immunol 7:929-
936. 
99. Volpe, E., N. Servant, R. Zollinger, S. I. Bogiatzi, P. Hupe, E. Barillot, and V. Soumelis. 
2008. A critical function for transforming growth factor-beta, interleukin 23 and 
proinflammatory cytokines in driving and modulating human T(H)-17 responses. Nat 
Immunol 9:650-657. 
100. Santarlasci, V., L. Maggi, M. Capone, F. Frosali, V. Querci, R. De Palma, F. Liotta, L. 
Cosmi, E. Maggi, S. Romagnani, and F. Annunziato. 2009. TGF-beta indirectly favors 
the development of human Th17 cells by inhibiting Th1 cells. Eur J Immunol 39:207-
215. 
42 
 
101. Das, J., G. Ren, L. Zhang, A. I. Roberts, X. Zhao, A. L. Bothwell, L. Van Kaer, Y. Shi, 
and G. Das. 2009. Transforming growth factor beta is dispensable for the molecular 
orchestration of Th17 cell differentiation. J Exp Med 206:2407-2416. 
102. Ankathatti Munegowda, M., Y. Deng, S. J. Mulligan, and J. Xiang. 2011. Th17 and 
Th17-stimulated CD8(+) T cells play a distinct role in Th17-induced preventive and 
therapeutic antitumor immunity. Cancer Immunol Immunother 60:1473-1484. 
103. Laurence, A., C. M. Tato, T. S. Davidson, Y. Kanno, Z. Chen, Z. Yao, R. B. Blank, F. 
Meylan, R. Siegel, L. Hennighausen, E. M. Shevach, and J. O'Shea J. 2007. Interleukin-2 
signaling via STAT5 constrains T helper 17 cell generation. Immunity 26:371-381. 
104. Brustle, A., S. Heink, M. Huber, C. Rosenplanter, C. Stadelmann, P. Yu, E. Arpaia, T. W. 
Mak, T. Kamradt, and M. Lohoff. 2007. The development of inflammatory T(H)-17 cells 
requires interferon-regulatory factor 4. Nat Immunol 8:958-966. 
105. Rangachari, M., N. Mauermann, R. R. Marty, S. Dirnhofer, M. O. Kurrer, V. 
Komnenovic, J. M. Penninger, and U. Eriksson. 2006. T-bet negatively regulates 
autoimmune myocarditis by suppressing local production of interleukin 17. J Exp Med 
203:2009-2019. 
106. Kimura, A., T. Naka, K. Nohara, Y. Fujii-Kuriyama, and T. Kishimoto. 2008. Aryl 
hydrocarbon receptor regulates Stat1 activation and participates in the development of 
Th17 cells. Proc Natl Acad Sci U S A 105:9721-9726. 
107. Weaver, C. T., R. D. Hatton, P. R. Mangan, and L. E. Harrington. 2007. IL-17 family 
cytokines and the expanding diversity of effector T cell lineages. Annu Rev Immunol 
25:821-852. 
108. Nakae, S., Y. Iwakura, H. Suto, and S. J. Galli. 2007. Phenotypic differences between 
Th1 and Th17 cells and negative regulation of Th1 cell differentiation by IL-17. J Leukoc 
Biol 81:1258-1268. 
109. Krakowski, M., and T. Owens. 1996. Interferon-gamma confers resistance to 
experimental allergic encephalomyelitis. Eur J Immunol 26:1641-1646. 
110. Langrish, C. L., Y. Chen, W. M. Blumenschein, J. Mattson, B. Basham, J. D. Sedgwick, 
T. McClanahan, R. A. Kastelein, and D. J. Cua. 2005. IL-23 drives a pathogenic T cell 
population that induces autoimmune inflammation. J Exp Med 201:233-240. 
43 
 
111. Tzartos, J. S., M. A. Friese, M. J. Craner, J. Palace, J. Newcombe, M. M. Esiri, and L. 
Fugger. 2008. Interleukin-17 production in central nervous system-infiltrating T cells and 
glial cells is associated with active disease in multiple sclerosis. Am J Pathol 172:146-
155. 
112. Park, H., Z. Li, X. O. Yang, S. H. Chang, R. Nurieva, Y. H. Wang, Y. Wang, L. Hood, Z. 
Zhu, Q. Tian, and C. Dong. 2005. A distinct lineage of CD4 T cells regulates tissue 
inflammation by producing interleukin 17. Nat Immunol 6:1133-1141. 
113. Zhang, B., G. Rong, H. Wei, M. Zhang, J. Bi, L. Ma, X. Xue, G. Wei, X. Liu, and G. 
Fang. 2008. The prevalence of Th17 cells in patients with gastric cancer. Biochem 
Biophys Res Commun 374:533-537. 
114. Sfanos, K. S., T. C. Bruno, C. H. Maris, L. Xu, C. J. Thoburn, A. M. DeMarzo, A. K. 
Meeker, W. B. Isaacs, and C. G. Drake. 2008. Phenotypic analysis of prostate-infiltrating 
lymphocytes reveals TH17 and Treg skewing. Clin Cancer Res 14:3254-3261. 
115. Benchetrit, F., A. Ciree, V. Vives, G. Warnier, A. Gey, C. Sautes-Fridman, F. Fossiez, N. 
Haicheur, W. H. Fridman, and E. Tartour. 2002. Interleukin-17 inhibits tumor cell growth 
by means of a T-cell-dependent mechanism. Blood 99:2114-2121. 
116. Hirahara, N., Y. Nio, S. Sasaki, Y. Minari, M. Takamura, C. Iguchi, M. Dong, K. 
Yamasawa, and K. Tamura. 2001. Inoculation of human interleukin-17 gene-transfected 
Meth-A fibrosarcoma cells induces T cell-dependent tumor-specific immunity in mice. 
Oncology 61:79-89. 
117. Numasaki, M., M. Watanabe, T. Suzuki, H. Takahashi, A. Nakamura, F. McAllister, T. 
Hishinuma, J. Goto, M. T. Lotze, J. K. Kolls, and H. Sasaki. 2005. IL-17 enhances the net 
angiogenic activity and in vivo growth of human non-small cell lung cancer in SCID 
mice through promoting CXCR-2-dependent angiogenesis. J Immunol 175:6177-6189. 
118. Numasaki, M., J. Fukushi, M. Ono, S. K. Narula, P. J. Zavodny, T. Kudo, P. D. Robbins, 
H. Tahara, and M. T. Lotze. 2003. Interleukin-17 promotes angiogenesis and tumor 
growth. Blood 101:2620-2627. 
119. Spolski, R., and W. J. Leonard. 2008. Interleukin-21: basic biology and implications for 
cancer and autoimmunity. Annu Rev Immunol 26:57-79. 
120. Kottke, T., L. Sanchez-Perez, R. M. Diaz, J. Thompson, H. Chong, K. Harrington, S. K. 
Calderwood, J. Pulido, N. Georgopoulos, P. Selby, A. Melcher, and R. Vile. 2007. 
44 
 
Induction of hsp70-mediated Th17 autoimmunity can be exploited as immunotherapy for 
metastatic prostate cancer. Cancer Res 67:11970-11979. 
121. Kryczek, I., S. Wei, W. Szeliga, L. Vatan, and W. Zou. 2009. Endogenous IL-17 
contributes to reduced tumor growth and metastasis. Blood 114:357-359. 
122. Khader, S. A., G. K. Bell, J. E. Pearl, J. J. Fountain, J. Rangel-Moreno, G. E. Cilley, F. 
Shen, S. M. Eaton, S. L. Gaffen, S. L. Swain, R. M. Locksley, L. Haynes, T. D. Randall, 
and A. M. Cooper. 2007. IL-23 and IL-17 in the establishment of protective pulmonary 
CD4+ T cell responses after vaccination and during Mycobacterium tuberculosis 
challenge. Nat Immunol 8:369-377. 
123. Sakaguchi, S., T. Yamaguchi, T. Nomura, and M. Ono. 2008. Regulatory T cells and 
immune tolerance. Cell 133:775-787. 
124. Yamaguchi, T., and S. Sakaguchi. 2006. Regulatory T cells in immune surveillance and 
treatment of cancer. Semin Cancer Biol 16:115-123. 
125. Bennett, C. L., J. Christie, F. Ramsdell, M. E. Brunkow, P. J. Ferguson, L. Whitesell, T. 
E. Kelly, F. T. Saulsbury, P. F. Chance, and H. D. Ochs. 2001. The immune 
dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome (IPEX) is caused by 
mutations of FOXP3. Nat Genet 27:20-21. 
126. Brunkow, M. E., E. W. Jeffery, K. A. Hjerrild, B. Paeper, L. B. Clark, S. A. Yasayko, J. 
E. Wilkinson, D. Galas, S. F. Ziegler, and F. Ramsdell. 2001. Disruption of a new 
forkhead/winged-helix protein, scurfin, results in the fatal lymphoproliferative disorder of 
the scurfy mouse. Nat Genet 27:68-73. 
127. Sakaguchi, S., and F. Powrie. 2007. Emerging challenges in regulatory T cell function 
and biology. Science 317:627-629. 
128. Chen, X., S. Vodanovic-Jankovic, B. Johnson, M. Keller, R. Komorowski, and W. R. 
Drobyski. 2007. Absence of regulatory T-cell control of TH1 and TH17 cells is 
responsible for the autoimmune-mediated pathology in chronic graft-versus-host disease. 
Blood 110:3804-3813. 
129. Pacholczyk, R., H. Ignatowicz, P. Kraj, and L. Ignatowicz. 2006. Origin and T cell 
receptor diversity of Foxp3+CD4+CD25+ T cells. Immunity 25:249-259. 
45 
 
130. Zhou, J., T. Ding, W. Pan, L. Y. Zhu, L. Li, and L. Zheng. 2009. Increased intratumoral 
regulatory T cells are related to intratumoral macrophages and poor prognosis in 
hepatocellular carcinoma patients. Int J Cancer 125:1640-1648. 
131. Sakaguchi, S., N. Sakaguchi, J. Shimizu, S. Yamazaki, T. Sakihama, M. Itoh, Y. 
Kuniyasu, T. Nomura, M. Toda, and T. Takahashi. 2001. Immunologic tolerance 
maintained by CD25+ CD4+ regulatory T cells: their common role in controlling 
autoimmunity, tumor immunity, and transplantation tolerance. Immunol Rev 182:18-32. 
132. Ziegler, S. F. 2006. FOXP3: of mice and men. Annu Rev Immunol 24:209-226. 
133. Lin, W., D. Haribhai, L. M. Relland, N. Truong, M. R. Carlson, C. B. Williams, and T. 
A. Chatila. 2007. Regulatory T cell development in the absence of functional Foxp3. Nat 
Immunol 8:359-368. 
134. Feuerer, M., J. A. Hill, D. Mathis, and C. Benoist. 2009. Foxp3+ regulatory T cells: 
differentiation, specification, subphenotypes. Nat Immunol 10:689-695. 
135. Gregori, S., D. Tomasoni, V. Pacciani, M. Scirpoli, M. Battaglia, C. F. Magnani, E. 
Hauben, and M. G. Roncarolo. 2010. Differentiation of type 1 T regulatory cells (Tr1) by 
tolerogenic DC-10 requires the IL-10-dependent ILT4/HLA-G pathway. Blood 116:935-
944. 
136. Ivanov, II, B. S. McKenzie, L. Zhou, C. E. Tadokoro, A. Lepelley, J. J. Lafaille, D. J. 
Cua, and D. R. Littman. 2006. The orphan nuclear receptor RORgammat directs the 
differentiation program of proinflammatory IL-17+ T helper cells. Cell 126:1121-1133. 
137. Manel, N., D. Unutmaz, and D. R. Littman. 2008. The differentiation of human T(H)-17 
cells requires transforming growth factor-beta and induction of the nuclear receptor 
RORgammat. Nat Immunol 9:641-649. 
138. Hori, S., T. Nomura, and S. Sakaguchi. 2003. Control of regulatory T cell development 
by the transcription factor Foxp3. Science 299:1057-1061. 
139. Dardalhon, V., A. Awasthi, H. Kwon, G. Galileos, W. Gao, R. A. Sobel, M. Mitsdoerffer, 
T. B. Strom, W. Elyaman, I. C. Ho, S. Khoury, M. Oukka, and V. K. Kuchroo. 2008. IL-
4 inhibits TGF-beta-induced Foxp3+ T cells and, together with TGF-beta, generates IL-
9+ IL-10+ Foxp3(-) effector T cells. Nat Immunol 9:1347-1355. 
46 
 
140. Gessner, A., H. Blum, and M. Rollinghoff. 1993. Differential regulation of IL-9-
expression after infection with Leishmania major in susceptible and resistant mice. 
Immunobiology 189:419-435. 
141. Erpenbeck, V. J., J. M. Hohlfeld, M. Discher, H. Krentel, A. Hagenberg, A. Braun, and 
N. Krug. 2003. Increased expression of interleukin-9 messenger RNA after segmental 
allergen challenge in allergic asthmatics. Chest 123:370S. 
142. Temann, U. A., G. P. Geba, J. A. Rankin, and R. A. Flavell. 1998. Expression of 
interleukin 9 in the lungs of transgenic mice causes airway inflammation, mast cell 
hyperplasia, and bronchial hyperresponsiveness. J Exp Med 188:1307-1320. 
143. Wu, B., C. Huang, M. Kato-Maeda, P. C. Hopewell, C. L. Daley, A. M. Krensky, and C. 
Clayberger. 2008. IL-9 is associated with an impaired Th1 immune response in patients 
with tuberculosis. Clin Immunol 126:202-210. 
144. Veldhoen, M., C. Uyttenhove, J. van Snick, H. Helmby, A. Westendorf, J. Buer, B. 
Martin, C. Wilhelm, and B. Stockinger. 2008. Transforming growth factor-beta 
'reprograms' the differentiation of T helper 2 cells and promotes an interleukin 9-
producing subset. Nat Immunol 9:1341-1346. 
145. Chang, H. C., S. Sehra, R. Goswami, W. Yao, Q. Yu, G. L. Stritesky, R. Jabeen, C. 
McKinley, A. N. Ahyi, L. Han, E. T. Nguyen, M. J. Robertson, N. B. Perumal, R. S. 
Tepper, S. L. Nutt, and M. H. Kaplan. 2010. The transcription factor PU.1 is required for 
the development of IL-9-producing T cells and allergic inflammation. Nat Immunol 
11:527-534. 
146. Elyaman, W., E. M. Bradshaw, C. Uyttenhove, V. Dardalhon, A. Awasthi, J. Imitola, E. 
Bettelli, M. Oukka, J. van Snick, J. C. Renauld, V. K. Kuchroo, and S. J. Khoury. 2009. 
IL-9 induces differentiation of TH17 cells and enhances function of FoxP3+ natural 
regulatory T cells. Proc Natl Acad Sci U S A 106:12885-12890. 
147. Nowak, E. C., C. T. Weaver, H. Turner, S. Begum-Haque, B. Becher, B. Schreiner, A. J. 
Coyle, L. H. Kasper, and R. J. Noelle. 2009. IL-9 as a mediator of Th17-driven 
inflammatory disease. J Exp Med 206:1653-1660. 
148. Acosta-Rodriguez, E. V., L. Rivino, J. Geginat, D. Jarrossay, M. Gattorno, A. 
Lanzavecchia, F. Sallusto, and G. Napolitani. 2007. Surface phenotype and antigenic 
47 
 
specificity of human interleukin 17-producing T helper memory cells. Nat Immunol 
8:639-646. 
149. Dumoutier, L., E. Van Roost, G. Ameye, L. Michaux, and J. C. Renauld. 2000. IL-
TIF/IL-22: genomic organization and mapping of the human and mouse genes. Genes 
Immun 1:488-494. 
150. Trifari, S., C. D. Kaplan, E. H. Tran, N. K. Crellin, and H. Spits. 2009. Identification of a 
human helper T cell population that has abundant production of interleukin 22 and is 
distinct from T(H)-17, T(H)1 and T(H)2 cells. Nat Immunol 10:864-871. 
151. Duhen, T., R. Geiger, D. Jarrossay, A. Lanzavecchia, and F. Sallusto. 2009. Production 
of interleukin 22 but not interleukin 17 by a subset of human skin-homing memory T 
cells. Nat Immunol 10:857-863. 
152. Witte, E., K. Witte, K. Warszawska, R. Sabat, and K. Wolk. 2010. Interleukin-22: a 
cytokine produced by T, NK and NKT cell subsets, with importance in the innate 
immune defense and tissue protection. Cytokine Growth Factor Rev 21:365-379. 
153. Veldhoen, M., K. Hirota, A. M. Westendorf, J. Buer, L. Dumoutier, J. C. Renauld, and B. 
Stockinger. 2008. The aryl hydrocarbon receptor links TH17-cell-mediated autoimmunity 
to environmental toxins. Nature 453:106-109. 
154. Quintana, F. J., A. S. Basso, A. H. Iglesias, T. Korn, M. F. Farez, E. Bettelli, M. 
Caccamo, M. Oukka, and H. L. Weiner. 2008. Control of T(reg) and T(H)17 cell 
differentiation by the aryl hydrocarbon receptor. Nature 453:65-71. 
155. Fujita, H., K. E. Nograles, T. Kikuchi, J. Gonzalez, J. A. Carucci, and J. G. Krueger. 
2009. Human Langerhans cells induce distinct IL-22-producing CD4+ T cells lacking IL-
17 production. Proc Natl Acad Sci U S A 106:21795-21800. 
156. Kagami, S., H. L. Rizzo, J. J. Lee, Y. Koguchi, and A. Blauvelt. 2010. Circulating Th17, 
Th22, and Th1 cells are increased in psoriasis. J Invest Dermatol 130:1373-1383. 
157. Wolk, K., E. Witte, E. Wallace, W. D. Docke, S. Kunz, K. Asadullah, H. D. Volk, W. 
Sterry, and R. Sabat. 2006. IL-22 regulates the expression of genes responsible for 
antimicrobial defense, cellular differentiation, and mobility in keratinocytes: a potential 
role in psoriasis. Eur J Immunol 36:1309-1323. 
48 
 
158. Ikeuchi, H., T. Kuroiwa, N. Hiramatsu, Y. Kaneko, K. Hiromura, K. Ueki, and Y. 
Nojima. 2005. Expression of interleukin-22 in rheumatoid arthritis: potential role as a 
proinflammatory cytokine. Arthritis Rheum 52:1037-1046. 
159. Geboes, L., L. Dumoutier, H. Kelchtermans, E. Schurgers, T. Mitera, J. C. Renauld, and 
P. Matthys. 2009. Proinflammatory role of the Th17 cytokine interleukin-22 in collagen-
induced arthritis in C57BL/6 mice. Arthritis Rheum 60:390-395. 
160. Harrington, L. E., K. M. Janowski, J. R. Oliver, A. J. Zajac, and C. T. Weaver. 2008. 
Memory CD4 T cells emerge from effector T-cell progenitors. Nature 452:356-360. 
161. Hegazy, A. N., M. Peine, C. Helmstetter, I. Panse, A. Frohlich, A. Bergthaler, L. Flatz, D. 
D. Pinschewer, A. Radbruch, and M. Lohning. 2010. Interferons direct Th2 cell 
reprogramming to generate a stable GATA-3(+)T-bet(+) cell subset with combined Th2 
and Th1 cell functions. Immunity 32:116-128. 
162. Murphy, E., K. Shibuya, N. Hosken, P. Openshaw, V. Maino, K. Davis, K. Murphy, and 
A. O'Garra. 1996. Reversibility of T helper 1 and 2 populations is lost after long-term 
stimulation. J Exp Med 183:901-913. 
163. Wei, G., L. Wei, J. Zhu, C. Zang, J. Hu-Li, Z. Yao, K. Cui, Y. Kanno, T. Y. Roh, W. T. 
Watford, D. E. Schones, W. Peng, H. W. Sun, W. E. Paul, J. J. O'Shea, and K. Zhao. 
2009. Global mapping of H3K4me3 and H3K27me3 reveals specificity and plasticity in 
lineage fate determination of differentiating CD4+ T cells. Immunity 30:155-167. 
164. Lee, Y. K., H. Turner, C. L. Maynard, J. R. Oliver, D. Chen, C. O. Elson, and C. T. 
Weaver. 2009. Late developmental plasticity in the T helper 17 lineage. Immunity 30:92-
107. 
165. Martin-Orozco, N., Y. Chung, S. H. Chang, Y. H. Wang, and C. Dong. 2009. Th17 cells 
promote pancreatic inflammation but only induce diabetes efficiently in lymphopenic 
hosts after conversion into Th1 cells. Eur J Immunol 39:216-224. 
166. Martin-Orozco, N., P. Muranski, Y. Chung, X. O. Yang, T. Yamazaki, S. Lu, P. Hwu, N. 
P. Restifo, W. W. Overwijk, and C. Dong. 2009. T helper 17 cells promote cytotoxic T 
cell activation in tumor immunity. Immunity 31:787-798. 
167. Nurieva, R., X. O. Yang, Y. Chung, and C. Dong. 2009. Cutting edge: in vitro generated 
Th17 cells maintain their cytokine expression program in normal but not lymphopenic 
hosts. J Immunol 182:2565-2568. 
49 
 
168. Sharma, M. D., D. Y. Hou, Y. Liu, P. A. Koni, R. Metz, P. Chandler, A. L. Mellor, Y. 
He, and D. H. Munn. 2009. Indoleamine 2,3-dioxygenase controls conversion of Foxp3+ 
Tregs to TH17-like cells in tumor-draining lymph nodes. Blood 113:6102-6111. 
169. Wan, Y. Y., and R. A. Flavell. 2007. Regulatory T-cell functions are subverted and 
converted owing to attenuated Foxp3 expression. Nature 445:766-770. 
170. Xu, L., A. Kitani, I. Fuss, and W. Strober. 2007. Cutting edge: regulatory T cells induce 
CD4+CD25-Foxp3- T cells or are self-induced to become Th17 cells in the absence of 
exogenous TGF-beta. J Immunol 178:6725-6729. 
171. Yang, X. O., R. Nurieva, G. J. Martinez, H. S. Kang, Y. Chung, B. P. Pappu, B. Shah, S. 
H. Chang, K. S. Schluns, S. S. Watowich, X. H. Feng, A. M. Jetten, and C. Dong. 2008. 
Molecular antagonism and plasticity of regulatory and inflammatory T cell programs. 
Immunity 29:44-56. 
172. Komatsu, N., M. E. Mariotti-Ferrandiz, Y. Wang, B. Malissen, H. Waldmann, and S. 
Hori. 2009. Heterogeneity of natural Foxp3+ T cells: a committed regulatory T-cell 
lineage and an uncommitted minor population retaining plasticity. Proc Natl Acad Sci U 
S A 106:1903-1908. 
173. Lochner, M., L. Peduto, M. Cherrier, S. Sawa, F. Langa, R. Varona, D. Riethmacher, M. 
Si-Tahar, J. P. Di Santo, and G. Eberl. 2008. In vivo equilibrium of proinflammatory IL-
17+ and regulatory IL-10+ Foxp3+ RORgamma t+ T cells. J Exp Med 205:1381-1393. 
174. Tartar, D. M., A. M. VanMorlan, X. Wan, F. B. Guloglu, R. Jain, C. L. Haymaker, J. S. 
Ellis, C. M. Hoeman, J. A. Cascio, M. Dhakal, M. Oukka, and H. Zaghouani. 
FoxP3+RORgammat+ T helper intermediates display suppressive function against 
autoimmune diabetes. J Immunol 184:3377-3385. 
175. Torchinsky, M. B., J. Garaude, A. P. Martin, and J. M. Blander. 2009. Innate immune 
recognition of infected apoptotic cells directs T(H)17 cell differentiation. Nature 458:78-
82. 
176. Martin-Fontecha, A., L. L. Thomsen, S. Brett, C. Gerard, M. Lipp, A. Lanzavecchia, and 
F. Sallusto. 2004. Induced recruitment of NK cells to lymph nodes provides IFN-gamma 
for T(H)1 priming. Nat Immunol 5:1260-1265. 
50 
 
177. Hwang, E. S., S. J. Szabo, P. L. Schwartzberg, and L. H. Glimcher. 2005. T helper cell 
fate specified by kinase-mediated interaction of T-bet with GATA-3. Science 307:430-
433. 
178. Zhou, L., J. E. Lopes, M. M. Chong, Ivanov, II, R. Min, G. D. Victora, Y. Shen, J. Du, Y. 
P. Rubtsov, A. Y. Rudensky, S. F. Ziegler, and D. R. Littman. 2008. TGF-beta-induced 
Foxp3 inhibits T(H)17 cell differentiation by antagonizing RORgammat function. Nature 
453:236-240. 
179. Joly, E., and D. Hudrisier. 2003. What is trogocytosis and what is its purpose? Nat 
Immunol 4:815. 
180. Davis, D. M. 2007. Intercellular transfer of cell-surface proteins is common and can 
affect many stages of an immune response. Nat Rev Immunol 7:238-243. 
181. Huang, J. F., Y. Yang, H. Sepulveda, W. Shi, I. Hwang, P. A. Peterson, M. R. Jackson, J. 
Sprent, and Z. Cai. 1999. TCR-Mediated internalization of peptide-MHC complexes 
acquired by T cells. Science 286:952-954. 
182. Tatari-Calderone, Z., R. T. Semnani, T. B. Nutman, J. Schlom, and H. Sabzevari. 2002. 
Acquisition of CD80 by human T cells at early stages of activation: functional 
involvement of CD80 acquisition in T cell to T cell interaction. J Immunol 169:6162-
6169. 
183. Brezinschek, R. I., N. Oppenheimer-Marks, and P. E. Lipsky. 1999. Activated T cells 
acquire endothelial cell surface determinants during transendothelial migration. J 
Immunol 162:1677-1684. 
184. He, T., C. Tang, Y. Liu, Z. Ye, X. Wu, Y. Wei, T. Moyana, and J. Xiang. 2007. 
Bidirectional membrane molecule transfer between dendritic and T cells. Biochem 
Biophys Res Commun 359:202-208. 
185. Sjostrom, A., M. Eriksson, C. Cerboni, M. H. Johansson, C. L. Sentman, K. Karre, and P. 
Hoglund. 2001. Acquisition of external major histocompatibility complex class I 
molecules by natural killer cells expressing inhibitory Ly49 receptors. J Exp Med 
194:1519-1530. 
186. Fuchs, A., M. Cella, E. Giurisato, A. S. Shaw, and M. Colonna. 2004. Cutting edge: 
CD96 (tactile) promotes NK cell-target cell adhesion by interacting with the poliovirus 
receptor (CD155). J Immunol 172:3994-3998. 
51 
 
187. Tabiasco, J., E. Espinosa, D. Hudrisier, E. Joly, J. J. Fournie, and A. Vercellone. 2002. 
Active trans-synaptic capture of membrane fragments by natural killer cells. Eur J 
Immunol 32:1502-1508. 
188. Batista, F. D., D. Iber, and M. S. Neuberger. 2001. B cells acquire antigen from target 
cells after synapse formation. Nature 411:489-494. 
189. Espinosa, E., J. Tabiasco, D. Hudrisier, and J. J. Fournie. 2002. Synaptic transfer by 
human gamma delta T cells stimulated with soluble or cellular antigens. J Immunol 
168:6336-6343. 
190. Ahmed, K. A., M. A. Munegowda, Y. Xie, and J. Xiang. 2008. Intercellular trogocytosis 
plays an important role in modulation of immune responses. Cell Mol Immunol 5:261-
269. 
191. Davis, M. M., J. J. Boniface, Z. Reich, D. Lyons, J. Hampl, B. Arden, and Y. Chien. 
1998. Ligand recognition by alpha beta T cell receptors. Annu Rev Immunol 16:523-544. 
192. Grakoui, A., S. K. Bromley, C. Sumen, M. M. Davis, A. S. Shaw, P. M. Allen, and M. L. 
Dustin. 1999. The immunological synapse: a molecular machine controlling T cell 
activation. Science 285:221-227. 
193. Viola, A., S. Schroeder, Y. Sakakibara, and A. Lanzavecchia. 1999. T lymphocyte 
costimulation mediated by reorganization of membrane microdomains. Science 283:680-
682. 
194. Cai, Z., H. Kishimoto, A. Brunmark, M. R. Jackson, P. A. Peterson, and J. Sprent. 1997. 
Requirements for peptide-induced T cell receptor downregulation on naive CD8+ T cells. 
J Exp Med 185:641-651. 
195. Puaux, A. L., J. Campanaud, A. Salles, X. Preville, B. Timmerman, E. Joly, and D. 
Hudrisier. 2006. A very rapid and simple assay based on trogocytosis to detect and 
measure specific T and B cell reactivity by flow cytometry. Eur J Immunol 36:779-788. 
196. Patel, D. M., and M. D. Mannie. 2001. Intercellular exchange of class II major 
histocompatibility complex/peptide complexes is a conserved process that requires 
activation of T cells but is constitutive in other types of antigen presenting cell. Cell 
Immunol 214:165-172. 
52 
 
197. Wetzel, S. A., T. W. McKeithan, and D. C. Parker. 2005. Peptide-specific intercellular 
transfer of MHC class II to CD4+ T cells directly from the immunological synapse upon 
cellular dissociation. J Immunol 174:80-89. 
198. Underhill, D. M., M. Bassetti, A. Rudensky, and A. Aderem. 1999. Dynamic interactions 
of macrophages with T cells during antigen presentation. J Exp Med 190:1909-1914. 
199. Gunzer, M., A. Schafer, S. Borgmann, S. Grabbe, K. S. Zanker, E. B. Brocker, E. 
Kampgen, and P. Friedl. 2000. Antigen presentation in extracellular matrix: interactions 
of T cells with dendritic cells are dynamic, short lived, and sequential. Immunity 13:323-
332. 
200. Morgan, B. P., J. R. Dankert, and A. F. Esser. 1987. Recovery of human neutrophils from 
complement attack: removal of the membrane attack complex by endocytosis and 
exocytosis. J Immunol 138:246-253. 
201. Lorber, M. I., M. R. Loken, A. M. Stall, and F. W. Fitch. 1982. I-A antigens on cloned 
alloreactive murine T lymphocytes are acquired passively. J Immunol 128:2798-2803. 
202. Yu, D. T., J. M. McCune, S. M. Fu, R. J. Winchester, and H. G. Kunkel. 1980. Two types 
of Ia-positive T cells. Synthesis and exchange of Ia antigens. J Exp Med 152:89s-98s. 
203. Stinchcombe, J. C., G. Bossi, S. Booth, and G. M. Griffiths. 2001. The immunological 
synapse of CTL contains a secretory domain and membrane bridges. Immunity 15:751-
761. 
204. Onfelt, B., S. Nedvetzki, R. K. Benninger, M. A. Purbhoo, S. Sowinski, A. N. Hume, M. 
C. Seabra, M. A. Neil, P. M. French, and D. M. Davis. 2006. Structurally distinct 
membrane nanotubes between human macrophages support long-distance vesicular 
traffic or surfing of bacteria. J Immunol 177:8476-8483. 
205. Onfelt, B., S. Nedvetzki, K. Yanagi, and D. M. Davis. 2004. Cutting edge: Membrane 
nanotubes connect immune cells. J Immunol 173:1511-1513. 
206. Sowinski, S., C. Jolly, O. Berninghausen, M. A. Purbhoo, A. Chauveau, K. Kohler, S. 
Oddos, P. Eissmann, F. M. Brodsky, C. Hopkins, B. Onfelt, Q. Sattentau, and D. M. 
Davis. 2008. Membrane nanotubes physically connect T cells over long distances 
presenting a novel route for HIV-1 transmission. Nat Cell Biol 10:211-219. 
207. Seder, R. A., and W. E. Paul. 1994. Acquisition of lymphokine-producing phenotype by 
CD4+ T cells. Annu Rev Immunol 12:635-673. 
53 
 
208. Yoshimoto, T., and W. E. Paul. 1994. CD4pos, NK1.1pos T cells promptly produce 
interleukin 4 in response to in vivo challenge with anti-CD3. J Exp Med 179:1285-1295. 
209. Ferrick, D. A., M. D. Schrenzel, T. Mulvania, B. Hsieh, W. G. Ferlin, and H. Lepper. 
1995. Differential production of interferon-gamma and interleukin-4 in response to Th1- 
and Th2-stimulating pathogens by gamma delta T cells in vivo. Nature 373:255-257. 
210. Cronin, D. C., 2nd, R. Stack, and F. W. Fitch. 1995. IL-4-producing CD8+ T cell clones 
can provide B cell help. J Immunol 154:3118-3127. 
211. Lardon, F., H. W. Snoeck, Z. N. Berneman, V. F. Van Tendeloo, G. Nijs, M. Lenjou, E. 
Henckaerts, C. J. Boeckxtaens, P. Vandenabeele, L. L. Kestens, D. R. Van Bockstaele, 
and G. L. Vanham. 1997. Generation of dendritic cells from bone marrow progenitors 
using GM-CSF, TNF-alpha, and additional cytokines: antagonistic effects of IL-4 and 
IFN-gamma and selective involvement of TNF-alpha receptor-1. Immunology 91:553-
559. 
212. Russell, S. M., A. D. Keegan, N. Harada, Y. Nakamura, M. Noguchi, P. Leland, M. C. 
Friedmann, A. Miyajima, R. K. Puri, W. E. Paul, and et al. 1993. Interleukin-2 receptor 
gamma chain: a functional component of the interleukin-4 receptor. Science 262:1880-
1883. 
213. Zheng, W., and R. A. Flavell. 1997. The transcription factor GATA-3 is necessary and 
sufficient for Th2 cytokine gene expression in CD4 T cells. Cell 89:587-596. 
214. Goenka, S., J. Youn, L. M. Dzurek, U. Schindler, L. Y. Yu-Lee, and M. Boothby. 1999. 
Paired Stat6 C-terminal transcription activation domains required both for inhibition of 
an IFN-responsive promoter and trans-activation. J Immunol 163:4663-4672. 
215. Ouyang, W., S. H. Ranganath, K. Weindel, D. Bhattacharya, T. L. Murphy, W. C. Sha, 
and K. M. Murphy. 1998. Inhibition of Th1 development mediated by GATA-3 through 
an IL-4-independent mechanism. Immunity 9:745-755. 
216. Elser, B., M. Lohoff, S. Kock, M. Giaisi, S. Kirchhoff, P. H. Krammer, and M. Li-Weber. 
2002. IFN-gamma represses IL-4 expression via IRF-1 and IRF-2. Immunity 17:703-712. 
217. Coffman, R. L., J. Ohara, M. W. Bond, J. Carty, A. Zlotnik, and W. E. Paul. 1986. B cell 
stimulatory factor-1 enhances the IgE response of lipopolysaccharide-activated B cells. J 
Immunol 136:4538-4541. 
54 
 
218. Vitetta, E. S., J. Ohara, C. D. Myers, J. E. Layton, P. H. Krammer, and W. E. Paul. 1985. 
Serological, biochemical, and functional identity of B cell-stimulatory factor 1 and B cell 
differentiation factor for IgG1. J Exp Med 162:1726-1731. 
219. Gascan, H., J. F. Gauchat, M. G. Roncarolo, H. Yssel, H. Spits, and J. E. de Vries. 1991. 
Human B cell clones can be induced to proliferate and to switch to IgE and IgG4 
synthesis by interleukin 4 and a signal provided by activated CD4+ T cell clones. J Exp 
Med 173:747-750. 
220. Howard, M., J. Farrar, M. Hilfiker, B. Johnson, K. Takatsu, T. Hamaoka, and W. E. Paul. 
1982. Identification of a T cell-derived b cell growth factor distinct from interleukin 2. J 
Exp Med 155:914-923. 
221. Noelle, R., P. H. Krammer, J. Ohara, J. W. Uhr, and E. S. Vitetta. 1984. Increased 
expression of Ia antigens on resting B cells: an additional role for B-cell growth factor. 
Proc Natl Acad Sci U S A 81:6149-6153. 
222. Thornhill, M. H., S. M. Wellicome, D. L. Mahiouz, J. S. Lanchbury, U. Kyan-Aung, and 
D. O. Haskard. 1991. Tumor necrosis factor combines with IL-4 or IFN-gamma to 
selectively enhance endothelial cell adhesiveness for T cells. The contribution of vascular 
cell adhesion molecule-1-dependent and -independent binding mechanisms. J Immunol 
146:592-598. 
223. Bennett, B. L., R. Cruz, R. G. Lacson, and A. M. Manning. 1997. Interleukin-4 
suppression of tumor necrosis factor alpha-stimulated E-selectin gene transcription is 
mediated by STAT6 antagonism of NF-kappaB. J Biol Chem 272:10212-10219. 
224. Kishimoto, T. 2005. Interleukin-6: from basic science to medicine--40 years in 
immunology. Annu Rev Immunol 23:1-21. 
225. Hirano, T., K. Yasukawa, H. Harada, T. Taga, Y. Watanabe, T. Matsuda, S. 
Kashiwamura, K. Nakajima, K. Koyama, A. Iwamatsu, and et al. 1986. Complementary 
DNA for a novel human interleukin (BSF-2) that induces B lymphocytes to produce 
immunoglobulin. Nature 324:73-76. 
226. Hirano, T., T. Matsuda, M. Turner, N. Miyasaka, G. Buchan, B. Tang, K. Sato, M. 
Shimizu, R. Maini, M. Feldmann, and et al. 1988. Excessive production of interleukin 
6/B cell stimulatory factor-2 in rheumatoid arthritis. Eur J Immunol 18:1797-1801. 
55 
 
227. Hibi, M., M. Murakami, M. Saito, T. Hirano, T. Taga, and T. Kishimoto. 1990. 
Molecular cloning and expression of an IL-6 signal transducer, gp130. Cell 63:1149-
1157. 
228. Taga, T., M. Hibi, Y. Hirata, K. Yamasaki, K. Yasukawa, T. Matsuda, T. Hirano, and T. 
Kishimoto. 1989. Interleukin-6 triggers the association of its receptor with a possible 
signal transducer, gp130. Cell 58:573-581. 
229. Taga, T., and T. Kishimoto. 1992. Cytokine receptors and signal transduction. FASEB J 
6:3387-3396. 
230. Kishimoto, T. 2010. IL-6: from its discovery to clinical applications. Int Immunol 22:347-
352. 
231. Jones, S. A. 2005. Directing transition from innate to acquired immunity: defining a role 
for IL-6. J Immunol 175:3463-3468. 
232. Zhong, Z., Z. Wen, and J. E. Darnell, Jr. 1994. Stat3: a STAT family member activated 
by tyrosine phosphorylation in response to epidermal growth factor and interleukin-6. 
Science 264:95-98. 
233. Yang, Y., J. Ochando, A. Yopp, J. S. Bromberg, and Y. Ding. 2005. IL-6 plays a unique 
role in initiating c-Maf expression during early stage of CD4 T cell activation. J Immunol 
174:2720-2729. 
234. Diehl, S., and M. Rincon. 2002. The two faces of IL-6 on Th1/Th2 differentiation. Mol 
Immunol 39:531-536. 
235. Suematsu, S., T. Matsuda, K. Aozasa, S. Akira, N. Nakano, S. Ohno, J. Miyazaki, K. 
Yamamura, T. Hirano, and T. Kishimoto. 1989. IgG1 plasmacytosis in interleukin 6 
transgenic mice. Proc Natl Acad Sci U S A 86:7547-7551. 
236. Kopf, M., S. Herren, M. V. Wiles, M. B. Pepys, and M. H. Kosco-Vilbois. 1998. 
Interleukin 6 influences germinal center development and antibody production via a 
contribution of C3 complement component. J Exp Med 188:1895-1906. 
237. Kimura, A., and T. Kishimoto. 2010. IL-6: regulator of Treg/Th17 balance. Eur J 
Immunol 40:1830-1835. 
238. Fiorentino, D. F., M. W. Bond, and T. R. Mosmann. 1989. Two types of mouse T helper 
cell. IV. Th2 clones secrete a factor that inhibits cytokine production by Th1 clones. J 
Exp Med 170:2081-2095. 
56 
 
239. Couper, K. N., D. G. Blount, and E. M. Riley. 2008. IL-10: the master regulator of 
immunity to infection. J Immunol 180:5771-5777. 
240. Wehinger, J., F. Gouilleux, B. Groner, J. Finke, R. Mertelsmann, and R. M. Weber-
Nordt. 1996. IL-10 induces DNA binding activity of three STAT proteins (Stat1, Stat3, 
and Stat5) and their distinct combinatorial assembly in the promoters of selected genes. 
FEBS Lett 394:365-370. 
241. Moore, K. W., R. de Waal Malefyt, R. L. Coffman, and A. O'Garra. 2001. Interleukin-10 
and the interleukin-10 receptor. Annu Rev Immunol 19:683-765. 
242. Demangel, C., P. Bertolino, and W. J. Britton. 2002. Autocrine IL-10 impairs dendritic 
cell (DC)-derived immune responses to mycobacterial infection by suppressing DC 
trafficking to draining lymph nodes and local IL-12 production. Eur J Immunol 32:994-
1002. 
243. Huang, H., W. Dawicki, X. Zhang, J. Town, and J. R. Gordon. 2010. Tolerogenic 
dendritic cells induce CD4+CD25hiFoxp3+ regulatory T cell differentiation from 
CD4+CD25-/loFoxp3- effector T cells. J Immunol 185:5003-5010. 
244. Levy, Y., and J. C. Brouet. 1994. Interleukin-10 prevents spontaneous death of germinal 
center B cells by induction of the bcl-2 protein. J Clin Invest 93:424-428. 
245. Kuhn, R., J. Lohler, D. Rennick, K. Rajewsky, and W. Muller. 1993. Interleukin-10-
deficient mice develop chronic enterocolitis. Cell 75:263-274. 
246. Yang, X., J. Gartner, L. Zhu, S. Wang, and R. C. Brunham. 1999. IL-10 gene knockout 
mice show enhanced Th1-like protective immunity and absent granuloma formation 
following Chlamydia trachomatis lung infection. J Immunol 162:1010-1017. 
247. O'Quinn, D. B., M. T. Palmer, Y. K. Lee, and C. T. Weaver. 2008. Emergence of the 
Th17 pathway and its role in host defense. Adv Immunol 99:115-163. 
248. Onishi, R. M., and S. L. Gaffen. 2010. Interleukin-17 and its target genes: mechanisms of 
interleukin-17 function in disease. Immunology 129:311-321. 
249. Kolls, J. K., and A. Linden. 2004. Interleukin-17 family members and inflammation. 
Immunity 21:467-476. 
250. Gaffen, S. L. 2009. Structure and signalling in the IL-17 receptor family. Nat Rev 
Immunol 9:556-567. 
57 
 
251. Yao, Z., M. K. Spriggs, J. M. Derry, L. Strockbine, L. S. Park, T. VandenBos, J. D. 
Zappone, S. L. Painter, and R. J. Armitage. 1997. Molecular characterization of the 
human interleukin (IL)-17 receptor. Cytokine 9:794-800. 
252. Moseley, T. A., D. R. Haudenschild, L. Rose, and A. H. Reddi. 2003. Interleukin-17 
family and IL-17 receptors. Cytokine Growth Factor Rev 14:155-174. 
253. Ye, P., P. B. Garvey, P. Zhang, S. Nelson, G. Bagby, W. R. Summer, P. 
Schwarzenberger, J. E. Shellito, and J. K. Kolls. 2001. Interleukin-17 and lung host 
defense against Klebsiella pneumoniae infection. Am J Respir Cell Mol Biol 25:335-340. 
254. Takahashi, H., M. Numasaki, M. T. Lotze, and H. Sasaki. 2005. Interleukin-17 enhances 
bFGF-, HGF- and VEGF-induced growth of vascular endothelial cells. Immunol Lett 
98:189-193. 
255. Xiang, J., H. Huang, and Y. Liu. 2005. A new dynamic model of CD8+ T effector cell 
responses via CD4+ T helper-antigen-presenting cells. J Immunol 174:7497-7505. 
256. Keene, J. A., and J. Forman. 1982. Helper activity is required for the in vivo generation 
of cytotoxic T lymphocytes. J Exp Med 155:768-782. 
257. Bousso, P., and E. Robey. 2003. Dynamics of CD8+ T cell priming by dendritic cells in 
intact lymph nodes. Nat Immunol 4:579-585. 
258. Ridge, J. P., F. Di Rosa, and P. Matzinger. 1998. A conditioned dendritic cell can be a 
temporal bridge between a CD4+ T-helper and a T-killer cell. Nature 393:474-478. 
259. Ahmed, K. A., and J. Xiang. 2011. Mechanisms of cellular communication through 
intercellular protein transfer. J Cell Mol Med 15:1458-1473. 
260. Hwang, I., J. F. Huang, H. Kishimoto, A. Brunmark, P. A. Peterson, M. R. Jackson, C. D. 
Surh, Z. Cai, and J. Sprent. 2000. T cells can use either T cell receptor or CD28 receptors 
to absorb and internalize cell surface molecules derived from antigen-presenting cells. J 
Exp Med 191:1137-1148. 
261. He, T., S. Zong, X. Wu, Y. Wei, and J. Xiang. 2007. CD4+ T cell acquisition of the 
bystander pMHC I colocalizing in the same immunological synapse comprising pMHC II 
and costimulatory CD40, CD54, CD80, OX40L, and 41BBL. Biochem Biophys Res 
Commun 362:822-828. 
262. Undale, A. H., P. J. van den Elsen, and E. Celis. 2004. Antigen-independent acquisition 
of MHC class II molecules by human T lymphocytes. Int Immunol 16:1523-1533. 
58 
 
263. Hao, S., J. Yuan, and J. Xiang. 2007. Nonspecific CD4(+) T cells with uptake of antigen-
specific dendritic cell-released exosomes stimulate antigen-specific CD8(+) CTL 
responses and long-term T cell memory. J Leukoc Biol 82:829-838. 
264. Hao, S., Y. Liu, J. Yuan, X. Zhang, T. He, X. Wu, Y. Wei, D. Sun, and J. Xiang. 2007. 
Novel exosome-targeted CD4+ T cell vaccine counteracting CD4+25+ regulatory T cell-
mediated immune suppression and stimulating efficient central memory CD8+ CTL 
responses. J Immunol 179:2731-2740. 
265. Shi, M., S. Hao, T. Chan, and J. Xiang. 2006. CD4(+) T cells stimulate memory CD8(+) 
T cell expansion via acquired pMHC I complexes and costimulatory molecules, and IL-2 
secretion. J Leukoc Biol 80:1354-1363. 
266. Huang, H., S. Hao, F. Li, Z. Ye, J. Yang, and J. Xiang. 2007. CD4+ Th1 cells promote 
CD8+ Tc1 cell survival, memory response, tumor localization and therapy by targeted 
delivery of interleukin 2 via acquired pMHC I complexes. Immunology 120:148-159. 
267. Ye, Z., K. A. Ahmed, S. Hao, X. Zhang, Y. Xie, M. A. Munegowda, Q. Meng, R. 
Chibbar, and J. Xiang. 2008. Active CD4+ helper T cells directly stimulate CD8+ 
cytotoxic T lymphocyte responses in wild-type and MHC II gene knockout C57BL/6 
mice and transgenic RIP-mOVA mice expressing islet beta-cell ovalbumin antigen 
leading to diabetes. Autoimmunity 41:501-511. 
268. Ahmed, K. A., Y. Xie, X. Zhang, and J. Xiang. 2008. Acquired pMHC I complexes 
greatly enhance CD4(+) Th cell's stimulatory effect on CD8(+) T cell-mediated diabetes 
in transgenic RIP-mOVA mice. Cell Mol Immunol 5:407-415. 
269. Ankathatti Munegowda, M., Y. Deng, R. Chibbar, Q. Xu, A. Freywald, S. J. Mulligan, S. 
van Drunen Littel-van den Hurk, D. Sun, S. Xiong, and J. Xiang. 2011. A distinct role of 
CD4+ Th17- and Th17-stimulated CD8+ CTL in the pathogenesis of type 1 diabetes and 
experimental autoimmune encephalomyelitis. J Clin Immunol 31:811-826. 
270. Xie, Y., O. Bai, J. Yuan, R. Chibbar, K. Slattery, Y. Wei, Y. Deng, and J. Xiang. 2009. 
Tumor apoptotic bodies inhibit CTL responses and antitumor immunity via membrane-
bound transforming growth factor-beta1 inducing CD8+ T-cell anergy and CD4+ Tr1 cell 
responses. Cancer Res 69:7756-7766. 
59 
 
271. Ye, Z., H. Huang, S. Hao, S. Xu, H. Yu, S. Van Den Hurk, and J. Xiang. 2007. IL-10 has 
a distinct immunoregulatory effect on naive and active T cell subsets. J Interferon 
Cytokine Res 27:1031-1038. 
272. Soliman, H., M. Mediavilla-Varela, and S. Antonia. 2010. Indoleamine 2,3-dioxygenase: 
is it an immune suppressor? Cancer J 16:354-359. 
273. Reiman, J. M., M. Kmieciak, M. H. Manjili, and K. L. Knutson. 2007. Tumor 
immunoediting and immunosculpting pathways to cancer progression. Semin Cancer Biol 
17:275-287. 
274. Zhang, X., M. A. Munegowda, J. Yuan, Y. Wei, and J. Xiang. 2010. Optimal TLR9 
signal converts tolerogenic CD4-8- DCs into immunogenic ones capable of stimulating 
antitumor immunity via activating CD4+ Th1/Th17 and NK cell responses. J Leukoc Biol 
88:393-403. 
275. Lehuen, A., J. Diana, P. Zaccone, and A. Cooke. Immune cell crosstalk in type 1 
diabetes. Nat Rev Immunol 10:501-513. 
276. Sibley, R. K., D. E. Sutherland, F. Goetz, and A. F. Michael. 1985. Recurrent diabetes 
mellitus in the pancreas iso- and allograft. A light and electron microscopic and 
immunohistochemical analysis of four cases. Lab Invest 53:132-144. 
277. Vukkadapu, S. S., J. M. Belli, K. Ishii, A. G. Jegga, J. J. Hutton, B. J. Aronow, and J. D. 
Katz. 2005. Dynamic interaction between T cell-mediated beta-cell damage and beta-cell 
repair in the run up to autoimmune diabetes of the NOD mouse. Physiol Genomics 
21:201-211. 
278. Jain, R., D. M. Tartar, R. K. Gregg, R. D. Divekar, J. J. Bell, H. H. Lee, P. Yu, J. S. Ellis, 
C. M. Hoeman, C. L. Franklin, and H. Zaghouani. 2008. Innocuous IFNgamma induced 
by adjuvant-free antigen restores normoglycemia in NOD mice through inhibition of IL-
17 production. J Exp Med 205:207-218. 
279. Wildin, R. S., and A. Freitas. 2005. IPEX and FOXP3: clinical and research perspectives. 
J Autoimmun 25 Suppl:56-62. 
280. Salomon, B., D. J. Lenschow, L. Rhee, N. Ashourian, B. Singh, A. Sharpe, and J. A. 
Bluestone. 2000. B7/CD28 costimulation is essential for the homeostasis of the 
CD4+CD25+ immunoregulatory T cells that control autoimmune diabetes. Immunity 
12:431-440. 
60 
 
281. Tang, Q., and J. A. Bluestone. 2008. The Foxp3+ regulatory T cell: a jack of all trades, 
master of regulation. Nat Immunol 9:239-244. 
282. Korn, T. 2008. Pathophysiology of multiple sclerosis. J Neurol 255 Suppl 6:2-6. 
283. Ferber, I. A., S. Brocke, C. Taylor-Edwards, W. Ridgway, C. Dinisco, L. Steinman, D. 
Dalton, and C. G. Fathman. 1996. Mice with a disrupted IFN-gamma gene are susceptible 
to the induction of experimental autoimmune encephalomyelitis (EAE). J Immunol 
156:5-7. 
284. Yang, Y., J. Weiner, Y. Liu, A. J. Smith, D. J. Huss, R. Winger, H. Peng, P. D. Cravens, 
M. K. Racke, and A. E. Lovett-Racke. 2009. T-bet is essential for encephalitogenicity of 
both Th1 and Th17 cells. J Exp Med 206:1549-1564. 
285. Kebir, H., K. Kreymborg, I. Ifergan, A. Dodelet-Devillers, R. Cayrol, M. Bernard, F. 
Giuliani, N. Arbour, B. Becher, and A. Prat. 2007. Human TH17 lymphocytes promote 
blood-brain barrier disruption and central nervous system inflammation. Nat Med 
13:1173-1175. 
286. Hirota, K., H. Yoshitomi, M. Hashimoto, S. Maeda, S. Teradaira, N. Sugimoto, T. 
Yamaguchi, T. Nomura, H. Ito, T. Nakamura, N. Sakaguchi, and S. Sakaguchi. 2007. 
Preferential recruitment of CCR6-expressing Th17 cells to inflamed joints via CCL20 in 
rheumatoid arthritis and its animal model. J Exp Med 204:2803-2812. 
287. Lowes, M. A., T. Kikuchi, J. Fuentes-Duculan, I. Cardinale, L. C. Zaba, A. S. Haider, E. 
P. Bowman, and J. G. Krueger. 2008. Psoriasis vulgaris lesions contain discrete 
populations of Th1 and Th17 T cells. J Invest Dermatol 128:1207-1211. 
288. Fujino, S., A. Andoh, S. Bamba, A. Ogawa, K. Hata, Y. Araki, T. Bamba, and Y. 
Fujiyama. 2003. Increased expression of interleukin 17 in inflammatory bowel disease. 
Gut 52:65-70. 
289. El-behi, M., A. Rostami, and B. Ciric. Current views on the roles of Th1 and Th17 cells 
in experimental autoimmune encephalomyelitis. J Neuroimmune Pharmacol 5:189-197. 
290. Stromnes, I. M., and J. M. Goverman. 2006. Active induction of experimental allergic 
encephalomyelitis. Nat Protoc 1:1810-1819. 
291. Sun, D., J. N. Whitaker, Z. Huang, D. Liu, C. Coleclough, H. Wekerle, and C. S. Raine. 
2001. Myelin antigen-specific CD8+ T cells are encephalitogenic and produce severe 
disease in C57BL/6 mice. J Immunol 166:7579-7587. 
61 
 
292. Haines, J. L., M. Ter-Minassian, A. Bazyk, J. F. Gusella, D. J. Kim, H. Terwedow, M. A. 
Pericak-Vance, J. B. Rimmler, C. S. Haynes, A. D. Roses, A. Lee, B. Shaner, M. Menold, 
E. Seboun, R. P. Fitoussi, C. Gartioux, C. Reyes, F. Ribierre, G. Gyapay, J. Weissenbach, 
S. L. Hauser, D. E. Goodkin, R. Lincoln, K. Usuku, J. R. Oksenberg, and et al. 1996. A 
complete genomic screen for multiple sclerosis underscores a role for the major 
histocompatability complex. The Multiple Sclerosis Genetics Group. Nat Genet 13:469-
471. 
293. Kuchroo, V. K., A. C. Anderson, H. Waldner, M. Munder, E. Bettelli, and L. B. 
Nicholson. 2002. T cell response in experimental autoimmune encephalomyelitis (EAE): 
role of self and cross-reactive antigens in shaping, tuning, and regulating the 
autopathogenic T cell repertoire. Annu Rev Immunol 20:101-123. 
294. Bettelli, E., B. Sullivan, S. J. Szabo, R. A. Sobel, L. H. Glimcher, and V. K. Kuchroo. 
2004. Loss of T-bet, but not STAT1, prevents the development of experimental 
autoimmune encephalomyelitis. J Exp Med 200:79-87. 
295. Korn, T., J. Reddy, W. Gao, E. Bettelli, A. Awasthi, T. R. Petersen, B. T. Backstrom, R. 
A. Sobel, K. W. Wucherpfennig, T. B. Strom, M. Oukka, and V. K. Kuchroo. 2007. 
Myelin-specific regulatory T cells accumulate in the CNS but fail to control autoimmune 
inflammation. Nat Med 13:423-431. 
296. Ford, M. L., and B. D. Evavold. 2005. Specificity, magnitude, and kinetics of MOG-
specific CD8+ T cell responses during experimental autoimmune encephalomyelitis. Eur 
J Immunol 35:76-85. 
297. Sun, D., Y. Zhang, B. Wei, S. C. Peiper, H. Shao, and H. J. Kaplan. 2003. 
Encephalitogenic activity of truncated myelin oligodendrocyte glycoprotein (MOG) 
peptides and their recognition by CD8+ MOG-specific T cells on oligomeric MHC class I 
molecules. Int Immunol 15:261-268. 
 
 
 
62 
 
CHAPTER 2 
2. Th17 and Th17-stimulated CD8
+
 T cells play a distinct role in Th17-induced preventive 
and therapeutic antitumor immunity. 
 
Brief introduction to chapter 2 
This chapter addresses the mechanism of stimulatory effect of Th17 cells on antitumor 
specific CD8
+
 CTL responses in preventive and therapeutic tumor models. It was demonstrated 
by various other studies that Th17 cells induce antitumor immunity leading to eradication of 
established tumors. However, the mechanism of CD8
+
 CTL activation by Th17 cells, and the 
distinct role of Th17, and Th17 activated CD8
+
 CTLs in antitumor immunity were still elusive. 
In this study, we have demonstrated that Th17 cells acquired major pMHC-I, and express 
RORγt, IL-17 and IL-2.  Th17 cells did not show any direct in vitro tumor cell killing activity, 
whereas  they were able to stimulate CD8
+
 CTL responses via IL-2, and pMHC-I, but was not 
via IL-17 signalling. The therapeutic effect of Th17 cells was shown to be associated with IL-17, 
but not with IFN-γ, and was mediated by Th17 stimulated CD8+ CTLs via the perforin pathway, 
which were recruited into B16 melanoma via Th17 stimulated CCL20 chemoattraction. Taken 
together, this study elucidates a distinct role of Th17 and Th17-stimulated CD8
+
 CTLs in 
induction of preventive and therapeutic antitumor immunity, which may greatly impact the 
development of Th17-based cancer immunotherapy. 
Reprinted with consent from Cancer Immunology Immunotherapy 2011 Oct;60(10):1473-
84.  
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Abstract CD4? Th17 cells induce antitumor immunity
leading to the eradication of established tumors. However,
the mechanism of antitumour immunity and CTL activa-
tion by Th17 cells and the distinct role of Th17 and Th17-
activated CTLs in antitumor immunity are still elusive. In
this study, we generated ovalbumin (OVA)-specific Th17
cells by cultivating OVA-pulsed dendritic cells with CD4?
T cells derived from transgenic OTII mice in the presence
of IL-6, IL-23, TGF-b, and anti-IFN-c antibody. We
demonstrated that Th17 cells acquired major histocom-
patibility complex/peptide (pMHC)-I and expressed
RORct, IL-17, and IL-2. Th17 cells did not have any direct
in vitro tumor cell–killing activity. However, Th17 cells
were able to stimulate CD8? CTL responses via IL-2 and
pMHC I, but not IL-17 signaling, which play a major role
in Th17-induced preventive immunity against OVA-
expressing B16 melanoma. Th17 cells stimulated the
expression of CCL2 and CCL20 in lung tumor microen-
vironments promoting the recruitment of various inflam-
matory leukocytes (DCs, CD4?, and CD8? T cells)
stimulating more pronounced therapeutic immunity for
early-stage (5-day lung metastases or 3 mm, s.c.) tumor
than for well-established (6 mm, s.c.) tumor. The thera-
peutic effect of Th17 cells is associated with IL-17 and is
mediated by Th17-stimulated CD8? CTLs and other
inflammatory leukocytes recruited into B16 melanoma via
Th17-stimulated CCL20 chemoattraction. Taken together,
our data elucidate a distinct role of Th17 and Th17-stim-
ulated CD8? CTLs in the induction of preventive and
therapeutic antitumor immunity, which may greatly impact
the development of Th17-based cancer immunotherapy.
Keywords Th17  pMHC I complexes  CD8? CTL 
CCL2/20  Antitumor immunity
Introduction
Effector CD4? T cells are classically divided into two
lineages based on distinct cytokine secretion profiles: the
IFN-c-producing Th1 lineage and IL-4/IL-13-producing
Th2 lineage. Recently, a lineage of effector Th17 cells that
produce IL-17A and IL-17F and express the transcription
factor RORct through activation of STAT3 by IL-6 and IL-
23 have been identified [1]. IL-17 cytokines are strongly
proinflammatory and induce the expression of several
chemokines such as CCL2, CCL7, and CCL20. Transgenic
overexpression of IL-17A in the lungs provokes proin-
flammatory gene expression and tissue infiltration of leu-
kocytes [2]. In contrast, inhibition of IL-17A expression
impairs host defense against bacterial infection [3] and
resistance to autoimmune diseases [4, 5].
Th17 cells and IL-17 expression have been found in
various human tumors [6–10]. However, the involvement
of IL-17 and Th17 cells in antitumor immunity is still
controversial. For example, transgenic IL-17 expression
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either induced tumor regression through enhanced antitu-
mor immunity in immune-competent mice [11, 12] or
promoted tumor progression through an increase in
inflammatory angiogenesis in immune-deficient mice [13].
It has been demonstrated that Th17 cells were indirectly
linked to antitumor immunity [14]. Tumor-specific Th17
polarized cells were found to inhibit the growth of well-
established melanoma via IFN-c production [15]. However,
the nature of Th17 cell’s role in the context of antitumor
immunity still remains largely unknown. Th17 cells have
been shown to stimulate antitumor immunity in both pre-
vention and therapeutic models by recruiting DCs, granu-
locytes, and CD4? and CD8? T cells [16]. However, (i) the
molecular mechanism of CD8? CTL activation by Th17
cells, (ii) the precise role of Th17 secreted IL-17 and dif-
ferent types of recruited leukocytes in Th17-induced anti-
tumor immunity, and (iii) the potentially distinct role of
Th17 and Th17-stimulated CD8? CTLs in Th17-induced
antitumor immunity are still unknown.
Intercellular membrane transfer through trogocytosis
plays an important role in immune modulation [17]. We
have recently demonstrated that CD4? T cells derived from
ovalbumin (OVA)-specific T-cell receptor (TCR) trans-
genic OTII mice, which were activated in vitro with OVA-
pulsed DCs (DCOVA), differentiated into Th1 cells [17].
These Th1 cells acquired peptide major histocompatibility
complexes I (pMHC I) and CD80 from DCOVA by DCova
activation and became capable of directly stimulating
CD8? CTL responses via endogenous IL-2 and acquired
pMHC I and CD80 signaling [18, 19]. However, whether
Th17 cells with distinctive phenotype from Th1 cell have a
similar stimulatory effect as Th1 cells on the stimulation of
CD8? CTL responses is elusive.
In this study, we generated RORct-expressing and IL-
17-secreting OVA-specific Th17 cells by cultivation of
OTII CD4? T cells with OVA-pulsed DCOVA in the pres-
ence of IL-6, IL-23, TGF-b, and anti-IFN-c antibody. We
then immunized C57BL/6 mice with these Th17 cells to
assess the potential stimulatory effect on CD8? T-cell
responses and antitumor immunity in preventive and ther-
apeutic models against OVA-expressing B16 melanoma
(BL6-10OVA).
Results
Th17 acquires pMHC I complexes by DCOVA
activation
Transgenic mouse OT II CD4? T cells activated with irra-
diated DCOVA in the presence of IL-23/IL-6/TGF-b and anti-
IFN-c antibody expressed cell surface FasL, intranuclear
RORct, and intracellular perforin and IL-17 by flow
cytometric and RT–PCR analysis (Fig. 1a, c). By using
double staining for IL-17 and IFN-c, polarized Th17 and Th1
cells expressed intracellular IL-17 and IFN-c, respectively
(Fig. 1b). These Th17 cells also secreted IL-2 (2.8 ng/ml),
IL-6 (4.5 ng/ml), IL-17 (1.8 ng/ml), and TGF-b (0.2 ng/ml)
byELISAanalysis, indicating that they are Th17 cells, which
is consistent with a recent report showing that Th17 simul-
taneously expressed both IL-17 and IL-2 [20]. There was no
CD11c? DCOVA contamination in these purified Th17 pop-
ulation (Fig. 1d). In addition, these Th17 cells did display
pMHC I (Fig. 1a), indicating that they may acquire pMHC I
fromDCOVA uponDCOVA activation. This was confirmed by
evidence that CD4? T cells derived from pMHC I-negative
(Kb-/-)DCOVA activation did not express pMHC I (Fig. 1e).
Th17 stimulates in vitro CD8? T-cell proliferation
via IL-2 and pMHC I, but not IL-17 signaling
We previously demonstrated that DCova-activated Th1
with acquired pMHC I stimulated CTL responses via IL-2
and pMHC I signaling [18, 19]. To assess Th17’s stimu-
latory effect, we performed 3H-thymidine incorporation
assay. DCova-activated Th17 with acquired pMHC I also
stimulated in vitro OTI CD8? T-cell proliferation in a
dose-dependent fashion. Interestingly, (Kb-/-)Th17 with-
out acquired pMHC I or Th17 in the presence of anti-IL-2
Ab, but not anti-IL-17 Ab, failed to stimulate CD8? T-cell
proliferation (Fig. 2a), indicating that the in vitro Th17’s
stimulatory effect on CTLs is via IL-2 and pMHC I, but not
via IL-17 signaling.
Th17-activated CD8? T, but not Th17, cells have
in vitro cytotoxicity
Since Th17 expressed cytotoxic FasL and perforin, they
may have killing activity to pMHC II-expressing target
cells. To assess their killing effect, we performed a chro-
mium release assay. We found that Th17-activated CTLs
showed killing activity to OVA-expressing EG7 tumor
cells, and the killing activity was significantly (P\ 0.01)
or slightly (P[ 0.05) reduced when T cells were pre-
incubated with CMA or emetin, indicating that CD8?
T-cell-mediated killing activity is mainly via perforin
pathway (Fig. 2b) [21]. In addition, we found that Th1
[19], but not Th17, killed OVAII peptide-pulsed LB27 cells
(Fig. 2c), indicating that Th17 do not have any direct
killing activity to tumor cells.
Th17 stimulates the host DC-independent CD8? CTL
responses
To assess DCova-activated Th17’s ability to induce in vivo
CD8? T-cell proliferation, we i.v. transferred B6 mice with
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DCova and Th17 and then performed an OVA-specific
tetramer staining assay to detect OVA-specific CD8?
T-cell proliferation [19]. As shown in Fig. 2d, DCova and
Th17 stimulated OVA-specific CD8? T cells accounted for
1.43 and 0.98% of the total CD8? T-cell population,
respectively. To assess whether the host DCs are involved
in Th17-stimulated CTL responses by the uptake of antigen
epitopes of Th17, we i.v. transferred the transgenic DTR-
CD11c mice with DT treatment for complete depletion of
endogenous DCs and macrophages (Clin Exp Immunol
141: 398, 2005) with Th17 and then performed an OVA-
specific tetramer staining assay to detect OVA-specific
CD8? T-cell proliferation. We found that Th17-stimulated
OVA-specific CTL responses in PBS- and DT-treated
DTR-CD11c mice with and without endogenous APCs
were similar (Fig. 2d), indicating that Th17 stimulates the
host DC-independent CD8? CTL responses.
Th17 stimulates CTL-mediated preventive antitumor
immunity via IL-2 and pMHC I, but not via IL-17
signaling
To elucidate the molecular mechanism of Th17-stimulated
CTL responses, DCova-activated Th17, (IL-2-/-)Th17
with IL-2 deficiency, (Kb-/-)Th17 without acquired
pMHC I, and CD3/CD28 bead-activated Th17 (bead-Th17)
without pMHC I expression (Fig. 1e) were used in the in
vivo proliferation and cytotoxicity experiments. To assess
the involvement of IL-17, Th17 cell transferred mice were
treated with anti-IL-17 Ab to block IL-17 effect. As shown
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a Irradiated DCOVA, Th17, (IL-2
-/-)Th17 and (Kb-/-)Th17, and
their 2-fold dilutions were co-cultured with OTI CD8? T cells. After
2 days, the proliferative responses of CD8? T cells were determined
by overnight 3H-thymidine uptake assay. b Th17-activated CD8? T
cells with or without preincubation of concanamycin A (CMA, 1 lM)
or emetin (5 lM) for 2 h were used as effector (E) cells, while
51Cr-labeled EG7 and EL4 cells were used as target (T) cells.
c DCOVA-activated Th17 and Th1 were used as effector (E) cells,
while 51Cr-labeled OVAII-pulsed LB27 cells and LB27 cells were
used as target (T) cells. *P\ 0.01 and **P[ 0.05 versus cohorts of
‘no inhibitor’ group (Student’s t test). d In tetramer staining assay, the
tail blood samples of wild-type B6 or DT-treated DTR-CD11c mice
(6 per group) transferred with Th17 were stained with PE-H-2Kb/
OVA I (PE-tetramer) and FITC-anti-CD8 Ab (FITC-CD8) and then
analyzed by flow cytometry. e In tetramer staining assay, the tail
blood samples from wild-type B6 mice (6 per group) transferred with
DCova-activated Th17, Th17 with various KO and CD3/CD28 bead-
activated Th17 (bead-Th17) or from anti-IL-17 Ab-treated B6 mice
transferred with Th17 or perforin-/- mice were stained with PE-H-
2Kb/OVA I (PE-tetramer) and FITC-anti-CD8 Ab (FITC-CD8) and
then analyzed by flow cytometry. The value represents the percentage
of tetramer-positive CD8? T cells in the total CD8? T-cell population
with standard deviation in parenthesis. In in vivo cytotoxicity assay
(in both panel d and e), the residual CFSEhigh (H) and CFSElow
(L) target cells remaining in the recipients’ spleens (6 per group) were
analyzed by flow cytometry. The value in each panel represents the
percentage of CFSEhigh vs CFSElow target cells remaining in the
spleen. (n = 6, average ± SD). *P\ 0.05 versus cohorts of mice
immunized with Th17 (Student’s t test). One representative experi-
ment of two is shown
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in Fig. 2e, the stimulatory effect was significantly reduced
in mice transferred with (Kb-/-)Th17, bead-Th17, and (IL-
2-/-)Th17 (P\ 0.05), but not in Th17-transferred mice
with the treatment of anti-IL-17 Ab, indicating that
endogenous IL-2 and acquired pMHC I, but not IL-17
signaling influence in vivo Th17’s stimulatory effect. In in
vivo cytotoxicity assay, we found that Th17-transferred
mice showed substantial loss of OVA-specific CFSEhigh
cells, indicating that Th17 can stimulate CD8? T-cell dif-
ferentiation into effector CTLs with killing activity for
OVA-specific target cells in vivo. To assess the pathway
responsible for the killing activity of CD4? Th17-stimu-
lated CD8? T cells in vivo, we also transferred CD4? Th17
cells into perforin-/- mice and repeated the above-stated
tetramer staining and in vivo cytotoxicity assays. We found
that OVA-specific CD8? T-cell in vivo proliferation in
C57BL/6 and perforin-/- mice were similar (Fig. 2e).
However, CD8
? T-cell-induced killing activity to OVA-
specific CFSEhigh target cells was lost in perforin-/- mice
(Fig. 2e), indicating that the in vivo CD4? Th17-stimulated
CD8? T-cell-induced killing activity to OVA-specific tar-
get cells is via perforin-dependent pathway. Interestingly,
(IL-2-/-)Th17-, (Kb-/-)Th17-, and bead-Th17-transferred
mice maintained their OVA-specific CFSEhigh target cell
numbers, indicating that in vivo stimulatory effect of Th17
is mediated by its IL-2 secretion and pMHC I targeting. To
assess preventive antitumor immunity, we performed ani-
mal studies by i.v. injection of BL6-10OVA cells into the
above-transferred mice 6 days subsequent to transfer. We
found that all mice (8/8) were free from metastasis,
whereas all (8/8) Th17-transferred mice with treatment of
anti-CD8 Ab completely lost their antitumor immunity
(Exp I of Table 1), indicating that Th17-induced antitumor
immunity is mainly mediated by CD8? T cells. We also
found that all (8/8) (IL-2-/-)Th17- and (Kb-/-)Th17-
transferred, but not mice with treatment of anti-IL-17 Ab,
lost their antitumor immunity (Exp I of Table 1), indicating
that Th17’s stimulatory effect on preventive antitumor
immunity is also mediated by IL-2 (not IL-17) signaling
and pMHC I targeting. To assess the long-term immunity,
we also challenged Th17-transferred mice 60 days after the
primary immunization. As shown in Exp II of Table 1, all
transferred mice had a long-term protective antitumor
immunity.
IL-17 is associated with DCova-activated
Th17-induced eradication of early-stage (5 day)
lung tumor metastases
To assess Th17’s therapeutic effect, we i.v. injected
C57BL/6 mice with BL6-10OVA tumor cells. Five days
after tumor cell injection, mice were i.v. transferred with
DCova-activated Th17 cells with pMHC I expression and
CD3/CD28 bead-activated Th17 (bead-Th17) cells without
pMHC I expression. Lung tumor colonies were numerated
10 days after transfer. Compared with untreated control
mice, those mice transferred with DCova-activated Th17,
but not with bead-Th17, had significantly fewer tumor foci
(P\ 0.05) (Fig. 3a), indicating that DCova-activated Th17
cells have efficient therapeutic effect on early-stage (5 day)
tumor lung metastasis via acquired pMHC I signaling. To
assess the role of Th17-secreted IL-17 in DCova-activated
Th17-induced antitumor immunity, we treated immunized
mice with anti-IL-17 Ab to block IL-17 signaling. We
found that Th17-transferred mice with treatment of anti-IL-
17 Ab had numerous tumor foci as the control mouse group
(Fig. 3a), indicating that IL-17 is critically involved in
DCova-activated Th17-induced therapeutic antitumor
immunity.
Th17 induces recruitment of leukocytes into tumors
via Th17-stimulated CCL2/CCL20 expression
To assess the potential Th17 stimulated CCL2/CCL20
expression, we first analyzed the expression of CCL2/
CCL20 by lung cells using real-time PCR. We found that
BL6-10 tumor cells and normal lungs did not express any
CCL2/CCL20 chemokines (Fig. 3b). However, the
expression of CCL2/CCL20 was greatly increased in lung
cell fractionations containing both tumor and lung cells,
indicating that Th17 cells stimulate expression of CCL2/
Table 1 Vaccination with Th17 protects against lung tumor metas-
tases in mice
Immunizationa Tumor-bearing mice (%)
Experiment I
Th17 0/8 (0)
Th17(IL-2-/-) 8/8 (100)
Th17(Kb-/-) 8/8 (100)
Th17 ? anti-IL17 Ab 0/8 (0)
Th17 ? anti-CD8 Ab 8/8 (100)
Th17 ? control Ab 0/8 (0)
PBS 8/8 (100)
Experiment II
Th17-immunized mice 0/8 (0)
PBS-treated mice 8/8 (100)
a In Experiment I, C57BL/6 mice (8 per group) were i.v. injected
with Th17 or Th17 with gene deficiency or Th17 plus antibody. Six
days after Th17 injection, mice were challenged with BL6-10OVA
cells. In Experiment II, C57BL/6 mice (8 per group) were i.v. injected
with Th17. Sixty days after Th17 injection, mice were challenged
with BL6-10OVA cells. The mice were killed 3 weeks after tumor cell
challenge, and lung metastatic tumor colonies were counted. One
representative experiment of two is shown
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CCL20. Further analysis of lung leukocyte fractionations
by flow cytometry revealed that CD11c? DCs, CD4?, and
CD8? T cells were significantly increased in Th17-treated
mouse lungs (Fig. 3c) (P\ 0.05). To assess the potential
recruitment of OVA-specific CD8? T cells, we transferred
DCOVA-activated OTI CD8
? T cells into B6 mice bearing
5-day lung tumor metastasis and then numerated tumor-
infiltrating CD8? T cells by flow cytometry. We found that
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Fig. 3 Therapeutic effect of OVA-specific Th17 cells on eradication
of established lung tumor metastasis. a C57BL/6 mice or Iab-/- KO
mice or toxin-treated DTR-CD11c mice or perforin-/- mice bearing
5-day lung B16 melanoma were i.v. immunized with DCova-
activated Th17 with or without various Abs against CD8, CD11c,
IL-17 for depletion of host CD8? T cells, DCs, and cytokine,
respectively. C57BL/6 mice bearing 5-day lung B16 melanoma were
also i.v. immunized with CD3/CD28 bead-activated Th17 (bead-
Th17). Tumor colonies were counted on day 16 after tumor challenge
(n = 8, average ± SD). *P\ 0.05, versus cohorts of tumor foci in
mice injected with control Ab (Student’s t test). b mRNA gene
expression analysis was assessed by RT–PCR. Data shown were
normalized to the reference gene GAPDH. Graphs represent the
average values of four mice after duplicate analysis per sample
(n = 4, average ± SD). c Total numbers of leukocytes from cell
fractions of tumor-bearing lungs were calculated from percentages of
live cells gated on CD45.2 (n = 4, average ± SD). d 5-day lung
tumor-bearing mice were transferred with 3 9 106 OTI CD8? T cells
and after 3 days percentages of OTI CD8? T cells out of total CD8?
T-cell population in lungs were measured by gating on FITC-CD8
and PE-tetramer-positive T cells (n = 4, average ± SD). One repre-
sentative experiment of two is shown
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Th17 significantly promoted tumor infiltration of OVA-
specific CD8? T cells indicating that Th17 cells promotes
tumor infiltration of OVA-specific CD8? T cells via
CCL20 chemoattraction.
Th17-activated CD8? T cells mediate therapeutic effect
via perforin-dependent pathway on early-stage (5 day)
lung tumor metastases
To assess the role of recruited DCs, CD4?, and CD8? T
cells, the above immunized C57BL/6 mice were treated
with different antibodies to deplete CD8? T cells or
DCs. Alternatively, DTR-CD11c transgenic mice with
the treatment of toxin to deplete the host DCs were
transferred with Th17. To assess the role of recruited
CD4? T cells in Th17-induced therapeutic effect, we also
i.v. transferred Iab-/- KO mice with Th17, which lack
the host CD4? T cells. We found that only the mice
treated with anti CD8 Ab (host CD8? T cells depleted),
but not mice with depletion of host DCs (anti CD11c Ab
or DTR-CD11c mice treated with toxin) or lacking host
CD4? T cells (Iab-/- KO mice), showed numerous
tumor foci (Fig. 3a), indicating that Th17-stimulated
CD8? CTLs play an important role, but the host DCs
and CD4? T cells recruited into tumor tissues are not
involved in Th17-induced therapeutic effect. To assess
the molecular mechanism of CD8? T-mediated killing,
we repeated Th17 treatment in tumor-bearing perforin-/-
mice, where Th17-stimulated host OVA-specific CD8? T
cells are perforin deficient. We found that Th17-trans-
ferred perforin-/- mice showed numerous tumor foci
(Fig. 3a), indicating that Th17-stimulated CTLs mediate
therapeutic effect via perforin-dependent pathway.
Th17-activated CD8? T cells are potent
in the eradication of early-stage (3 mm), but not
well-established (6 mm), s.c. tumors
To determine whether Th17 protects against tumors in
different tissues in addition to lung tissues, we s.c. inoc-
ulated B6 mice with BL6-10OVA cells. We then treated
mice bearing different sizes (early stage: 3 mm and well-
established tumor: 6 mm) of B16 melanoma with Th17.
We found that all tumor (3 mm)-bearing mice (8/8) died of
tumor within 21 days without treatment, whereas all 8/8
tumor-bearing mice with treated with Th17 survived
(Fig. 4a), indicating that DCova-activated Th17 cells have
immunotherapeutic effect on early-stage tumors. To assess
the role of IFN-c expression, and host CD4? and CD8? T
cells in the immunotherapeutic effect, we used IFN-c-/-,
Iab-/-, and H-2 Kb-/- KO mice in the above experiments.
We found that DCova-activated Th17 cell-induced thera-
peutic effect was not affected in IFN-c-/- and Iab-/- KO
mice (Fig. 4b), indicating that Th17-induced therapeutic
effect is not mediated via host IFN-c and CD4? T cells.
However, its therapeutic effect was completely lost in
H-2 Kb-/- KO mice lacking host CD8? T cells (Fig. 4b),
confirming that Th17-stimulated host CD8? CTLs play a
major role in Th17-induced therapeutic antitumor immu-
nity. To assess the potential immunotherapeutic effect on
well-established tumors, we repeated experiments in mice
bearing BL6-10OVA tumors (6 mm). We found that none
(0/8) of the treated mice survived though their survival was
significantly prolonged (P\ 0.05) (Fig. 4c), indicating
that DCova-activated Th17 cells, though having thera-
peutic effect, are not potent enough in well-established
tumors.
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Fig. 4 Therapeutic effect of OVA-specific Th17 cells on the
eradication of established s.c. tumors. a Wild-type C57BL/6 mice
(n = 8) bearing early-stage (3 mm) B16 melanoma were i.v.
immunized with DCova-activated Th17 cells or PBS as a control.
b Wild-type C57BL/6, IFN-c-/-, H-2 Kb-/-, and Iab-/- gene KO
mice (n = 8) bearing early-stage (3 mm) B16 melanoma were i.v.
immunized with DCoav-activated Th17 cells. Tumor regression or
growth was monitored. The evolution of the tumors in individual
mouse is depicted for their survival period. c Wild-type C57BL/6
mice (n = 8) bearing well-established (6 mm) B16 melanoma were
i.v. immunized with Th17. Tumor size was measured daily using an
engineering caliper. The evolution of the tumors in individual mouse
is depicted for their survival period. *P\ 0.05 versus cohorts of
control group (Log rank test). One representative experiment of three
is shown
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Discussion
Th17 cells are an important inflammatory component and
have been shown to promote inflammation in autoimmune
diseases [22, 23]. Recent evidence suggests that Th17 cells
are also involved in tumor immunology and may be a target
for cancer immunotherapy [24]. We have previously
demonstrated that Th1 cells acquired pMHC I complexes
and co-stimulatory molecules from DCOVA upon DCOVA
activation and became capable of stimulating OVA-spe-
cific CD8? CTL responses via IL-2 and pMHC I signaling
and antitumor immunity [15, 19]. In our current study, we
demonstrated for the first time that (i) in vitro DCOVA-
activated Th17 cells expressing RORct, IL-17, and IL-2
also acquire pMHC I complexes upon activation by DCOVA
and (ii) Th17 with cytokine profile distinct from Th1 is also
capable of stimulating CD8? CTL responses and long-term
memory via IL-2 and pMHC I, but not IL-17 signaling.
Endogenous IL-2 of Th17 cells is important in CTL
induction, though Il-2 has been shown to constrain Th17
generation from CD4? T precursors via STAT5 [25]. In
addition, we also demonstrated that Th17-induced pre-
ventive antitumor immunity is mainly mediated by Th17-
stimulated CTLs.
In the therapeutic model for early-stage (5 day) lung
tumor metastases, we found that (i) it is Th17-activated
CD8? T cells that play a major role in the eradication of
lung metastatic tumors and (ii) Th17 stimulated the
expression of CCL2/20 in lung tumor microenvironments,
which promoted the recruitment of various inflammatory
leukocytes (DCs, CD4?, and CD8? T cells) to induce
therapeutic immunity. Our study elucidates the molecular
mechanism of Th17’s stimulatory effect on CD8? CTL
responses and also demonstrated that (i) it is the Th17-
stimulated CTLs, but not Th17 cells, that themselves have
direct in vitro killing activity to tumor cells, (ii) Th17-
secreted IL-17, but not the host IFN-c, is associated with
Th17-induced therapeutic effect, and (iii) although Th17
cells promote tumor infiltration of various inflammatory
leukocytes, the tumor-specific CD8? T cells with killing
activity via perforin pathway [26], but not DCs and CD4?
T cells recruited via CCL20 chemoattraction, play a major
role in Th17-induced therapeutic effect. To date, adoptive
T-cell immunotherapy for cancer by using in vitro expan-
ded tumor-infiltrating CD8? T cells has achieved some
degree of success [27, 28]. However, one of the major
obstacles in this therapy is only very limited number of
transferred CD8? T cells that eventually infiltrate into
tumors [29, 30], which greatly affects its therapeutic effi-
cacy. Therefore, Th17 cells may be useful in enhancing
adoptive CD8? T-cell immunotherapy for cancer.
Th17-polarized cells derived from TRP-1-specific TCR
transgenic mice inhibited the growth of large s.c.
established B16 melanoma (*0.6 cm2, equal to*7–8 mm
in diameter) after adoptive transfer of Th17 cells [15].
However, in our current study, we found that Th17 cells
efficiently cured s.c B16 melanoma only in early stage
(3 mm), but not well-established stage (6 mm), which is
consistent with a previous report on the eradication of
6-day s.c. tumors [31]. The discrepancy in therapeutic
efficiency may be due to the different treatment protocols
in these reports. In our protocol, we simply i.v. transferred
OVA-specific Th17 into B16 melanoma-bearing mice for
direct assessment of Th17 therapeutic effect. In their pro-
tocol [15], they have combined adoptive transfer of Th17
with an extra-total body sublethal irradiation plus TRP-1
virus and IL-2 administration. Their complex protocol will
definitely interfere with the assessment of Th17-mediated
therapeutic effect. For example, sublethal irradiation will
induce lymphopenia leading to proliferation and prolonged
survival of transferred T cells [32, 33] and conversion of
Th17 into Th1 [34, 35], whereas TRP-1 virus vaccine alone
can activate both Th1 and CTL responses important for
tumor rejection [36, 37].
Based upon previous reports and our own findings, we
propose the following model for Th17-induced antitumor
immunity: (i) Th17 directly stimulates tumor-specific
CD8? T-cell responses via pMHC I and IL-2 signaling, (ii)
homing molecule (CXCR4, CCR6, and CD161)-expressing
Th17 migrates into tumors [20, 38] by tumor environ-
mental RANTES and MCP-1 chemoattraction [39], (iii)
tumor-infiltrating Th17 stimulates tumor tissues to express
CCL20 for recruiting CCR6-expressing tumor-specific
CD8? T cells into tumors via CCL20 chemoattraction, and
(iv) tumor-specific CD8? T cells exert direct killing
activity to tumor cells via perforin/granzyme B pathway
(Fig. 5).
Taken together, our data demonstrate a distinct role of
Th17 and Th17-stimulated CD8? T-cell responses in pre-
ventive and therapeutic antitumor immunity, which may
greatly impact the development of Th17-based cancer
immunotherapy.
Materials and methods
Reagents, antibodies, cell lines, and animals
The biotin-labeled anti-CD4 (GK1.5), CD11c (HL3), CD25
(7D4), CD40L (TRAP1), CD69 (H1.2F3), FasL (CD178),
and major histocompatibility complex (MHC) class I (H-
2 Kb) (AF6-88) antibodies (Abs) were purchased from BD
Biosciences (San Diego, CA). The R-phycoerythrin (PE)-
conjugated anti-mouse IFN-c (XMG1.2), perforin (dG9),
and FITC-conjugated IL-17 (TC11-18H10) Abs were
obtained from Pharmingen Inc. (Mississauga, Ontario,
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Canada). The PE-conjugated anti-mouse RORct (RORg2)
Abs were purchased from BioLegend (San Diego, CA). The
FITC-conjugated avidinwas obtained from Jackson Immuno
Research Laboratory Inc. (West Grove, PN). Peptides OVAI
(OVA257–264) specific for H-2K
b, OVAII (OVA323–339)
specific for Iab, and 3LL lung carcinoma antigen (Ag) Mut1
peptide specific for H-2Kb were synthesized by Multiple
Peptide Systems (San Diego, CA). The FITC-labeled anti-
CD8 Ab and PE-H-2Kb/OVAI tetramer were obtained from
Beckman Coulter (Mississauga, Ontario, Canada). Recom-
binant cytokines were obtained from R&D Systems Inc.
(Minneapolis, MN). Tumor cell lines including ovalbumin
(OVA)-expressing thymoma (EG7) and BL6-10OVA and Ia
b-
expressingLB27were available in our laboratory [40].Wild-
type C57BL/6, IL-2?/-, perforin-/-, Iab-/- and H-2Kb-/-
knockout (KO), diphtheria toxin receptor (DTR)-CD11c
transgenic mice [41], and OVA-specific T-cell receptor
(TCR) transgenic OTI and OTII mice, which express TCR
specific for OVAI and OVAII, respectively, were all pur-
chased from the Jackson Laboratory (Bar Harbor, MA).
Homozygous OTII/H-2Kb-/- and OTII/IL-2-/- mice were
generated by backcrossing the designated gene KO mice
onto OTII background. All mice were treated according to
Animal Care Committee guidelines of University of
Saskatchewan.
Preparation of dendritic cells
Bone marrow–derived dendritic cells (DCs) of C57BL/6
mice were generated in the presence of GM-CSF (20 ng/
ml) and IL-4 (20 ng/ml) as described previously [18, 19].
These DCs expressed MHC II, CD40, and CD80, indicat-
ing that they were mature DCs. They were then pulsed with
OVA (0.3 mg/ml) overnight at 37°C and termed as DCOVA.
OVA-pulsed DCs generated from H-2Kb gene KO mice
were referred to as (Kb-/-)DCOVA.
Preparation of OVA-specific T cells
To generate OVA-specific Th17 cells, naı¨ve CD4? T cells
(2 9 105 cells/ml) from OT II mice were stimulated for
3 days with irradiated (4,000 rads) DCOVA (1 9 10
5 cells/
ml) in the presence of IL-6 (10 ng/ml), IL-23 (10 ng/ml),
TGF-b (10 ng/ml), and anti-IFN-c antibody (20 lg/ml).
These DCova-activated Th17 cells were purified by posi-
tive selection using CD4 microbeads (Miltenyi Biotech,
Auburn, CA). (Kb-/-)DCOVA-activated CD4
? T cells
derived from OTII mice were termed (Kb-/-)Th17,
whereas DCOVA-activated CD4
? T cells derived from
OTII/IL-2-/- mice were termed (IL-2-/-)Th17. Alterna-
tively, naı¨ve CD4? T cells (2 9 105 cells/ml) from OT II
mice were stimulated with CD3/CD28 T-cell expander
Dynabeads (Invitrogen) at a ratio of 1:1 (bead:cell) for
4–5 days in the presence of IL-6 (10 ng/ml), IL-23 (10 ng/
ml), and TGF-b (10 ng/ml) [42]. The cytokine profiles of
the above various gene KO Th17 or CD3/CD28-bead-
activated Th17 (bead-Th17) were similar to the cytokine
profile of DCova-activated Th17 cells except for the spe-
cific molecule deficiency (data not shown). Preparation of
DCOVA-activated OVA-specific Th1 cells expressing IL-2,
IFN-c, FasL, and perforin, but not IL-4 and OVA-specific
CD8? T cells, were previously described [19, 43].
Phenotypic characterization of OVA-specific Th17
cells
The above Th17 cells and Th17 cells with various gene KO
were stained with antibodies and analyzed by flow
cytometry. To measure intracellular expression of cyto-
kines, Th17 were processed using a intracellular staining
commercial kit (BD Biosciences, San Diego, CA) and
stained with anti-perforin and RORct Ab or double stained
with FITC-conjugated anti-IL-17 Ab and PE-conjugated
anti-IFN-c Ab. Culture supernatants of Th17 re-stimulated
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Fig. 5 Mechanism of Th17-
mediated antitumor immune
responses. Tumor-infiltrating
Th17 cells stimulate tumor
microenvironment to express
CCL2/20 leading to the
recruitment of inflammatory
cells such as CD8? CTLs
derived from direct Th17
stimulation via pMHC I and
IL-2 signaling into the tumor
site, which exert direct killing
activity to tumor cells via
perforin/granzyme B pathway
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with irradiated (4,000 rads) OVAII peptide-pulsed LB27
cells [18, 19] were analyzed for cytokine expression using
ELISA kits (Endogen, Cambridge, MA).
CD8? T-cell proliferation assays
To assess the functional effect of OVA-specific Th17, we
performed in vitro CD8? T-cell proliferation assay. Two-
fold serially diluted irradiated (4,000 rads) DCOVA, Th17,
(IL-2-/-),Th17, and (Kb-/-)Th17 cells (0.4 9 105 cells/
well) were co-cultured with a constant number of naive OT
I CD8? T cells (1 9 105 cells/well). After culturing for
48 h, overnight thymidine incorporation was quantified by
liquid scintillation counting. In in vivo proliferation assay,
C57BL/6 or perforin-/- mice (6 per group), or transgenic
DTR-CD11c mice (6 per group) with a single dose (4 ng/g
mouse body weight) of i.v. diphtheria toxin (DT) treatment
1 day before Th17 transfer were i.v. transferred with
DCOVA (1 9 10
6 cells), DCova-activated Th17 (3 9 106
cells) or Th17 (3 9 106 cells) with various gene KO or
CD3/CD28 bead-activated Th17 (bead-Th17) (3 9 106
cells). Six days subsequent to transfer, tail blood samples
were stained with FITC-anti-CD8 Ab and PE-H-2 Kb/
OVAI tetramer and analyzed by flow cytometry.
Cytotoxicity assays
In in vitro cytotoxicity assay, DCOVA-activated OTII Th17
and Th1 were used as effector (E) cells, while 51Cr-labeled
OVAII-pulsed LB27 cells were used as target (T) cells. In
another experiment, Th17-activated OTI CD8? cytotoxic
(Tc) cells were used as effector (E) cells, while 51Cr-labeled
EG7 were used as target (T) cells in a chromium release
assay. CMA and emetin inhibitors were used in Th17-acti-
vated OTI CD8? cytotoxic (Tc) cell cytotoxicity assay to
inhibit perforin and FAS ligand–mediated cytotoxicity,
respectively [19]. In in vivo cytotoxicity assay, 6 days fol-
lowing Th17 transfer, the Th-transferred C57BL/6 mice (6
per group) were i.v. injected with a 1:1 (OVA-specific
CFSEhigh:nonspecific control CFSElow) mixture of spleno-
cyte targets. Sixteen hours subsequent to target cell delivery,
the proportion of CFSEhigh and CFSElow target cells
remaining in the spleens was analyzed by flow cytometry
[21].
Real-time RT–PCR
Total RNA was extracted from BL6-10OVA cells, lung cell
fraction from normal or tumor-bearing lungs with Qiagen
RNeasy purification kit (Qiagen, Mississauga, Ontario,
Canada) as per manufacturer’s protocols. The primer sets
for real-time PCR analysis of RORct, CCL2, and CCL20
were designed as previously described [16]. Qiagen
quantitative reverse transcription kit (Qiagen) was used to
synthesize cDNA, which was then analyzed by real-time
quantitative PCR in triplicates by using SYBR Green PCR
mastermix (Applied Biosystems, Foster City, CA, USA) in
the Stepone Real-time PCR system (Applied Biosystems).
Each gene expression was normalized to GAPDH expres-
sion level using comparative CT method.
Lung fractionation and cell analysis
Mouse lungs were digested with collagenase D (1 mg/ml,
Worthington Biochemical, Freehold, NJ) at 37°C for
30 min and 5 min with 0.01 M EDTA for prevention of
DC–T-cell aggregate formation [44]. The cells were sep-
arated using Histopaque (Sigma, St. Louis, MO). The
middle section of the gradient, which was enriched with
leukocytes, was counted and analyzed by flow cytometry,
whereas the bottom fraction that was enriched with tumor
cells and lung cells was used for RNA extraction.
Animal studies
In preventive immunity model, wild-type C57BL/6 mice (8
per group) were i.v. transferred with OVA-specific Th17
(3 9 106), Th17 (3 9 106) with various gene KO and Th17
(3X106) with various antibodies. Six days subsequent to
transfer, mice were i.v. challenged with BL6-10OVA cells
(0.5 9 106). Mice were killed after 3 weeks, and the
numbers of metastatic lung tumor colonies were counted
[18]. In the lung tumor metastasis therapeutic model,
C57BL/6 mice (8 per group) were i.v. injected with BL6-
10OVA tumor cells (0.5 9 10
6). After 5 days of tumor cell
injection (5-day lung tumor metastasis), mice were i.v.
injected with Th17 or CD3/CD28 bead-activated Th17
(bead-Th17) (3 9 106 cells/mouse) cells. To deplete CD8?
T cells or DCs or to block IL-17, C57BL/6 mice were i.p.
injected with anti-CD8 or anti-CD11c or anti-IL-17 Ab
(each, 0.5 mg/mouse) 1 day before Th17 transfer and fol-
lowed by another two injections (once every 3 days). To
assess the involvement of host CD4? T cells or DCs or host
CD8? T-cell’s perforin in therapeutic effect, Iab-/- KO
mice (lacking CD4? T cells) or DTR-CD11c transgenic
mice (8 per group) with diphtheria toxin (DT) treatment (a
single dose of 4 ng/g body weight of mouse; i.p.) to deplete
host CD11c? DCs or perforin-/- mice were used [45].
Mice were killed on day 16 after i.v. injection of tumor
cells. The metastatic lung tumor colonies were counted. In
the s.c. tumor therapeutic model, C57BL/6 or Kb-/- or
Iab-/- or IFN-c-/- KO mice (8 per group) were s.c.
injected with BL6-10OVA tumor cells (0.5 9 10
6). When
s.c. tumors reached 3 or 6 mm in diameter, these mice were
i.v. injected with Th17 cells (3 9 106 cells). Tumor growth
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was monitored by measuring tumor diameter using caliper;
for ethical reasons, all mice with tumors that achieved a
size of 1.5 cm in diameter were killed.
Statistical analysis
Mouse survival was analyzed using log rank test [46, 47],
and all other experiments were tested for statistical dif-
ferences using unpaired, two-tailed, Student’s t test. Dif-
ferences were considered significant if P\ 0.05.
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CHAPTER 3 
3. A Distinct Roles of CD4
+
 Th17 and Th17-Stimulated CD8
+
 CTL in the Pathogenesis of 
Type 1 Diabetes and Experimental Autoimmune Encephalomyelitis. 
 
Brief introduction to chapter 3 
This chapter addresses the mechanism of stimulatory effect of Th17 cells on self antigen 
specific CD8
+
 CTL responses in EAE and T1D models. Earlier studies had shown that both 
CD4
+
 Th17 cells and CD8
+
 CTLs are involved in T1D and EAE. However, their relationship in 
pathogenesis was still elusive.  In this study, we found that CD4
+
 Th17 cells stimulate OVA- and 
MOG-specific CD8
+
 CTL responses, respectively, in mice. When CD4
+
 Th17 cells were 
transferred into (i) transgenic RIP-mOVA and wild-type C57BL/6 mice, where both CD4
+
 Th17 
cells and CD4
+
 Th17-stimulated CD8
+
 CTLs existed, (ii) RIP-mOVA mice treated with anti-CD8 
antibody to eliminate Th17-stimulated CD8
+
 T cells, and (iii) H-2Kb
-/-
 mice, lacking the ability 
to generate  Th17-stimulated CD8
+
 T cells, we found that  OVA specific CD4
+
 Th17 cells 
stimulated CD8
+
 CTLs, but not CD4
+
 Th17 cells themselves, induce diabetes in RIP-mOVA, 
whereas MOG-specific CD4
+
 Th17 lymphocytes, but not CD4
+
 Th17-activated CD8
+
  CTL 
induced EAE in C57BL/6 mice. This study demonstrated the distinct roles of CD4
+
 Th17 and 
CD4
+
 Th17 stimulated CD8
+
 CTLs in the pathogenesis of autoimmune diseases, which may have 
great impact on the overall understanding of CD4
+
 Th17 cells in the pathogenesis of autoimmune 
diseases. 
Reprinted with consent from Journal of Clinical Immunology 2011;31(5):811-26. 
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Abstract Both CD4+ Th17-cells and CD8+ cytotoxic T
lymphocytes (CTLs) are involved in type 1 diabetes and
experimental autoimmune encephalomyelitis (EAE).
However, their relationship in pathogenesis of these
autoimmune diseases is still elusive. We generated ovalbumin
(OVA)- or myelin oligodendrocyte glycoprotein (MOG)-
specific Th17 cells expressing RORγt and IL-17 by in vitro
co-culturing OVA-pulsed and MOG35-55 peptide-pulsed
dendritic cells (DCOVA and DCMOG) with CD4
+ T cells
derived from transgenic OTII and MOG-T cell receptor
mice, respectively. We found that these Th17 cells when
transferred into C57BL/6 mice stimulated OVA- and
MOG-specific CTL responses, respectively. To assess the
above question, we adoptively transferred OVA-specific
Th17 cells into transgenic rat insulin promoter (RIP)-
mOVA mice or RIP-mOVA mice treated with anti-CD8
antibody to deplete Th17-stimulated CD8+ T cells. We
demonstrated that OVA-specific Th17-stimulated CTLs,
but not Th17 cells themselves, induced diabetes in RIP-
mOVA. We also transferred MOG-specific Th17 cells into
C57BL/6 mice and H-2Kb−/− mice lacking of the ability to
generate Th17-stimulated CTLs. We further found that
MOG-specific Th17 cells, but not Th17-activated CTLs
induced EAE in C57BL/6 mice. Taken together, our data
indicate a distinct role of Th17 cells and Th17-stimulated
CTLs in the pathogenesis of TID and EAE, which may
have great impact on the overall understanding of Th17
cells in the pathogenesis of autoimmune diseases.
Keywords Th17 . pMHC I complex . CD8+ CTL . type 1
diabetes . experimental autoimmune encephalitis
Introduction
CD4+ Th17 lymphocytes have unique cytokine expression
profile, transcriptional regulation, and biological function,
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and represent an independent lineage of CD4+ Th cells [1, 2].
The discovery of CD4+ Th17 subset not only changes the
classical Th1/Th2 paradigm of Th differentiation, but also
markedly facilitates our understanding of immune responses
under both physiological and pathological conditions [3, 4].
The differentiation and regulation of Th17 cells have been
extensively studied. Transcriptional factors RORγt and
STAT3 are critical and are required for the development of
Th17 cells [5, 6], and cytokine transforming growth factor
(TGF)-β, IL-6, and IL-21 are critical for initiation and
differentiation of Th17 cells [7–10].
Accumulated data suggest that Th17 cells play an
important role in host defense against microbial infections
and in the pathogenesis of autoimmune diseases such as
type 1 diabetes (T1D) and experimental autoimmune
encephalomyelitis (EAE) [11]. In T1D, the involvement of
CD8+ T cells in pathogenesis has been recognized. T1D is
caused by autoimmune destruction of insulin-producing
islet β cells of the pancreas [12]. Antigen-specific CD8+ T
cells have been found in the peripheral blood of T1D
patients [13]. Studies in a nonobese diabetic (NOD) mouse
model of T1D have indicated that CD8+ T cells inflict
damage to islet β cells both at the early stage in diabetes
development and at the final effector phase of the disease
[14–16]. On the contrary, there is some preliminary
evidence showing that Th17 cells may be considered as a
contributing factor in the pathogenic process of T1D. For
example, it has been found that IL-17 is expressed in the
pancreas of T1D mouse model [17], and the reduction of
Th17 cells with the induction of IFN-γ inhibited IL-17
production and restored normoglycemia at the prediabetic
stage [18]. However, the relative contribution of Th17 cells
and CTLs in T1D has not been addressed.
EAE is a rodent model that has been valuable for the
characterization of the immunopathogenic processes of
human multiple sclerosis (MS). Attention has originally been
focused on the role of CD4+ T cells in the induction of EAE
because susceptibility to MS is associated with MHC class II
genes [19–21] and the critical role of CD4+ Th17 cells in
pathogenesis of EAE has, eventually, been demonstrated
[22–26]. Recently, both CD4+ Th17 and CD8+ T cells have
been identified in active lesions in brains of MS patients
[27]. It has been shown that myelin oligodendrocyte
glycoprotein (MOG)-specific CD8+ T cell responses are
involved prior to and after the onset of EAE [28, 29], and
adoptive transfer of MOG-specific CD8+ T cells can also
induce EAE [30–32]. However, (a) the potential relationship
between the pathogenic CD4+ Th17 and CD8+ T cells and
(b) the extent of their relative involvement in the pathogen-
esis of T1D and EAE are still not very clear.
Intercellular membrane transfer through trogocytosis
plays an important role in immune modulation [33]. We
have recently demonstrated that ovalbumin (OVA)-specific
T cell receptor (TCR) transgenic OT II mouse CD4+ Th1
cells in vitro activated by OVA-specific dendritic cells
(DCOVA) acquired DCOVA’s peptide-MHC (pMHC) I and
co-stimulatory molecules and became capable of directly
stimulating antigen-specific CD8+ cytotoxic T lymphocyte
(CTL) responses leading to antitumor immunity in wild-
type C57BL/6 mice [34, 35] and diabetes in transgenic rat
insulin promoter (RIP)-mOVA mice expressing islet β-cell
antigen OVA [36, 37]. Based on the phenomenon of
trogocytosis, we speculate that CD4+ Th17 cells may
similarly acquire pMHC I by APC activation and become
capable of stimulating CD8+ T cell responses in autoimmune
diseases such as T1D and EAE.
In this study, we generated OVA-specific CD4+ Th17
cells and MOG-specific CD4+ MOG-TCR-Th17 cells by
cultivating OVA-pulsed dendritic cells (DCOVA) or MOG
peptide-pulsed dendritic cells (DCMOG) with CD4
+ T cells
derived from Tcell receptor transgenic OTII mice or MOG-
TCR transgenic mice, respectively. We also generated MOG-
specific CD4+ Th17 by culturing MOG35-55 peptide-
pulsed splenocytes with CD4+ T cells purified from
C57BL/6 mice with MOG35-55 immunization-induced
EAE in presence of IL-6/IL-23/TGF-β. Through the
utilization of this experimental model, we found that
CD4+ Th17 cells acquired pMHC I in the process of
activation by dendritic cells (DCs) and became capable of
stimulating OVA or MOG-specific CD8+ CTL responses,
when transferred into the mice. To assess the pathogenic
behavior of CD4+ Th17- and Th17-induced CD8+ T cells
in T1D and EAE, we transferred OVA- and MOG-specific
CD4+ Th17 cells into RIP-mOVA and C57BL/6 mice,
where both CD4+ Th17- and Th17-stimulated CD8+ CTL
populations co-existed. We also used anti-CD8 antibody
treatment in RIP-mOVA mice to deplete Th17-stimulated
CD8+ T cells or employed H-2Kb−/− mice lacking the
endogenous CD8+ population to independently assess the
effect of CD4+ Th17 cells or of Th17-stimulated CD8+
CTLs in pathogenesis of T1D and EAE. These experiments
have clearly showed a distinct role of CD4+ Th17- and
Th17-stimulated CD8+ CTLs in pathogenesis of autoimmune
diseases demonstrating that T1D is directly mediated by
CD8+ lymphocytes, whereas EAE appears to be induced by
the CD4+ Th17 cells.
Materials and Methods
Reagents, Antibodies, Cell Lines, and Animals
The biotin-labeled anti-CD4 (GK1.5), CD11c (HL3),
CD25 (7D4), CD40L (TRAP1), CD69 (H1.2 F3), FasL
(CD178), and major histocompatibility complex (MHC)
class I (Kb) (AF6-88) and II (Iab) (KH74) antibodies (Abs)
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were purchased from BD-Biosciences (San Diego, CA).
Anti-mouse IFN-γ (XMG1.2), IL-17 (TC11-18H10),
and perforin (δG9) Abs were obtained from Pharmingen Inc.
(Mississauga, Ontario, Canada).The PE-conjugated anti-
mouse T-bet (4B10) and RORγt (RORg2) Abs were
purchased from BioLegend (San Diego, CA). The
FITC-conjugated avidin was obtained from Jackson
Immuno Research Laboratory Inc, West Grove, PN. Chicken
OVA protein was purchased from Sigma, St. Louis, MO.
Various peptides including OVAI (OVA257-264, SIINFEKL)
peptide specific for H-2Kb, OVAII (OVA323-339, ISOAVHAA-
HAAHAEINEAGR) peptide specific for Iab, 3LL lung
carcinoma antigen Mut1 (FEQNTAQP) peptide specific for
H-2Kb, MOG peptide (MOG35-55, MEVGWYRSPFSRVVH-
LYRNGK) specific for both H-2Kb and Iab, and MOGI
(MOG41-50, RSPFSRVVHL) peptide specific for H-2K
b
were synthesized by Multiple Peptide Systems (San
Diego, CA). The FITC-labeled anti-CD8 Ab and PE-
H-2Kb/OVAI tetramer were obtained from Beckman
Coulter, Mississauga, Ontario, Canada. PE-H-2Db/MOGI
pentamer was obtained from Proimmune, Oxford, UK. The
recombinant granulocyte macrophage colony-stimulating
factor (GM-CSF), IL-2, IL-4, IL-6, IL-23, TGF-β, and
anti-IL-2 antibody were obtained from R&D Systems Inc,
Minneapolis, MN. Thymoma cell lines EL4 and OVA-
expressing EG7 were obtained from American type culture
collection (ATCC, Rockville, MD). Wild-type C57BL/6 mice
were obtained from Charles River Laboratories (St. Laurent,
Quebec, Canada). The OVA-specific TCR transgenic OTII
mice, and Iab−/−, H-2Kb−/−, and perforin−/− knockout (KO)
mice were purchased from the Jackson Laboratory (Bar
Harbor, MA). Homozygous OTII/H-2Kb−/− mice were
generated by backcrossing the designated H-2Kb−/− KO
mice onto OTII background for two generations. The
homozygosity was confirmed through PCR analysis
according to Jackson laboratory’s protocols. Transgenic
RIP-mOVA mice with C57BL/6 background were
obtained from Dr. W. Heath, Walter and Eliza Hall
Institute of Medical Research (Melbourne, Australia).
These transgenic RIP-mOVA mice express OVA under the
control of RIP. They are transgenic for truncated OVA
gene that is expressed as a membrane bound molecule in
pancreatic islets, kidney proximal tubules, and testis of
male mice [38]. All mice were housed in the animal
facility at the Saskatoon Cancer Center and treated
according to Animal Care Committee guidelines of
University of Saskatchewan.
Preparation of Dendritic Cell and OVA-Specific CD4+ Th1
and CD8+ Tc1 Cells
Bone marrow-derived DCs were generated in presence of
GM-CSF (20 ng/ml) and IL-4 (20 ng/ml) as described
previously [39]. DC derived from wild-type C57BL/6 mice
were pulsed with OVA (0.3 mg/ml) overnight at 37°C, and
termed as DCOVA. DC derived from MOG-TCR transgenic
mice were pulsed with MOG35-55 peptide (20 μg/ml) for
2 h at 37°C, and termed as DCMOG. OVA-pulsed DC
generated from H-2Kb−/− was referred to as (Kb−/−)DCOVA.
The preparation of DCOVA-activated OVA-specific OT II
CD4+ type 1 help T (Th1) and OT I CD8+ type 1 cytotoxic
T (Tc1) cells was previously described [35, 40].
OVA- and MOG-specific CD4+ Th17 Cell Preparation
Spleens were removed from OT II, transgenic MOG-TCR,
and EAE-induced mice, and were mechanically disrupted to
obtain a single-cell suspension. The erythrocytes were lysed
using 0.84% ammonium chloride. Naïve T cells were
enriched by passing through nylon wool columns (C&A
Scientific Inc, Mannose, VA). Naïve OVA-specific CD4+ T
cells were then purified by negative selection using anti-
mouse CD8 (Ly2) paramagnetic beads (DYNAL Inc, Lake
Success, NY). To generate OVA-specific CD4+ Th17 cells,
naïve CD4+ T cells (2×105 cells/ml) from OT II mice were
stimulated for 3 days with irradiated (4,000 rads) DCOVA
(1×105 cells/ml) in the presence of IL-6 (10 ng/ml), IL-23
(10 ng/ml), TGF-β (5 ng/ml), and anti-IFN-γ antibody
(20 μg/ml). These in vitro-activated CD4+ Th17 cells
were separated by Ficoll-Paque (Sigma) density gradient
centrifugation, further purified by positive selection using
CD4-microbeads (Miltenyi Biotech, Auburn, CA). In vitro
(Kb−/−)DCOVA-activated CD4
+ T cells derived from OTII
mice with Kb−/− KO were termed CD4+ (Kb−/−)Th17 cells.
The cytokine profiles of the above (Kb−/−)Th17 were
similar to CD4+ Th17 cells (data not shown). MOG-specific
CD4+ Th17 cells were generated by incubation of irradiated
(4,000 rad) wild-type C57BL6 mouse splenocytes with
CD4+ T cells purified from spleens of MOG35-55
immunization-induced EAE mice with clinical score ≥2.5
at 1:1 ratio in presence of MOG35-55 peptide (20 μg/ml), IL-
6 (10 ng/ml), IL-23 (10 ng/ml), and TGF-β (5 ng/ml). MOG-
specific CD4+ MOG-TCR-Th17 cells were generated by co-
stimulating naïve CD4+ Tcells (2×105 cells/ml) from MOG-
TCR transgenic mice with irradiated (4,000 rads) DCMOG
(1×105 cells/ml) in the presence of IL-6 (10 ng/ml), IL-23
(10 ng/ml), TGF-β (5 ng/ml), and anti-IFN-γ antibody
(20 μg/ml) for 3 days. Three days subsequent to incubation,
MOG-specific CD4+ Th17 and CD4+ MOG-TCR-Th17 cells
were purified by positive selection using CD4-microbeads.
Phenotypic Characterization of OVA- and MOG-specific
CD4+ Th17 Cells
The above CD4+ Th17 cells were stained with a panel of
Abs and analyzed for expression of various cell-surface
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molecules by flow cytometry. To measure intracellular
expression of cytokines, CD4+ Th17 cells were processed
using a commercial kit (Cytofix/CytoPerm Plus with
GolgiPlug; BD-Biosciences, San Diego, CA) and stained
with PE-conjugated anti-IFN-γ, IL-17, perforin, T-bet, and
RORγt Abs. Culture supernatants of these OVA-specific
and MOG-specific CD4+ Th17 cells re-stimulated with
irradiated (4,000 rad) OVAII peptide-pulsed and MOG
peptide-pulsed LB27 cells, respectively, were analyzed for
cytokine expression using ELISA kits (Endogen, Cam-
bridge, MA).
CD8+ T Cell Proliferation Assays
To assess the functional effect of OVA-specific CD4+ Th17,
we performed in vitro CD8+ T cell proliferation assay.
Irradiated (4,000 rad) DCOVA, CD4
+ Th17, CD4+ Th17
with anti-Il-2 antibody, and (Kb−/−)Th17 cells (0.4×
105 cells/well) were co-cultured with a constant number
of naive OT I CD8+ T cells (1×105 cells/well). After
culturing for 48 h, an overnight thymidine incorporation
was determined by liquid scintillation counting. In in vivo
proliferation assay, irradiated (400 rad) RIP-mOVA or
perforin−/− mice (six mice per group) were i.v. adoptively
transferred with DCOVA (1×10
6 cells), CD4+ Th17 cells
(3×106 cells), or CD4+ (Kb−/−)Th17 cells. Six days
subsequent to adoptive transfer, mouse tail blood samples
and pancreatic lymph node cell suspensions were stained
with FITC-anti-CD8 Ab and PE-H-2Kb/OVAI tetramer, and
analyzed by flow cytometry. In another set of experiments,
tail blood samples of mice immunized with MOG35-55
peptide or injected with MOG-specific CD4+ Th17 cells
(3×106 cells) and CD4+ MOG-TCR-Th17 cells (3×
106 cells) were stained using FITC-anti-CD8 Ab and PE-
H2-Db/RSPFSRVVHL pentamer (Proimmune, Oxford, UK)
and analyzed by flow cytometry 6 days after MOG35-55
peptide immunization or Th17 cell injection.
Cytotoxicity Assays
In in vitro cytotoxicity assay, Th17-activated OTI CD8+ Tc1
cells were used as effector (E) cells, while 51Cr-labeled EG7
and EL4 cells were used as target (T) cells in a chromium
release assay. For testing the killing mechanisms, the
effector cells were preincubated with CMA (1 μM) and
emetin (5 μM) for 2 h before incubation with the target
cells to prevent perforin and Fas/FasL interaction-mediated
cytotoxicity. Specific killing was calculated as: 100×
[(experimental cpm−spontaneous cpm)/(maximal cpm−
spontaneous cpm) as previously described [34]. In in vivo
cytotoxicity assay, C57BL/6 mouse splenocytes were
incubated with either high (3.0 μM, CFSEhigh) and low
(0.6 μM, CFSElow) concentrations of CFSE, and pulsed with
OVAI or MOGI peptide and Mut1 peptide, respectively, and
i.v. injected at 1:1 ratio into the OVA-specific or MOG-
specific CD4+ Th17 cell-transferred and MOG peptide-
immunized mice. Sixteen hours after target cell delivery,
the spleens were removed, and residual CFSEhigh and
CFSElow target cells remaining in recipient spleens were
sorted and analyzed by flow cytometry.
RT-PCR
Total RNAwas extracted with Qiagen RNeasy purification kit
(Qiagen, Mississauga, Ontario, Canada) as per manufacturer’s
protocol. Qiagen quantitative reverse transcription kit
(Qiagen) was used to synthesize cDNA. Later, RORγt and
GAPDH were analyzed by conventional PCR analysis.
Following primer pairs were used for RT-PCR; RORγt: 5′
GCGGAGCAGACACACTTACA 3′, 5′ TTGGCAAACTC
CACCACATA 3′ and GAPDH: 5′ CAGGTTGTCTCCTGC
GACTT 3′, 5′ CTTGCTCAGTGTCCTTGCTG.3′. The
protocol employed for amplification of mRNA comprised: 1
cycle of 94°C (5 min) and 25 cycles of 94°C (1 min), 52°C
(1 min), and 72°C (1 min). All PCR reaction products were
resolved using ethidium bromide stained 1% agarose gels.
EAE Induction
EAE was induced in wild-type C57BL/6 mice (15 mice/
group) by s.c. injection over four sites in the flank with
MOG35-55 peptide (200 μg/mouse) emulsified in CFA
containing 0.6 mg mycobacterium tuberculosis (BD-
Biosciences, San Diego, CA). To assess whether CD4+
or CD8+ Tcells are the major pathogenic effector Tcells in
EAE, Iab−/−, and H-2Kb−/− gene KO mice (ten mice/group)
lacking CD4+ and CD8+ T cells were similarly s.c.
immunized with MOG35-55 peptide. Two days after
immunization, these MOG-sensitized mice were i.p.
injected with 400 ng pertussis toxin (PT; Sigma) [31].
EAE was also induced by i.v. adoptive transfer of MOG-
specific CD4+ Th17 and CD4+ MOG-TCR-Th17 cells (5×
106 cells) into C57BL/6 or H-2Kb−/− mice. Mice were
examined daily for clinical signs. Mice were scored on
scale of 0 to 5: 0, no clinical sign; 0.5, partially limp
tail; 1, limp/flaccid tail; 2, moderate hind limb weakness; 2.5,
one hind limb paralyzed; 3, both hind limbs paralyzed; 3.5,
hind limbs paralyzed and weakness in forelimbs; 4, forelimbs
paralyzed; and 5, moribund/death [31]. The analysis was
performed on the raw data that included all clinical scores for
each mouse at each time point in each group.
Histopathology
Pancreas was collected in 10% formalin from RIP-mOVA
mice injected with CD4+ Th17 and PBS. Pancreatic tissue
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sections were stained with hematoxylin and eosin (H&E)
and slides were assessed for inflammatory cell infiltration
and tissue destruction in a blind fashion. EAE mice were
extensively perfused with ice-cold PBS with 2 U/ml
heparin (Sigma), and spinal cords were harvested and fixed
in formalin. Sections (6 mm) were stained with Luxol fast
blue (myelin stain) along with H&E counterstaining. Slides
were assessed in a blind fashion for inflammation: 0, none;
1, a few inflammatory cells; 2, organization of perivascular
infiltrates; and 3, increasing severity of perivascular cuffing
with extension into adjacent tissue. For demyelination: 0,
none; 1, rare foci; 2, a few areas of demyelination; and 3,
large (confluent) areas of demyelination.
Statistical Analysis
Mouse survival and clinical score were analyzed using Log
rank and Mann–Whitney U test [41, 42], respectively, and
all other experiments were tested for statistical differences
using unpaired, two tailed, Student’s t test. Differences were
considered significant if p<0.05.
Results
CD4+ Th17 Cells Acquire pMHC I Complexes from DCOVA
in the Course of Activation
To activate naïve OT II CD4+ Tcells, we co-incubated them
with irradiated DCOVA in the presence of the IL-23/IL-6/
TGF-β/anti-IFN-γ antibody cocktail. While naïve OT II
CD4+ Tcells did not express CD25, CD40L, CD69 and Iab,
the co-incubated CD4+ lymphocytes acquired the above
molecules (Fig. 1a), which clearly confirmed their activation
status. The activated CD4+ also expressed the cell-surface
FasL, intranuclear RORγt [43], and intracellular perforin,
IL-17 (Fig. 1a, b), but not IL-4, indicating that they
represented the CD4+ Th17 cells. To further confirm this,
we performed RT-PCR analysis to show that these cells
express transcription factor RORγt (Fig. 1c), but not T-bet
(data not shown). ELISA assays also revealed the CD4+
Th17 nature of the activated cell, since they proved to
secrete the IL-2 (2.8 ng/ml), IL-6 (4.5 ng/ml), IL-17
(1.8 ng/ml), and TGF-β (0.2 ng/ml) cytokines. No
CD11c+ DCOVA contamination could be observed in these
CD4+ Th17 cell populations (Fig. 1d). We previously
showed that CD4+ Th1 cells acquired DC’s pMHC
complexes in the course of DC activation [35]. In this
study, we also showed that CD4+ Th17 cells resulting
from DCOVA activation did display some DC’s molecules
such as pMHC I complexes (Fig. 1a), whereas CD4+ (Kb−/−)
Th17 cells obtained by co-incubation with pMHC I-
deficient (Kb−/−)DCOVA did not (Fig. 1e) but were
activated similar to CD4+ Th17 cells (data not shown),
indicating that CD4+ T cells acquire pMHC I complexes
from DCOVA upon co-culturing.
CD4+ Th17 Cells Stimulate Effector CD8+ CTL Responses
In Vitro
Our further work showed that DCOVA-activated CD4
+
Th17 cells with acquired pMHC I also stimulated in vitro
OT I CD8+ Tcell proliferation in a dose-dependent fashion
(Fig. 2a). Interestingly, CD4+ (Kb−/−)Th17 cells without
acquired pMHC I failed in stimulation of CD8+ T cell
proliferation. To assess whether CD4+ Th17-activated
CD8+ T cells have any functional effect, we performed a
chromium release assay, in which CD4+ Th17-activated
CD8+ T cells and OVA-expressing EG7 tumor cells were
used as effector and target cells, respectively. We found
that CD4+ Th17-activated CD8+ T cells showed killing
activity to OVA-expressing EG7 tumor cells, but not to the
control EL4 tumor cells without OVA expression (Fig. 2b),
indicating that their killing activities are specific for
OVA. To assess the pathway responsible for the killing
activity of CD8+ Tcells, we preincubated effector CD8+ T
cells with CMA or emetin to prevent perforin- and Fas/
FasL interaction-mediated cytotoxicity. We found that CMA
but not emetin treatment significantly abolished CD8+ Tcells’
killing activity (p<0.05), indicating that the killing activity of
CD4+ Th17-stimulated CTLs was mediated by the perforin
pathway.
CD4+ Th17 Cells Stimulate Effector CD8+ CTL Responses
In Vivo in RIP-mOVA Mice
To assess the ability of CD4+ Th17 cells to induce in vivo
CD8+ T cell proliferation, we performed an OVA-specific
tetramer staining assay in transgenic RIP-mOVA mice
adoptively transferred with CD4+ Th17 cells [35]. As
shown in Fig. 2c, CD4+ Th17 cells stimulated in vivo
proliferation of OVA-specific CD8+ T cells accounting for
0.68% and 1.18% of total CD8+ T cell population in
peripheral blood and pancreatic lymph nodes, respectively.
To investigate the role of acquired pMHC I, we repeated
the above assay using (Kb−/−)DCOVA-activated CD4
+
(Kb−/−)Th17 cells, lacking acquired pMHC I. We found
that CD4+ (Kb−/−)Th17 cells completely lost their in vivo
stimulatory effect, indicating that the acquired pMHC I
complexes play an important role in targeting CD4+
Th17’s stimulatory effect onto CD8+ T cells. To assess
the influence of CD4+ Th17 cell-induced CD8+ T cell
differentiation into CTLs, we performed the in vivo
cytotoxicity assay. This assay monitored eradication of
an adoptively transferred target population of splenocytes
in RIP-mOVA mice adoptively transferred with CD4+
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Th17 cells. Six days following the adaptive transfer of
CD4+ Th17, these mice were infused with syngeneic
splenocytes pulsed with OVA I peptide and labeled with a
high concentration of CFSE (CFSEhigh) or pulsed with an
irrelevant Mut1 peptide and labeled with low concentra-
tion of CFSE (CFSElow) as OVA-specific or control target
cells at a 1:1 ratio [35]. Sixteen hours later, the remaining
CFSE-labeled target cells were enumerated and their
numbers compared with the reference population. We
found that there was substantial loss of the OVA-specific
and CFSEhigh-labeled target cells in Th17 cell-immunized
(43.9%) mice (Fig. 2c), indicating that CD4+ Th17 cells
can stimulate CD8+ T cell differentiation into effector
CTLs with killing activity for OVA I-pulsed target cells. In
addition, the CD4+ (Kb−/−)Th17 cell-vaccinated mice did
not display any killing activity for the OVA-specific and
CFSEhigh-labeled target cells in cytotoxicity assay. To
assess the pathway responsible for the killing activity of
CD4+ Th17-stimulated CD8+ T cells in vivo, we repeated
the above experiments using perforin−/− mice in tetramer
staining and in vivo cytotoxicity assays. We found that
OVA-specific CD8+ T cell responses in C57BL/6 and
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perforin−/− mice with transfer of CD4+ Th17 cells were
similar (Fig. 2d). However, CD8+ T cell-induced killing
activity to OVA-specific CFSEhigh target cells was lost in
perforin−/− mice (Fig. 2d), indicating that the in vivo CD4+
Th17-stimulated CD8+ T cell-induced killing activity to
OVA-specific target cells is also via perforin-dependent
pathway.
CD4+ Th17 Cell-Induced Diabetes in Transgenic RIP-mOVA
Mice is Mediated by Th17-Stimulated CD8+ CTLs
Interestingly, all (6/6) RIP-mOVA mice adoptively trans-
ferred with CD4+ Th17 cells carrying acquired pMHC I
developed diabetes, while none (0/6) of the mice adop-
tively transferred with CD4+ (Kb−/−)Th17 cells without
acquired pMHC I complexes developed diabetes (Fig. 2e).
As expected, pancreatic islet tissues were destroyed and
infiltrated with numerous lymphocytes in the diabetic
mice (Fig. 2f). To assess the importance of CD8+ Tcells in
pathogenesis of diabetes, we treated adoptively transferred
mice with anti-CD8 Ab to deplete CD4+ Th17-stimulated
OVA-specific CD8+ T cells. We found that this treatment
completely prevented diabetes development in the exper-
imental animals (0/6). The effect proved to be very
specific, since similar treatment with control irrelevant
antibody has not suppressed disease onset (Fig. 2e),
indicating that CD4+ Th17 cell-induced diabetes in
transgenic RIP-mOVA mice is mainly mediated by Th17-
stimulated CD8+ CTLs.
EAE Induction byMOG35-55 Peptide Immunization is Mainly
by CD4+ T Cells
To induce EAE, we s.c. administered MOG35-55 peptide to
C57BL/6 mice, following previously described procedures
[30]. All treated animals were found to develop chronic-
progressive EAE with apparent clinical scores subsequent
to MOG35-55 immunization (Fig. 3a). To assess the MOG-
specific CD8+ T cell responses, we performed MOG-
specific PE-pentamer staining using tail blood from mice
2 weeks subsequent to the immunization with MOG35-55
peptide. We found that MOG35-55 peptide immunization
stimulated in vivo proliferation of MOG-specific CD8+ T
cells accounting for 0.56% of total CD8+ T cell population
(Fig. 3b), and these MOG-specific CD8+ T cells are
cytotoxic effector cells since there was a substantial loss
of the MOG-specific and CFSEhigh-labeled target cells
(38%) in MOG35-55-immunized mice (Fig. 3c). Consistent
with the above clinical finding, the histological examination
of the spinal column revealed dramatic pathological
changes in the immunized mice, with multiple inflammatory
foci and extensive demyelination in the white matter of
the spinal cord (Fig. 3d). Mean inflammation and
demyelination scores were 2.6 and 1.5, respectively
(Fig. 3e), which were significantly higher than in control
animals (p<0.01). To assess whether MOG-specific CD4+
or CD8+ Tcells play a major role in EAE pathogenesis, we
immunized H-2Kb−/− and Iab−/− KO mice with MOG
peptide for EAE induction. As shown in Fig. 3a, Iab−/− and
H-2Kb−/− mice, lacking CD4+ and CD8+ T cells, revealed
practically no clinical score (p<0.01) and slightly lower
clinical scores (p<0.05), respectively, compared to the
control MOG35-55-immunized C57BL/6 mice, indicating
that CD4+ Tcells, but not CD8+ Tcells, are predominantly
involved in EAE induction.
In Vitro-Generated CD4+ MOG-TCR-Th17 Cells Play
a Major Role in Pathogenesis of EAE
To assess whether CD4+ Th17 cells have a pathogenic
function in EAE, we generated MOG-specific CD4+ MOG-
TCR-Th17 cells in vitro by co-incubating DCMOG with
CD4+ T cells derived from MOG-TCR transgenic mice in
presence of the IL-23, IL-6, TGF-β cytokines, and anti-
IFN-γ antibody. The resulting activated CD4+ T cells were
subjected to flow cytometry, ELISA, and RT-PCR analysis.
These CD4+ T cells proved to be, indeed, efficiently
activated as they strongly expressed CD25 and CD69 on
their membranes (Fig. 4a). They also produced intracellular
IL-17, but not IL-4, and expressed intranuclear RORγt, but
not T-bet, indicating that they represent the CD4+ Th17
subset (Fig. 4a). The RT-PCR analysis also revealed RORγt
expression, thus further confirming the CD4+ Th17 nature
of the obtained population (Fig. 4b). As expected, they
secreted the IL-2 (1.8 ng/ml), IL-6 (3.3 ng/ml), IL-17
(1.5 ng/ml), and TGF-β (0.1 ng/ml), confirming that they
belong to CD4+ Th17 cells. To assess their potential
stimulatory effect, we i.v. injected them into C57BL/6 mice
and performed MOG-specific PE-pentamer staining assay.
As shown in Fig. 4c, MOG-specific CD8+ T cells were
detected in CD4+ MOG-TCR-Th17-immunized mice and
accounted for 0.36% of the total CD8+ T cell population,
indicating that MOG-specific CD4+ MOG-TCR-Th17 cells
are capable of stimulating MOG-specific CD8+ T cell
responses. To assess MOG-specific CD8+ T cell killing
activity, we performed the in vivo cytotoxicity assay. A
moderate (20%) loss of the MOG-specific, CFSEhigh-
labeled target cells was observed in CD4+ MOG-TCR-
Th17 cell-transferred mice (Fig. 4d), indicating that CD4+
MOG-TCR-Th17 immunization was likely to stimulate
CD8+ T cell differentiation into effector CTLs with
cytotoxic activity specific for MOG peptide-pulsed target
cells. To examine their ability to induce EAE, we injected
C57BL/6 mice with the in vitro-amplified CD4+ MOG-
TCR-Th17 cells. All mice injected with MOG-specific
CD4+ Th17 cells, but not with OVA-specific Th17 control,
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developed chronic-progressive EAE, indicating that CD4+
Th17-induced EAE was MOG specific (Fig. 4e). In
addition, no significant difference in EAE initiation
between C57BL/6 mice and H-2Kb−/− mice lacking
CD8+ T cells could be observed (Fig. 4e), suggesting that
CD4+ Th17 cells, but not Th17-stimulated CD8+ T cells,
played a major role in EAE pathogenesis. Consistent with
this clinical finding, histological examination of CNS
tissues revealed pathological changes in C57BL/6 mice
adoptively transferred with MOG-specific CD4+ MOG-
TCR-Th17 cells (Fig. 4f). In these adoptively transferred
mice, multiple inflammatory foci and demyelination were
observed in the white matter of the spinal cord, and mean
inflammation and demyelination scores were 1.6 and 0.6,
respectively, which was significantly higher than the
control mice (p<0.01; Fig. 4g).
CD4+ Th17 Cells Derived from EAE Mice also Play
a Major Role in Pathogenesis of EAE
It has been demonstrated that in vivo-generated CD8+ T
cells derived from MOG35-55 peptide-immunized mice can
induce EAE after they are amplified in vitro by MOG35-55
peptide stimulation and then i.v. transferred into C57BL/6
mice [31]. To assess whether the in vivo-generated CD4+
Th17 cells derived from MOG35-55 peptide-immunized
mice could also induce EAE, we amplified the MOG-
specific CD4+ Th17 cells by culturing CD4+ T cells
obtained from MOG35-55-immunized mice with MOG35-55
peptide-pulsed splenocytes in the presence of IL-6, IL-23,
and TGF-β. The amplified CD4+ T cells were purified
using CD4-microbeads and phenotypically analyzed by
flow cytometry, ELISA, and RT-PCR approaches. The
purified CD4+ T cells proved to express CD25 and CD69
and produced IL-17 and RORγt, but not IL-4 or T-bet,
confirming that they are active CD4+ Th17 cells (Fig. 5a,
b). In agreement, they also secreted IL-2 (1.2 ng/ml), IL-6
(3.0 ng/ml), IL-17 (1.3 ng/ml), and TGF-β (0.1 ng/ml). To
assess their potential stimulatory effect, we injected MOG-
specific CD4+ Th17 cells into C57BL/6 mice and followed
it by the MOG-specific PE-pentamer staining assay. As
shown in Fig. 5c, MOG-specific CD8+ T cells accounting
for 0.46% of the total CD8+ Tcell population were detected
in the injected mice, indicating that in vivo-generated
MOG-specific CD4+ Th17 cells are also capable of
stimulating MOG-specific CD8+ Tcell responses. To assess
MOG-specific CD8+ T cell killing activity, we performed
the in vivo cytotoxicity assay. We observed a 22% reduction
within the MOG-specific, CFSEhigh-labeled target cells in
the MOG-CD4+ Th17 transferred mice (Fig. 5d), showing
again that MOG-CD4+ Th17 cells could stimulate CD8+ T
cell differentiation into effector CTLs specifically targeting
MOG peptide-pulsed target cells. To determine whether
they are capable of inducing EAE, we injected C57BL/6
mice with the in vitro-amplified MOG-CD4+ Th17 cells
originally obtained from MOG35-55-immunized mice. As
shown in Fig. 5e, all C57BL/6 mice developed chronic-
progressive EAE with apparent clinical scores occurring
subsequent to adoptive transfer of MOG-specific CD4+
Th17 cells, but not OVA-specific Th17 control. In addition,
there is no significant difference in EAE between C57BL/6
mice and CD8+ T cell-deficient H-2Kb−/− mice, indicating
that CD4+ Th17 cells, rather than Th17-stimulated CD8+ T
cells, play a central role in EAE pathogenesis. Consistent with
this clinical finding, histological examination of CNS tissues
revealed pathological changes in C57BL/6 mice immunized
with MOG-specific CD4+ Th17 cells (Fig. 5f). In particular,
multiple inflammatory foci and demyelination were observed
in the white matter of the spinal cord of the immunized
animals, with mean inflammation and demyelination scores of
Fig. 2 CD4+ Th17 cells induced CTL leads to diabetes in transgenic
RIP-mOVA mice. a In vitro CD8+ T cell proliferation assay. Irradiated
DCOVA, CD4
+ Th17, CD4+ Th17 with anti-IL-2 Ab and (Kb−/−)Th17
cells, and their twofold dilutions were co-cultured with naïve OTI
CD8+ Tcells. After 2 days, the proliferative responses of CD8+ Tcells
were determined by overnight 3H-thymidine uptake assay. b In vitro
cytotoxicity assay. Th17-activated OTI CD8+ Tc1 cells were used as
effector (E) cells and in another experiment, Th17-activated CD8+ T
cells with or without preincubation of concanamycin A (CMA, 1 μM)
or emetin (5 μM) for 2 h were used as effector (E) cells, while 51Cr-
labeled EG7 and EL4 cells were used as target (T) cells in a chromium
release assay. c In tetramer staining assay, the tail blood samples and
pancreatic lymph node cells of transgenic RIP-mOVA mice adoptively
transferred with CD4+ Th17 cells, DCOVA, (K
b−/−)CD4+ Th17 cells,
and PBS (controls) were stained with PE-H-2Kb/OVAI (PE-tetramer)
and FITC-CD8 Ab (FITC-CD8), and then analyzed by flow
cytometry. The values in each panel represent the percentage of
tetramer-positive CD8+ Tcells versus the total CD8+ Tcell population.
The value in parenthesis represents the standard deviation. In in vivo
cytotoxicity assay, 16 h after target cell delivery, the residual OVAI-
pulsed CFSEhigh and Mut1-pulsed CFSElow target cells remaining in
the spleens of the above cohorts of mice were sorted and analyzed by
flow cytometry. The value in parenthesis represents the standard
deviation; (n=6, average±SD), *p<0.05 versus cohorts of mice
adoptively transferred with DCOVA (Student’s t test). d In tetramer
staining assay, the tail blood samples of wild-type C57BL/6 and
perforin−/− mice adoptively transferred with CD4+ Th17 cells were
stained with PE-H-2Kb/OVAI (PE-tetramer) and FITC-CD8 Ab
(FITC-CD8), and then analyzed by flow cytometry. In in vivo
cytotoxicity assay, 16 h after target cell delivery, the residual OVAI-
pulsed CFSEhigh and Mut1-pulsed CFSElow target cells remaining in
the spleens of the above cohorts of mice were sorted and analyzed by
flow cytometry. The value in parenthesis represents the standard
deviation; (n=6, average±SD), *p<0.05 versus cohorts of perforin−/−
mice (Student’s t test). e Urine test for diabetes. Glucose levels in
urine samples from transgenic RIP-mOVA mice adoptively transferred
with irradiated CD4+ Th17 cells, DCOVA, (K
b−/−)CD4+ Th17 cells, and
PBS (controls). The cutoff line of urine glucose concentration for
diabetes is shown. f Hematoxylin and eosin-stained sections from
Th17- and PBS-injected mice at higher magnification showing
extensive cellular infiltration in Th17-injected mice compared to
control. Magnifications, ×10 and ×20. One representative experiment
of two in the above different experiments is shown
R
J Clin Immunol
84
1.1 and 0.6, respectively, which was significantly higher than
the scores in control mice (p<0.01; Fig. 5g).
Discussion
T1D is an organ-specific autoimmune disease characterized
by predominantly T cell-mediated destruction of insulin-
producing β-cells of the islets of Langerhans, culminating
in the lifelong insulin dependence [44]. Before 1990, vast
range of evidence favored a sole role of CD4+ T cells in
T1D: (a) CD4+ T cells could be detected in abundance in
islet cell infiltrates, (b) transfer of CD4+ T cells from NOD
mice caused diabetes in disease free young mice [45], and
(c) the genetic region to which the defective genes mapped
was the MHC II that interacts specifically with CD4+ T
cells [46, 47]. The development of T1D has usually been
ascribed to a CD4+ Th1 response with disease transfer in
animal models being mediated by Th1 clones and lines [48,
49]. In addition, a potential involvement of Th17 cells in
the course of T1D has recently been demonstrated in the
mouse model [17]. However, over the time, new evidence
has mounted implicating CD8+ Tcells in T1D initiation and
progression. The primacy of CD8+ T cells in autoimmunity,
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Fig. 3 MOG peptide immunization stimulate MOG-specific CTL
responses and induce EAE. a Wild-type C57BL/6 and CD4+ Tcell- or
CD8+ T cell-deficient Iab and H-2Kb mice were immunized with
MOG35-55 + CFA. C57BL/6 mice immunized with CFA only were
used as control. Clinical EAE was scored according to 0–5 scale. The
difference between C57BL/6 and CD4+ T cell-depleted mice (two
asterisks) or CD8+ T cell-depleted C57BL/6 mice (single) is very
significant (p<0.01) or significant (p<0.05; Mann–Whitney U test). b
The tail blood samples of mice immunized with MOG peptide or
OVAI peptide (control) were stained with PE-H-2Db/MOGI pentamer
(PE-pentamer) and FITC-anti-CD8 Ab (FITC-CD8), and then ana-
lyzed by flow cytometry. The value in each panel represents the
percentage of pentamer-positive CD8+ T cells versus the total CD8+ T
cell population. c In in vivo cytotoxicity assay, 16 h after target cell
delivery, the residual MOGI-pulsed CFSEhigh and Mut1-pulsed
CFSElow target cells remaining in the spleens of the above immunized
mice were sorted and analyzed by flow cytometry. The value in
parenthesis represents the standard deviation. d Photographs of
sections of spinal cords derived from mice with EAE; tissue sections
were stained with Luxol fast blue along with H&E counterstaining.
Control mice (a and c) and MOG-immunized mice (b and d).
Magnifications, ×5 (a and b) and ×20 (c and d). Inflammatory
infiltration and demyelination are shown with arrows. e Mean scores
of inflammation and demyelination±SD. *p<0.01 versus cohorts of
the control groups (Student’s t test). One representative experiment of
three in the above experiments is shown
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including diabetes, came into focus with a study of human
monozygotic twins and NOD mice [50, 51], that expressed
low density of certain types of class I protein on the surface
of APCs. Remarkably, similar studies in NOD mice also
confirmed that the APCs of this spontaneously autoimmune
animal model also had defects in MHC class I presentation
[52]. It has been demonstrated that defects in loading of self
antigens into class I polypeptides are associated with T1D
pathogenesis [53, 54], indicating that defects in class I
assembly and loading could lead to T1D, as a result of a
negative selection defect. It has also been shown that CD8+
T cells killed beta-cells expressing self-peptides in class I
groove in murine models [55, 56], suggesting that CD8+ T
cells exert a strong role in the etiology of T1D.
To assess (a) the potential relationship between the
pathogenic CD4+ Th17 and CD8+ T cells in T1D and (b)
to determine the extent of their effect on pathogenesis of
T1D, we generated RORγt- and IL-17-expressing OVA-
specific CD4+ Th17 cells by co-culturing OVA-specific
TCR transgenic OTII CD4+ T cells with OVA-pulsed
DCOVA in presence of IL-6, IL-23, TGF-β, and anti-IFN-γ
antibody. We found that (a) OVA-specific Th17 cells
stimulated OVA-specific CTL responses via IL-2 and
acquired pMHC I signaling when transferred into RIP-
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Fig. 4 In vitro-activated MOG-specific CD4+ MOG-TCR-Th17 cells
stimulate MOG-specific CD8+ CTL responses and induce EAE. a
Phenotypic analysis of MOG-specific CD4+ MOG-TCR-Th17 cells.
MOG-specific CD4+ MOG-TCR-Th17 cells derived from transgenic
MOG-TCR mice were stained with a panel of biotin-conjugated Abs
(solid lines) followed by staining with FITC-conjugated avidin and
analyzed by flow cytometry. Irrelevant isotype-matched biotin-
conjugated Abs were used as controls (light dotted lines). b RNA
extracted from MOG-specific CD4+ MOG-TCR-Th17 and Con A-
stimulated CD4+ T (control) cells were analyzed by RT-PCR for
assessment of expression of RORγt. c Pentamer staining assay. The
tail blood samples of mice adaptively transferred with CD4+ MOG-
TCR-Th17 cells or Con A-stimulated CD4+ T (control) cells were
stained with PE-H-2Db/MOGI pentamer (PE-pentamer) and FITC-anti-
CD8 Ab (FITC-CD8), and then analyzed by flow cytometry. The value
in each panel represents the percentage of pentamer-positive CD8+ T
cells versus the total CD8+ T cell population. The value in parenthesis
represents the standard deviation. d In vivo cytotoxicity assay. Sixteen
hours after target cell delivery, the residual MOGI-pulsed CFSEhigh and
Mut1-pulsed CFSElow target cells remaining in the spleens of the above
cohorts of mice were sorted and analyzed by flow cytometry. The value
in parenthesis represents the standard deviation. e Wild-type C57BL/6
mice were adoptively transferred with MOG-specific MOG-TCR-Th17
cells or OVA-specific Th17 cells (control). The clinical EAE was scored
according to 0–5 scale. f Photographs of sections of spinal cords derived
from mice with EAE; tissue sections were stained with Luxol fast blue
along with H&E counterstaining. Control mice (a and c) and MOG-
immunized mice (b and d). Magnifications, ×5 (a and b) and ×20 (c and
d). Inflammatory infiltration and demyelination are shown with arrows.
gMean scores of inflammation and demyelination±SD. *p<0.01 versus
cohorts of the control groups (Student’s t test). One representative
experiment of three in the above experiments is shown
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mOVA mice, and (b) Th17-stimulated CD8+ T cells were
capable of killing OVA-expressing target cells via perforin
pathway. To assess the pathogenesis of OVA-specific CD4+
Th17 cells or CD8+ CTLs in T1D, we transferred these Th17
cells into RIP-mOVA mice or RIP-mOVA mice with anti-
CD8 Ab treatment to deplete Th17-stimulated CD8+ T cells.
We showed that Th17-stimulated CD8+ CTLs, but not Th17
cells themselves were required for T1D induction in RIP-
mOVA mice (Fig. 6). Our findings are consistent with some
previous reports showing that (a) transfer of islet-specific
Th17 cells failed in diabetes induction, though it caused an
extensive insulitis [57], and (b) treatment with neutralizing IL-
17-specific Abs did not prevent T1D in NOD/SCID mice,
which were derived from transfer of highly purified Th17
cells from BDC2.5 transgenic mice [49]. Furthermore,
autoreactive CD8+ T cells have been shown to play an
important role in the pathogenesis of T1D [47, 58]. CD8+
CTLs kill target cells through two distinct cytolytic pathways,
the perforin-dependent granule exocytosis and the Fas/FasL
interaction pathways [59]. The perforin in the presence of
calcium has the ability to insert into lipid bilayer membrane,
polymerize, and form structural and functional pores that can
lead to cell lysis, whereas the binding of FasL on CTLs to
Fas initiates the death pathway of apoptosis in the Fas-
C
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Fig. 5 In vivo-generated MOG-specific CD4+ Th17 cells stimulate
MOG-specific CD8+ CTL responses and induce EAE. a Phenotypic
analysis of in vivo-generated MOG-specific CD4+ Th17 cells. MOG-
specific CD4+ Th17 cells derived from MOG peptide-immunized mice
with EAE and expanded in vitro by co-culturing with MOG peptide-
pulsed splenocytes were stained with a panel of biotin-conjugated Abs
(solid lines) followed by staining with FITC-conjugated avidin and
analyzed by flow cytometry. Irrelevant isotype-matched biotin-
conjugated Abs were used as controls (light dotted lines). b RNA
extracted from MOG-specific CD4+ Th17 and Con A-stimulated CD4+ T
(control) cells were analyzed by RT-PCR for assessment of expression of
RORγt. c Pentamer staining assay. The tail blood samples of mice
adoptively transferred with CD4+ Th17 cells or Con A-stimulated CD4+
T (control) cells were stained with PE-H-2Db/MOGI pentamer (PE-
pentamer) and FITC-anti-CD8 Ab (FITC-CD8), and then analyzed by
flow cytometry. The value in each panel represents the percentage of
pentamer-positive CD8+ T cells versus the total CD8+ T cell population.
The value in parenthesis represents the standard deviation. d In vivo
cytotoxicity assay. Sixteen hours after target cell delivery, the residual
MOGI-pulsed CFSEhigh and Mut1-pulsed CFSElow target cells remaining
in the spleens of the above cohorts of mice were sorted and analyzed by
flow cytometry. The value in parenthesis represents the standard
deviation. e Wild-type C57BL/6 mice were adoptively transferred with
MOG-specific Th17 cells or OVA-specific Th17 cells (control). The
clinical EAE was scored according to 0–5 scale. f Photographs of
sections of spinal cords derived from mice with EAE; tissue sections
were stained with Luxol fast blue along with H&E counterstaining.
Control mice (a and c) and MOG-immunized mice (b and d).
Magnifications, ×5 (a and b) and ×20 (c and d). Inflammatory infiltration
and demyelination are shown with arrows. g Mean scores of
inflammation and demyelination±SD. *p<0.01 versus cohorts of the
control groups (Student’s t test). One representative experiment of three
in the above experiments is shown
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bearing target cells. In this study, we demonstrated that CD4+
Th17-stimulated CD8+ T cells were able to kill OVA-
expressing target cells both in vitro and in vivo via
perforin-dependent pathway [60], indicating that CD4+
Th17 induces diabetes in RIP-mOVA mice, may be through
OVA-expressing pancreatic beta-cells killing by CD4+ Th17-
stimulated CD8+ CTLs via perforin-dependent pathway.
In addition to T1D, we used EAE in our work as a model
of human multiple sclerosis induced by autoreactive CD4+
Th cells that mediate tissue inflammation and demyelination
in the central nervous system. EAE can be induced
through adjuvant and pertussis toxin-based immunization
of C57BL/6 mice with a peptide, representing a fragment
of an external myelin component, the encephalitogenic
MOG peptide. Following the immunization, myelin
sheaths of oligodendrocytes are attacked [61]. Although
the predominant evidence has shown the critical role of
CD4+ Th17 cells in EAE pathogenesis [22–26], a potential
involvement of CD8+ T cells in EAE has also been
recognized [28]. Whereas, the work of Abdul-Majid et al.
has previously demonstrated that both CD4+ and CD8+ T
cells were involved in EAE pathogenesis in MOG-
immunized DBA/1 mice [62].
To assess whether CD4+ or CD8+ T cells were involved
in pathogenesis of EAE, we immunized wild-type C57BL/6
mice or H-2Kb−/− and Iab−/− mice lacking CD8+ and CD4+ T
cells with MOG35-55 peptide. Our experiments showed that
MOG immunization-induced EAE only in C57BL/6 and H-
2Kb−/− mice, but not in CD4+ T cell-deficient Iab−/− mice,
indicating that CD4+ T cells are likely to play a critical role
in MOG immunization-induced EAE in C57BL/6 mice. The
apparent discrepancy between our findings and the previous
report [62] may potentially result from genetic differences
between different strains (DBA/1 and C57BL/6) of mice
used in these two studies. DBA/1 mice are very sensitive to
MOG immunization leading to EAE induction even in the
absence of PT treatment, whereas C57BL/6 mice only
develop MOG immunization-induced EAE, when mice are
boosted with pertussis toxin, which greatly enhances CD4+ T
cell responses [62].
To further dissect (a) the potential relationship between
the pathogenic CD4+ Th17 and CD8+ T cells in EAE and
(b) to establish the extent of their influence on EAE
pathogenesis, we generated two types of RORγt- and IL-
17-expressing MOG-specific CD4+ Th17 cells by cultiva-
tion of (a) naïve CD4+ T cells derived from MOG-specific
TCR transgenic mice and (b) primed MOG-specific CD4+
T cells derived from EAE mice. We found that both MOG-
specific CD4+ Th17 cells were capable of stimulating
MOG-specific CD8+ CTL responses when transferred into
C57BL/6 mice. To assess EAE induction by these MOG-
specific CD4+ Th17 cells or MOG-specific Th17-stimulated
IL-6 IL-23
Co
-stimulation
APC
TCR
pMHC I
pMHC II
CD4+T
Th17
Th17
CD8+T
CTL
Killing
(Perforin)
Co -stimulation
IL-2
IL
-17
Inflammatory cell infiltration 
leading to demyelination
EAE
Type 1 diabetes
Fig. 6 Distinct role of CD4+ Th17- and Th17-stimulated CD8+ CTL in
pathogenesis of T1D and EAE. Both CD4+ Th17 cells and Th17-
stimulated CD8+ CTLs are involved in pathogenesis of T1D and EAE.
However, T1D is directly mediated by Th17-stimulated CD8+ CTLs to
destroy OVA-expressing pancreatic islets of RIP-mOVA mice via
perforin-mediated cytotoxicity. On the contrary, CD4+ Th17 cells play
a major role in pathogenesis of EAE by Th17 cytokine-mediated tissue
inflammation leading to demyelination in the central nervous system
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CD8+ T cells, we transferred them into C57BL/6 mice or
into H-2Kb−/− mice with deficiency in the production of
Th17-stimulated CD8+ T cells. We have showed that the
adoptively transferred CD4+ Th17 cells, but not in vivo
CD4+ Th17-stimulated CD8+ CTLs, are responsible for
EAE initiation in C57BL/6 mice, indicating that CD4+
Th17 cells play a crucial role in pathogenesis of EAE
(Fig. 6). The failure of in vivo CD4+ Th17-stimulated CD8+
CTLs to trigger EAE may be due to their efficiency being
lower than the efficiency of in vitro expanded MOG-
specific CD8+ T cells that were successful in EAE
induction, when adoptively transferred into experimental
mice [30–32]. Nevertheless, our observations indicate that
CD4+ Th17 cells, but not in vivo Th17-stimulated CD8+
CTLs are likely to induce EAE under physiological
conditions. Our data are also consistent with some recent
reports showing that (a) IL-17A significantly contributes to
the induction of EAE in immunized mice [63] and (b)
adoptive transfer of MOG-specific Th17 cells induce EAE
in C57BL/6 mice leading to the induction of EAE in wild-
type C57BL/6 mice [22]. Increasing evidence suggests that
Th17 cells mediate inflammatory responses through selective
migration, accumulative retention at specific sites and
secretion of inflammatory cytokines, such as IL-17 [64]
inducing tissue inflammation, eventually leading to demye-
lination in the central nervous system [65–67].
EAE has long been considered the prototypic IFN-γ-
secreting Th1-mediated autoimmune disease [68, 69]. Until
some findings suggested a primary role for IL-17-secreting
Th17 cells in this model [70, 71]. It has been shown that
Th1 cells facilitate the entry of Th17 cells to the central
nervous system during EAE [72]. Th1 and Th17 cells are
shown to have different regulatory roles in inflammation of
the brain and spinal cord [26] and EAE with different
pathological phenotypes [73]. IFN-β was effective in
reducing EAE symptoms induced by Th1 cells, but
exacerbated disease induced by Th17 cells [74]. Therefore,
this paradigm shift has sparked a rapid and remarkable
change in emphasis in the search for disease-modifying
drugs away from the Th1 pathway toward the Th17
pathway [75].
Conclusions
Taken together, our study shows that CD4+ Th17 cells
acquired pMHC I in the process of activation by DCs and
became capable of stimulating OVA or MOG-specific CD8+
CTL responses, when transferred into the mice. Our data
also elucidate a distinct role of CD4+ Th17 and Th17-
stimulated CD8+ T cells in autoimmune diseases, that T1D
being directly mediated by Th17-stimulated CD8+ cells,
whereas EAE is likely to be triggered by CD4+ Th17 cells.
Therefore, this work may have great impact on the overall
understanding of CD4+ Th17 cells in the pathogenesis of
autoimmune diseases.
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CHAPTER 4 
4.  CD4
+
 Th2 cells function alike effector Tr1 and Th1 cells through the deletion of a single 
cytokine IL-6 and IL-10 gene. 
 
Brief introduction to chapter 4  
To demonstrate that a single signature cytokine gene deletion might lead to functional 
conversion of naive CD4
+
 T helper cells cultured under Th2 differentiation conditions, into 
different subsets, we generated OVA-specific wild-type (WT) Th2, and Th2(IL-5 KO), or 
Th2(IL-5 KO), or Th2(IL-6 KO), or Th2(IL-10 KO) cells, and assessed their capacity in 
modulating DCOVA-induced CD8
+
 cytotoxic T lymphocyte (CTL) responses, and antitumor 
immunity in WT C57BL/6 mice. We conclusively demonstrate that GATA-3-expressing Th2 
cells enhance DCOVA-induced CTL responses via IL-6 secretion. We also show that IL-6 and IL-
10 gene deficient Th2(IL-6 KO) and Th2(IL-10 KO) cells, but not IL-4 and IL-5 gene deficient  
Th2(IL-4 KO) and Th2(IL-5 KO) cells, behave like functional Tr1 and Th1 cells by inhibiting 
and enhancing DCOVA-induced OVA-specific CD8
+
 CTL responses and antitumor immunity, 
respectively. We have further demonstrated that inhibition and enhancement of DCOVA-induced 
OVA-specific CTL responses by Th2(IL-6 KO) and Th2(IL-10 KO) cells are mediated by their 
immune suppressive IL-10 and pro-inflammatory IL-6 secretions, respectively. Taken together, 
our experiments suggest that deletion of a single cytokine gene IL-6 and IL-10 converts’ naive 
CD4
+
 T helper cells cultured under Th2 differentiation condition into functional CD4
+
 Tr1 and 
Th1 cells. Our data thus not only provide new evidence for another type of CD4
+ 
T cell 
plasticity, but also have a potential to impact the  development of a new direction in 
immunotherapy of allergic diseases. 
Manuscript is in press for publication in Molecular Immunology, 2012. 
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4.2 ABSTRACT 
 
Depending on polarizing cytokine signals during activation by antigen, naïve CD4
+
 T cells 
can be stimulated and differentiated into distinct functional CD4
+
 T cell subsets such as Th1, Th2 
and Tr1 cells. Among them, Th2 cells are pathogenic in allergic diseases such as asthma, which are 
characterized by transcription factor GATA3 expression and IL-4, IL-5, IL-6, and IL-10 cytokine 
secretion. The overlapping expression of some signature cytokines by Th2 and other subsets of 
CD4
+
 T cells may not only indicate the plasticity of CD4
+
 T cells, but could also suggest the 
possibility of the deletion of a single signature cytokine gene leading to the functional 
differentiation of naïve CD4
+
 T cells into effector Th1 or Tr1 cells under Th2 differentiation 
conditions. In this work, we stimulated naïve CD4
+
 T cells derived from OT II mice or OT II mice 
that were deficient in individual cytokines (IL-4, IL-5, IL-6 and IL-10) with OVA-pulsed dendritic 
cells (DCOVA) in the presence of IL-4 and anti-IFN-γ, to generate OVA-specific wild-type (WT) 
Th2, and Th2(IL-4 KO), or Th2(IL-5 KO), or Th2(IL-6 KO), or Th2(IL-10 KO) cells, and to 
assess their capacity in modulating DCOVA-induced CD8
+
 cytotoxic T lymphocyte (CTL) 
responses, and antitumor immunity in WT C57BL/6 mice. We conclusively demonstrate that 
GATA-3-expressing Th2 cells enhance DCOVA-induced CTL responses via IL-6 secretion. We 
also show that IL-6 and IL-10 gene deficient Th2(IL-6 KO) and Th2(IL-10 KO) cells, but not IL-4 
and IL-5 gene deficient  Th2(IL-4 KO) and Th2(IL-5 KO) cells, behave like functional Tr1 and 
Th1 cells by inhibiting and enhancing DCOVA-induced OVA-specific CD8
+
 CTL responses and 
antitumor immunity, respectively. We further elucidate that inhibition and enhancement of 
DCOVA-induced OVA-specific CTL responses by Th2(IL-6 KO) and Th2(IL-10 KO) cells are 
mediated by their immune suppressive IL-10 and pro-inflammatory IL-6 secretion, respectively. 
Taken together, our study suggests that deletion of a single cytokine gene IL-6 and IL-10 makes 
CD4
+
 Th2 cells become effector CD4
+
 Tr1- and Th1-like cells, respectively. Our data thus not only 
provide new evidence for another type of CD4
+
 T cell plasticity, but also have a potential to impact 
the  development of a new direction in immunotherapy of allergic diseases.  
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4.3 INTRODUCTION 
 
In response to infections, various types of immune cells are involved in both innate and 
adoptive immune responses, and are activated to control and eliminate the invading pathogens. 
Among them, CD4
+
 T cells play an important role in the defensive immunity. These lymphocytes 
activate macrophages to develop enhanced microbicidal activity and recruit neutrophils, 
eosinophils and basophils to sites of inflammation via their secreted cytokines or chemokines thus 
assisting the innate immunity. In addition, they also help B cells to produce antibodies and license 
dendritic cells (DCs) to modulate different types of CD8
+
 cytotoxic T lymphocyte (CTL) immune 
responses in adoptive immunity (1).  
Depending on polarizing cytokine signals during activation by antigen (Ag), naïve CD4
+
 
T cells can initiate various differentiation programs that lead to the development of distinct 
functional CD4
+
 T cell subsets. Key transcriptional factors act as lineage-specifying regulators 
coordinating expression of specific cytokine genes (2). For example, the transcriptional factor 
T-box-containing protein expressed in T cells (T-bet) controls type 1 T help (Th1) cell 
differentiation program associated with the production of Th1 signature cytokine IFN- required 
for efficient immune responses against intracellular pathogens (3) and tumors (4). In contrast, 
GATA-binding protein 3 (GATA-3) is a regulator of the development of type 2 T help (Th2) cells 
that express IL-4, IL-5, IL-6 and IL-10. These signature cytokines are critical for the immunity 
against helminthes and other extracellular pathogens (5) or for antibodies production (6). 
Unfortunately, Th2 cells are also pathogenic in allergic diseases such as asthma (7). Another 
subset of CD4
+
 T cells is the Foxp3
+
 IL-10-and IFN-γ-secreting CD4+ type 1 regulatory T (Tr1) 
cells that are generated from naive T cells in the periphery after encounter with Ag presented by 
DCs in the status distinct from those for promoting the differentiation of Th1 and Th2 cells (8). 
TGF-β plays a major role in Tr1 differentiation (9, 10) and development (11) by activation of 
Smad3 to promote Foxp3 expression (12). These CD4
+
 Tr cells, which are specific for 
pathogen-derived Ags, suppressed immune responses via their signature cytokine IL-10 secretion 
(13).  
We previously established an ovabumin (OVA)-specific animal model using 
OVA-specific T cell receptor (TCR) transgenic OT II CD4
+
 T cell subsets to study the functional 
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effect and molecular mechanisms associated with different subsets of CD4
+
 T cells (13-15). In this 
study, we investigate whether manipulation of a single signature cytokine can differentiate naïve 
CD4
+
 T cells into functional Th1 and Tr1 cells under Th2 differentiation conditions. To assess the 
role of specific cytokines, we have generated OVA-specific CD4
+
 Th2 cells by in vitro stimulation 
of naïve CD4
+
 T cells derived from OT II mice or OT II mice with deficiency in individual 
cytokine (IL-4, IL-6, IL-5 or IL-10) with OVA-pulsed DCs (DCOVA) in the presence of IL-4 and 
anti-IFN-γ antibody, and then compared their capacities in stimulating or inhibiting OVA-specific 
CD8
+
 T cell responses, and antitumor immunity induced by DCOVA immunization in wild-type 
C57BL/6 mice.  
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4.4 MATERIALS AND METHODS 
 
Tumor cells, reagents and animals.  
 
The OVA-transfected BL6-10 (BL6-10OVA) cell lines were generated in our laboratory (16). The 
biotin-labeled antibodies (Abs) specific for CD4 (GK1.5), CD11c (HL3), CD25 (7D4), CD40 
(K19), CD69 (H1.2F3) and CD80 (16-10A) were obtained from BD Pharmingen, Mississauga, 
ON, Canada. The FITC conjugated avidin was obtained from Jackson Immuno Research 
Laboratory Inc. (West Grove, PN). The anti-H-2K
b
/OVAI (pMHC I) Ab was obtained from Dr. 
Germain, National Institute of Health, Bethesda, MD (17). Recombinant cytokines IL-2, IL-4, 
GM-CSF and TGF-β were purchased from R&D systems Inc. (Minneapolis, MN). IL-6 
(MP5-20F3) neutralizing antibody was purchased from eBiosciences (San Diego, CA) and IL-10 
(JES5-2A5) neutralizing antibody was purchased from BD Pharmingen, Mississauga, ON, 
Canada. The PE-H-2K
b
/OVAI tetramer and FITC-anti-CD8 Ab (PK135) were obtained from 
Beckman Coulter, Mississauga, Ontario, Canada. The OVAI (SIINFEKL) peptide specific for 
H-2K
b
 and Mut1 (FEQNTAQP) specific for H-2K
b
 of irrelevant 3LL lung carcinoma (16) were 
synthesized by Multiple Peptide Systems (San Diego, CA). The C57BL/6 (B6, CD45.2
+
), 
OVA-specific TCR-transgenic OT II mice, and IL-4, IL-5, IL-6 and IL-10 gene knockout (KO) 
mice on a C57BL/6 background were obtained from the Jackson Laboratory (Bar Harbor, MA). 
Homozygous OT II/IL-4
-/-
,  OT II/IL-5
-/-
,  OT II/IL-6
-/-
,  and OT II/IL-10
-/-
 mice were generated by 
backcrossing the designated gene KO mice onto the OT II background for three generations; 
homozygosity was confirmed by polymerase-chain reaction (PCR) according to Jackson 
laboratory’s protocols.  
 
Preparation of dendritic cells.  
 
Mature bone marrow-derived DCs, expressing high levels of CD11c, CD40, CD80 and pMHC 
class I, were generated as described previously (16). Briefly, bone marrow cells were collected 
from femora and tibiae of wild type C57BL/6 mice and RBCs are depleted with 0.84% ammonium 
chloride. Obtained cells were plated in DC culture medium (DMEM plus 10% FCS, 20ng/ml 
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GM-CSF and 20ng/ml IL-4). On day 3 non adherent granulocytes, T cells and B cells were gently 
removed and replaced with medium. Two days later, loosely adherent DC’s were dislodged and 
replated and grown till 6 days. On 6
th
 day non adherent DCs were harvested and pulsed overnight 
at 37°C with 0.1 mg/ml OVA (Sigma, St. Louis, MO) and termed DCOVA. Inhibitory DCOVA was 
derived expressing high levels of IL-10 as described earlier (18). Briefly, bone marrow cells 
depleted with RBCs were cultured in presence of 20ng/ml GM-CSF in 10% FCS containing 
DMEM for 10 days, carefully changing medium every 48 hrs. After 10 days they were cultured for 
3 days in presence of 7.5ng/ml GM-CSF, 50ng/ml IL-10 in 10% FCS containing DMEM and 
loosely bound DCs are harvested on last day and pulsed overnight with 0.1 mg/ml OVA.  
 
Preparation of OT II CD4
+
 Th2 cells.   
 
Naïve OVA-specific CD4
+
 T cells were isolated from OT II mouse spleens. T cells were enriched 
by passage through nylon wool columns and then CD4
+
 cells were purified by negative selection 
using anti-mouse CD8  paramagnetic beads (DYNAL Inc, Lake Success, NY) to yield populations 
that were >95% CD4
+/Vα2Vβ5+ T cells. To generate in vitro DCOVA-activated CD4
+
 Th2 cells, 
CD4
+
 T cells (2X10
5
 cells/ml) from OT II mice or designated gene-deleted OT II mice were 
stimulated for three days with irradiated (4,000 rad) bone marrow derived DCOVA (1X10
5
 cells/ml) 
in presence of IL-4 (20 ng/ml) and anti-IFN-γ Ab (10 μg/ml) (R&D Systems, Minneapolis, MN). 
In vitro DCOVA-activated CD4
+
 T cells derived from OT II with respective IL-4, IL-5, IL-6 and 
IL-10 gene KO mice were referred to as Th2(IL-4 KO), Th2(IL-5 KO), Th2(IL-6 KO) and 
Th2(IL-10 KO), respectively.  
 
Preparation of OT II CD4
+
 Th1 cells.  
 
Naïve OVA-specific CD4
+
 T cells isolated as explained earlier. To generate in vitro 
DCOVA-activated CD4
+
 Th1 cells, CD4
+
 T cells (2X10
5
 cells/ml) from OT II mice were stimulated 
for three days with irradiated (4,000 rad) bone marrow derived DCOVA (1X10
5
 cells/ml) in 
presence of IL-2 (20U/ml), IL-12 (5ng/ml) and anti-IL-4 Ab (10μg/ml) (R&D Systems, 
Minneapolis, MN). 
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Preparation of OT II CD4
+
 Tr1 cells.  
 
Naïve OVA-specific CD4
+
 T cells isolated as explained earlier. To generate in vitro 
DCOVA-activated CD4
+
 Tr1 cells, CD4
+
 T cells (2X10
5
 cells/ml) from OT II mice were stimulated 
for five days with irradiated (4,000 rad) bone marrow derived inhibitory IL-10 secreting DCOVA 
(1X10
5
 cells/ml) in presence of IL-2 (20U/ml), IL-10 (20ng/ml) and  TGF-β (20ng/ml) (R&D 
Systems, Minneapolis, MN). 
 
 Phenotypic characterization of CD4
+
 Th1, Th2 and Tr1 cells.   
 
For the phenotypic analyses, the above Th1, Th2 and Tr1 cells were stained with a panel of 
biotin-conjugated Abs. After washing with PBS, these cells were further stained with 
R-phycoerythrin (PE)-conjugated avidin and analyzed by flow cytometry. Their culture 
supernatants were analyzed for cytokine expression using ELISA kits (Endogen, Cambridge, 
MA), as previously described (16). 
 
RT-PCR.  
 
Total RNA was extracted from Th1, Th2 and Tr1 cells with Qiagen RNeasy purification kit 
(Qiagen, Mississauga, Ontario, Canada) as per manufacturer’s protocols. Qiagen quantitative 
reverse transcription kit (Qiagen) was used to synthesize cDNA, which was then analysed by 
semi-quantitative PCR in triplicates.  
 
In vivo CD8
+
 T cell proliferation assay.  
 
Wild type C57BL/6 (n=6) mice were i.v. immunized with irradiated (4,000 rad) DCOVA (0.5X10
6
 
cells) or DCOVA (0.5X10
6
 cells) plus Th1 or Tr1 or Th2 or Th2(KO) (3X10
6
 cells), respectively. In 
another experiment wild type C57BL/6 mice were i.v. immunized with irradiated (4,000 rad) 
DCOVA (0.5X10
6
 cells) plus Th2(IL-6 KO) or Th2(IL-10 KO) (3X10
6
 cells) along with anti-IL-10 
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or anti-IL-6 neutralizing antibodies on 0 and 3
rd
 day after immunization, respectively. Six days 
subsequent to immunization, the mouse blood samples were harvested and stained with 
PE-H-2K
b
/OVAI tetramer and FITC-anti-CD8 Ab (PK135) (Beckman Coulter). The erythrocytes 
were then lysed using lysis/fixed buffer (Beckman Coulter) and samples were analyzed by flow 
cytometry according to the company's protocol. 
 
In vivo CD8
+
 T cell cytotoxicity assay.  
 
In in vivo cytotoxicity assay, six days after  immunization, the cohort of above immunized mice 
were i.v. co-injected with 1:1 ratio of splenocytes labeled with high (3.0 µM, CFSE
high
) and low 
(0.6 µM, CFSE
low
) concentrations of CFSE and pulsed with OVAI and Mut1, respectively (16). 
Sixteen hours after target cell delivery, the spleens were removed and residual CFSE
high
 and 
CFSE
low
 target cells remaining in the recipients' spleens were sorted and analyzed by flow 
cytometry.  
 
Animal studies.  
 
Wild-type C57BL/6 mice (n=8) were i.v. immunized with irradiated (4,000 Rad) DCOVA (0.5X10
6
 
cells per mouse) alone or in combination with Th1, Tr1, Th2, Th2(IL-6 KO) and Th2(IL-10 KO) 
(3X10
6
 cells per mouse), respectively. Eight days later, the mice were i.v. challenged with  
BL6-10OVA  (0.3X10
6 
cells per mouse) tumor cells. The mice were sacrificed 3 weeks after tumor 
cell challenge and lung metastatic tumor colonies were counted. 
 
Statistical analysis.  
 
All experiments were tested for statistical significance using unpaired, two tailed, student’s t test. 
Differences were considered significant if p<0.05. 
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4.5 RESULTS 
 
4.5.1 Phenotypic characterization of OVA-specific CD4
+
 Th1, Th2 and Tr1 cells 
 
To generate different subsets of ovalbumin (OVA)-specific Th1, Th2  and Tr1 cells, naive 
OT II mouse CD4
+
 T cells were cultured with OVA-pulsed dendritic cells (DCOVA) expressing 
CD11c, Ia
b
, CD40, CD80 and pMHC I (Fig 4.1A) in the presence of  subset specific differentiation 
medium. To phenotypically characterize them, these DCOVA-activated CD4
+
 T cells were analyzed 
by flow cytometry, RT-PCR and ELISA for assessment of expression of cell surface markers, 
intracellular transcription factors and cytokine secretion, respectively. We demonstrated that these 
T cells were positive for CD4, CD25, and CD69 expression (Fig 4.1B), indicating that they are 
active CD4
+
 T cells.  CD4
+
 Th1 cells expressed transcription factor T-bet (Fig 4.1C) and secreted 
IL-2 (2.5 ng/ml), IL-6 (0.9 ng/ml), IFN-γ (3.4 ng/ml) but no IL-4, IL-5 and IL-10 (Fig 4.1D), 
whereas CD4
+
 Th2 cells expressed transcription factor GATA-3 and secreted IL-2 (1.4 ng/ml), 
IL-4 (1.3 ng/ml), IL-5 (1.5 ng/ml), IL-6 (1 ng/ml), IL-10 (0.4 ng/ml) and undetectable levels of 
IFN-γ, which are consistent with  typical phenotypes of CD4+ Th1 and Th2 cells, respectively. In 
contrast, CD4
+
 Tr1 cells expressed transcription factor Foxp3 and secreted IL-5 (0.5 ng/ml), IL-10 
(2.5 ng/ml), IFN-γ (1.9 ng/ml), as we previously described (13). 
 
4.5.2 Th1 and Th2 cells augment whereas Tr1 cells inhibit DCOVA-induced CTL responses 
 
To assess the functional effect of different CD4
+
 T subsets on DCOVA-induced CTL 
responses, DCOVA were injected intravenously into wild type C57BL/6 mice. DCOVA-immunized 
mice showed OVA-specific CD8
+
 T cell proliferation accounting for 0.79 % of the total CD8
+
 T 
cell population in the peripheral blood (Fig 4.2A). When Th2 cells were co-injected with DCOVA, 
OVA-specific CD8
+
 T cells were increased to 0.97 % (p<0.05), indicating that in vitro generated 
Th2 cells enhance DCOVA-induced CTL responses (Fig 4.2A). To assess the functional effect of 
activated CTLs, we adoptively transferred OVAI peptide-pulsed wild-type (WT) C57BL/6 mouse 
splenocytes strongly labeled with CFSE (CFSE
high
) and equal proportion of control peptide Mut1 
pulsed wild type splenocytes weakly labeled with CFSE (CFSE
low
) to wild type C57BL/6 mice 
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that were immunized 6 days earlier with DCOVA alone or co-injected with DCOVA and Th1 or Th2 
or Tr1 cells. Sixteen hrs after their transfer, we found that 50.3% of CFSE
high
 labeled cells were 
killed and none of the CFSE
low
 labeled cells were killed in DCOVA-immunized mice, whereas in 
Th2 and DCOVA co-injected mice 68.7% of CFSE
high
 cells were killed (Fig 4.2B). In concurrence 
with CD8
+
 T cell proliferative responses (Fig 4.2A), there was significantly increased cytotoxicity 
associated with Th2 co-injection with DCOVA (p<0.05), indicating that Th2-enhanced CTLs are 
functional effectors with killing activity to OVA-specific target cells. 
 
4.5.3 IL-6 gene deficient CD4
+
 Th2 cells behave like functional Tr1 cells by inhibiting 
DCOVA-induced CTL responses in an IL-10 dependent manner 
 
IL-6 gene deficient CD4
+
 Th2 [Th2(IL-6 KO)] cells were obtained by culturing DCOVA 
with naïve CD4
+
 T cells derived from OTII/IL-6
-/-
 mice in the presence of IL-4 and anti-IFN-γ Ab. 
These Th2(IL-6 KO) cells had similar phenotypes, including expression of cell surface markers 
and transcription factor, as WT Th2 cells (data not shown). In addition, while being IL-6 deficient, 
they secreted IL-2 (0.5 ng/ml), IL-4 (0.6 ng/ml), IL-5 (1.1 ng/ml), IL-10 (2.5 ng/ml), IFN-γ (1.4 
ng/ml) (Fig 4.3A). Interestingly, we found that DCOVA-induced OVA-specific CTL responses 
dramatically declined from the original 0.79% (DCova) to only 0.18% [DCoav+Th2(IL6KO)] 
(Fig 4.3B). In contrast, control, IL-4 gene deficient CD4
+
 Th2 [Th2(IL-4 KO)] cells and IL-5 gene 
deficient CD4
+
 Th2 [Th2(IL-5 KO)] cells did not modulate DCOVA-stimulated OVA-specific CTL 
responses. To elucidate the molecular mechanism underlying immune suppression by Th2(IL-6 
KO) cells, we i.v. injected mice with neutralizing anti-IL-10 Ab simultaneously with Th2(IL-6 
KO) cells to block IL-10 signal. We found anti-IL-10 Ab to completely inhibit the immune 
suppressive effect of Th2(IL-6 KO) cells on DCOVA-induced OVA-specific CTL responses (Fig 
4.3C), indicating that Th2(IL-6 KO) cells behaving in analogy to Tr1 cells suppress immune 
responses by secretion of IL-10 cytokine, which is consistent with our previously published 
observation (13). 
  
4.5.4 IL-10 gene deficient CD4
+
Th2 cells behave like functional Th1 cells by enhancing 
DCOVA-induced CTL responses through IL-6 cytokine 
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IL-10 gene deficient CD4
+
 Th2 [Th2(IL-10 KO)] cells were obtained by culturing DCOVA 
with naïve CD4
+
 T cells derived from OTII/IL-10
-/-
 mice in the presence of IL-4 and anti-IFN-γ 
Ab. Based on the expression of cell surface markers and of the GATA-3  transcription factor, these 
Th2(IL-10 KO) cells had a phenotype resembling WT Th2 cells (data not shown). In addition, 
despite IL-10 deficiency, they secreted IL-2 (0.5 ng/ml), IL-4 (1.2 ng/ml), IL-5 (2.5 ng/ml), IL-6 
(1.5 ng/ml), IFN-γ (2.4 ng/ml) (Fig 4.3A). Interestingly, we found that DCOVA-stimulated 
OVA-specific CTL responses significantly increased from the original 0.97%, triggered by 
DCOVA, to 1.28% (P<0.01) in the presence of  DCOVA and Th2(IL-10 KO) co-stimulation (Fig 
4.3B), which is similar to enhancement of CTL responses by Th1 cells (Fig 4.2A).  To elucidate 
the molecular mechanism underlying the immune enhancement by Th2(IL-10 KO) cells, we 
co-injected the mice with neutralizing anti-IL-6 Ab and Th2(IL-10 KO) cells to block IL-6 signal. 
In this experiment, anti-IL-6 Ab completely blocked the enhancement of DCOVA-induced CTL 
responses initiated by Th2(IL-10 KO) cells (Fig 4.3C), indicating that Th2(IL-10 KO) behave 
similar to Th1 population and augment immune responses by  secreting IL-6. 
 
4.5.5 IL-6 gene deficient CD4
+
 Th2 cells inhibit and IL-10 deficient cells enhance  
DCOVA-triggered OVA-specific antitumor immunity 
 
To confirm the above observations that IL-6 gene deficient CD4
+
 Th2 cells suppress, while IL-10 
deficient cells promote DCOVA-induced OVA-specific CTL responses, we conducted animal 
experiments and monitored antitumor immunity.  Wild-type C57BL/6 mice were immunized with 
DCOVA and DCOVA accompanied by Th1, Th2, Tr1 or Th2(KO) cells. All immunized mice were 
challenged with BL6-10OVA tumor cells eight days following the immunization. DCOVA 
immunized mice demonstrated complete protection (8/8) from lung tumor metastasis (Table 4.2). 
 DCOVA-immunized mice with the co-injection of Th1, Th2 or Th2(IL-10 KO) cells were equally 
protected (8/8), however mice co-injected with Tr1 or Th2(IL-6 KO) cells all (8/8) died of lung 
tumor metastasis,  confirming that Th2(IL-10 KO) cells act like functional Th1 and Th2(IL-6 KO) 
 behave similar to Tr1 cells  in stimulating, and suppressing  DCOVA-induced antitumor immunity. 
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4.6 DISCUSSION 
 
It is canonically accepted that Th1 and Th2 responses are counter-regulated by one 
another. Cross-regulation of Th1- and Th2-specific cytokines has been documented, and Th1 
cytokines IFN-γ and IL-12 have been shown to dampen IL-4-mediated granuloma formation in 
schistasomiasis (19-21). Originally, Khoruts el al showed that Th2 cells were inefficient in 
suppression of Th1 cell-mediated experimental autoimmune encephalomyelitis (EAE) (22). 
Fernando et al demonstrated that Th2 cells neither enhanced nor suppressed antitumor CTL 
responses (23). Later, however, another group showed Th2 cells to play role in suppressing Th1 
responses during helminth infection (24). In addition, Th2 cells also inhibited alloantigen-specific 
delayed-type hypersensitivity (25) and marrow graft rejection (26). In this study, we generated 
OVA-specific CD4
+
 T-bet-expressing Th1, GATA-3-expressing Th2 and Foxp3-expressing Tr1 
cells by culturing OVA-pulsed DCOVA with OTII CD4
+
 T cells under different culture conditions 
and assessed their modulatory effect on DCOVA-induced OVA-specific CD8
+
 CTL responses. We 
demonstrate that OVA-specific CD4
+
 Th1 and Tr1 cells enhance and suppress DCOVA-induced 
CTL responses, respectively, consistent with our previous reports (13). Interestingly, we clearly 
show that OVA-specific CD4
+
 Th2 cells also enhance DCOVA-induced CTL responses via 
inflammatory IL-6 secretion possibly due to the stimulatory effect on T cell proliferation (27) and 
counteractive effect on CD4
+
CD25
+
 Tr cell-mediated inhibition (28) mediated by the IL-6 
cytokine.   
The overlapping expression of some signature cytokines in different subsets of CD4
+
 T 
cells not only indicate the plasticity of CD4
+
 T cells (29), but also suggest the possibility of 
deletion of a single signature cytokine gene leading to functional differentiation of naïve CD4
+
 T 
cells  into Th1 or Tr1 cells under Th2 cell differentiation conditions. In this study, we show that 
IL-6 and IL-10 gene deficient CD4
+
 Th2(IL-6 KO) and Th2(IL-10 KO) cells behave like 
functional Tr1 and Th1 cells by inhibiting and enhancing DCOVA-induced OVA-specific CD8
+
 
CTL responses and antitumor immunity, respectively. We demonstrate that the inhibition of 
DCOVA-induced OVA-specific CTL responses by CD4
+
 Th2(IL-6 KO) cells is mediated by 
suppressive IL-10 secretion, consistent with previous reports (13, 30, 31), since the neutralizing 
anti-IL-10 Ab treatment completely blocked its inhibitory effect. We also demonstrate that the 
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enhancement of DCOVA-induced OVA-specific CTL responses by CD4
+
 Th2(IL-10 KO) cells is 
mediated by inflammatory IL-6 secretion since neutralizing anti-IL-6 Ab treatment completely 
blocked the enhancive effect. Our data indicate that potential immune stimulatory and suppressive 
effect of Th2 cells are balanced by IL-6 and IL-10 cytokines, and shift in this balance is likely lead 
to potential generation of either immunogenic Th1-like or immune-suppressive Tr1-like cells.  
Therefore, our study provides the first evidence for another type of CD4
+
 T cell plasticity with 
converting one type of functional T subset into another by depletion of one single key signature 
cytokine gene.  Since Th2 cells are pathogenic in allergic diseases such as asthma (7), converting 
Th2 cell lineage commitment with different mechanisms becomes a key target for 
allergen-specific immunotherapy (32, 33). Therefore, our study may provide another direction for 
immunotherapeutic approach to allergic diseases by converting pathogenic Th2 cells into immune 
suppressive Tr1 cells via blocking IL-6 by neutralizing anti-IL-6 Ab treatment.   
Conclusions 
 
Taken together, our study suggests that deletion of a single cytokine gene IL-6 and IL-10 
makes CD4
+
 Th2 cells become effector CD4
+
 Tr1- and Th1-like cells, respectively. Our data 
therefore, not only provide new evidence for another type of CD4
+
 T cell plasticity, but also may 
have positive impact on the development of a new immunotherapy approach to the treatment of 
allergic diseases.  
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Table 4.1.  Polarizing culture conditions of different subsets of T-helper cells. 
________________________________________________________________________ 
T-helper subset                             polarizing culture conditions condition 
___                                                                                                                                  ____ 
Th1                                           IL-2 (20 U/ml), IL-12 (5 ng/ml) and anti-IL-4 Ab (10 μg/ml) 
Th2                                      IL-4 (20 ng/ml) and anti-IFN-γ Ab (10 μg/ml) 
Tr1                                           IL-2 (20 U/ml), IL-10 (20 ng/ml) and  TGF-β (20 ng/ml) 
_______________________________________________________________________ 
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Table 4.2. Inhibitory or stimulatory effects of Th2 cells on DCOVA-induced immunity against 
lung tumor metastases 
________________________________________________________________________ 
Immunization                                      Tumor bearing mice (%) Median number of 
__________________________________________________________colonies_______ 
DCOVA                                                             0/8 (0)                                     0 
Th2 + DCOVA                                                        0/8 (0)                                     0  
Th1 + DCOVA                                                  0/8 (0)                                      0 
Tr1 + DCOVA                                                   8/8 (100)                               >100      
Th2(IL-6 KO) + DCOVA                                  8/8 (100)                               >100      
Th2(IL-10 KO) + DCOVA                                0/8 (0)                                      0 
PBS                                                                 8/8 (100)                               >100 
_______________________________________________________________________ 
 
C57BL/6 mice (8 per group) were i.v. immunized with DCOVA and injected with Th2 or Th1 or 
Tr1or Th2 with cytokine gene deficiency. Eight days after injection, mice were challenged with 
BL6-10OVA cells. The mice were sacrificed 3 weeks after tumor cell challenge and lung metastatic 
tumor colonies were counted. One representative experiment of two is shown.  
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Figure 4.1. Phenotypic characterization of Th1, Th2, Tr1 and DCOVA. (A) Flow cytometric 
analysis of DCOVA. In vitro generated DCOVA were stained with panel of Abs for analysis of cell 
surface expression of CD11c, CD40, CD80 and pMHC-I (thick solid lines). Isotype-matched 
irrelevant Abs were used as controls (dotted lines). (B) Flow cytometric analysis. In vitro 
DCOVA-activated Th1 and Th2, and in vitro inhibitory DCOVA activated-Tr1 population were 
stained with a panel of Abs for analysis of cell surface expression of CD4, CD25 and CD69 (thick 
solid lines). Isotype-matched irrelevant Abs were used as controls (dotted lines). (C) RNA 
extracted from Th1, Th2 and Tr1 cells were analyzed by RT-PCR to assess the expression of T-bet, 
GATA-3 and Foxp-3. (D) The supernatants of Th1, Th2 and Tr1 cells were assayed for IL-2, IL-4, 
IL-5, IL-6, IL-10 and IFN-γ secretion by ELISA.  One representative experiment of three is 
displayed. 
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Figure 4.2. Stimulatory or inhibitory effects of Th1, Th2 and Tr1 cells on DCOVA induced 
CD8
+
 T cell response. (A) Tetramer staining assay. Wild type C57BL/6 mice (6 mice per group) 
were immunized with PBS, DCOVA, DCOVA along with Th1/Th2/Tr1 cells. Six days after 
immunization tail blood samples of immunized mice were stained with PE-H-2K
b
/OVAI tetramer 
and FITC-anti-CD8 Ab, and analyzed by flow cytometry. The value in each panel represents the 
percentage of tetramer-positive CD8
+
 T cells versus the total CD8
+
 T cells with standard deviation 
in parenthesis. The differences between DCOVA and Th2+DCOVA mice (*) or Th1+DCOVA and 
Tr1+DCOVA mice (**) are significant (p<0.05) or very significant (p<0.01) (students t test).  (B) In 
vivo cytotoxicity assay. The residual CFSE
high
 (H) and CFSE
low
 (L) target cells remaining in the 
recipient spleens were analyzed by flow cytometry. The value in each panel represents the 
percentage of CFSE
high
 vs CFSE
low
 target cells remaining in the spleen with standard deviation in 
parenthesis. (n=6, average±SD). One representative experiment of two is shown. 
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Figure 4.3. Stimulatory or inhibitory impacts of cytokine gene deficient Th2 cells on DCOVA 
induced CD8
+
 T cell responses. (A) The supernatants of Th2, Th2(IL-6 KO) and Th2(IL-10 KO) 
cells were analyzed cytokines IL-2, IL-4, IL-5, IL-6, IL-10 and IFN-γ secretion by ELISA. (B & 
C) Tetramer staining assay. In experiment B, wild type C57BL/6 mice (6 mice per group) were 
immunized with DCOVA and different knockout Th2. In experiment C, C57BL/6 mice (6 mice per 
group) were immunized with DCOVA and different knockout Th2, and simultaneously these mice 
were injected twice (day 0 and day 3) with depicted neutralizing antibodies. Six days after 
immunization tail blood samples of immunized mice were stained with PE-H-2K
b
/OVAI tetramer 
and FITC-anti-CD8 Ab, and analyzed by flow cytometry. The value in each panel represents the 
percentage of tetramer-positive CD8
+
 T cells versus the total CD8
+
 T cells with standard deviation 
in parenthesis (n=6, average±SD). 
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CHAPTER 5 
DISCUSSION, CONCLUSIONS, AND FUTURE DIRECTIONS 
5.1 General discussion 
Specific discussions associated with each objective pursued in this thesis work are 
presented under each chapter (chapters 2 to 4). The purpose of this discussion is to 
comprehensively understand the thesis as whole. Though each chapter deals with different 
aspects, they all come under the aegis of CD4
+
 T cell biology. CD4
+
 T helper cells are the 
conductors of immune responses, controlling/helping other cells in eliciting favourable immune-
response and in keeping memories of antigen encounters. A naive CD4
+
 T cell develops into 
different types of CD4
+
 T helper cell subsets under different microenvironments. Recent 
evidence has also shown that some of the terminally differentiated CD4
+
 T cells can re-
differentiate into a different subtype because of the plasticity associated with these cells. An 
infection or an aberrant growth of tumor cells or autoimmunity occurs when there is an 
imbalance in immune responses. CD4
+
 T cells being the conductors controlling different arms of 
immune-response, most of the time an imbalance in immune responses in the above said 
conditions occurs from deregulated CD4
+
 T cell response. Because of the importance associated 
with CD4
+
 T cells, it is very important to understand the patho-physiology and biology 
associated with CD4
+
 T cells. In our study, we have deciphered the role of CD4
+
 Th17 cells in 
tumor immunity (chapter 2), and in autoimmune T1D and EAE (chapter 3). We have also 
understood the biology associated with CD4
+
 Th2 cells (chapter 4). 
 
5.2 CD4
+
 Th17 cells in tumor immunity 
During the course of this thesis work, there has been a flow of enormous information 
related to Th17-cells. When we started our study, there was no literature indicating antitumor 
responses of Th17 cells, though there were various studies showing the presence of these cells in 
different tumors. There were controversial results regarding the role of Th17 cells and Th17- 
cytokine IL-17, since transgenic expression of IL-17 induced tumor regression through enhanced 
antitumor immunity in immune-competent mice (1, 2) or promoted tumor growth through 
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increased inflammatory angiogenesis in immune deficient mice (3). When we understand the 
studies relating to IL-17, we have to treat IL-17 and Th17 cells as different factors because, apart 
from Th17 cells, various other cells like smooth muscle, NK, γδ T cells also secrete IL-17. There 
were studies showing the role of Th17 cells in autoimmunity and Th17 cells as a pro-
inflammatory subset. Understanding this pro-inflammatory nature of Th17 cells, we speculated 
that they might be beneficial cells in tumors.  During the course of our study, there were other 
studies suggesting the antitumor response of Th17 cells (4, 5). In Dr. Jim Xiang’s laboratory, it 
was demonstrated that CD4
+
 Th1 cells acquire DC’s molecules through trogocytosis during their 
interaction; in our study, we speculated that CD4
+
 Th17 cells which are functionally and 
phenotypically different from CD4
+
 Th1 cells will acquire DC’s molecules (6-8).  Moreover, for 
the first time we have demonstrated that in vitro DCOVA activated Th17 cells expressing Ror-γt 
and secreting IL-17, IL-2 also acquired pMHC I and stimulated antigen-specific CD8
+
 CTL 
response and long term memory via IL-2 and pMHC I, but not via IL-17.  We have also 
demonstrated that Th17-induced preventive antitumor immunity is mediated through Th17-
stimulated CD8
+
 CTLs. Our study elucidates that the molecular mechanism of Th17 cells has a 
stimulatory effect on CD8
+
 CTL response; apart from that, we have also shown that it is the 
Th17-stimulated CD8
+
 CTLs, but not Th17 cells themselves, which have direct in vitro killing 
activity on tumor cells. In the therapeutic model, we found that it is the Th17-activated CD8
+
 T 
cells that play a major role in the eradication of metastatic lung tumors, where Th17-cytokine IL-
17, but not host IFN-γ, was associated with the Th17- induced therapeutic effect. We have also 
demonstrated that Th17 cells aid in the recruitment of various inflammatory cells (DCs, CD4
+
 
and CD8
+
 T cells) to the tumor site through CCL2/20 chemoattraction. Although Th17 cell 
cytokine IL-17 helps in the chemoattraction of various inflammatory cells to a tumor site, it was 
the CD8
+
 T cells which played the major role in tumor therapy through their perforin mediated 
killing. Overall, our study demonstrated a distinct role played by Th17 cell and Th17-stimulated 
CD8
+
 T cells in preventive and therapeutic antitumor immunity. To date, adaptive T-cell 
immunotherapy for tumors by infusing antigen-specific CD8
+
 T cells had seen some success; 
however, the major problem was the targeting of these cells to a tumor site. With our findings, 
we speculate that injecting Th17 cells may help in targeting those cells and also aid in tumor 
therapy through other mechanisms elucidated in our findings. To further perceive our 
speculation, Dr. Jim Xiang’s lab is working to find out the possibility of enhancing antitumor 
120 
 
immunity in adoptive CD8
+
 T cell therapy by co-immunizing with Th17 cells. With our findings 
we could also further evaluate the use of Th17 based therapies for tumor therapy by modifying 
the tumor immune environment to favour Th17 differentiation at tumor sites. Various studies 
have shown the involvement of TGF-β in the differentiation of Th17 cells as well as Treg cells. 
At tumor sites, tumors maintain immune suppressive conditions through various suppressor cells 
and immune suppressive cytokines. One of such immune suppressive cytokines is TGF-β. We 
speculate that we can use the TGF-β present at the tumor site to elicit Th17 responses. By local 
expression of IL-6 at the tumor site, we might increase Th17 differentiation through the local 
environment containing both IL-6 and TGF-β, which may help in tumor destruction through 
various mechanisms deciphered in our study.  
 
5.3 CD4
+
 Th17 cells in autoimmune T1D and EAE 
During the course of this study, there has been accumulated data suggesting the role of 
Th17 cells in autoimmune T1D and EAE. However, there was a lacuna in understanding the 
mechanism of the pathogenic role played by Th17 cells. In our study, we have addressed this 
lacuna by deciphering the potential involvement of Th17 cells and Th17-stimulated CD8
+
 T cells 
in the pathogenesis of T1D and EAE and we also addressed the potential relationship between 
Th17 and CD8
+
 T cells. 
Type 1 diabetes (T1D) is an organ-specific autoimmune disease characterized by 
predominantly T cell-mediated destruction of insulin producing β cells of the islets of 
Langerhans, culminating in lifelong insulin dependence (9). Before 1990, a vast range of 
evidence favoured the sole role of CD4
+
 T cells in T1D (10). The development of T1D has 
usually been ascribed to a CD4
+
 Th1 response with disease transfer in animal models being 
mediated by Th1 clones and lines (11, 12). In addition, a potential involvement of Th17 cells in 
the course of T1D was also demonstrated in the mouse model (13). However, over time, new 
evidence has mounted to implicate CD8
+
 T cells in T1D initiation and progression, suggesting 
that CD8
+
 T cells exert a strong role in the aetiology of T1D (14-20). Nonetheless, the potential 
relationship between the pathogenic CD4
+
 Th17 and CD8
+
 T cells and their relative effect on 
pathogenesis of T1D remained elusive. In our study, we found that OVA-specific Th17 cells 
121 
 
stimulated OVA-specific CTL responses via IL-2 and acquired pMHC I signalling when 
transferred into RIP-mOVA mice, and Th17-stimulated CD8
+
 T cells were capable of killing 
OVA-expressing target cells via the perforin pathway. We also showed that Th17-stimulated 
CD8
+
 CTLs, but not Th17 cells themselves, were required for T1D induction in RIP-mOVA 
mice. Our findings are consistent with some previous reports showing that transfer of islet-
specific Th17 cells failed in diabetes  induction, though it caused an extensive insulitis (21); 
treatment with neutralizing IL-17-specific Abs did not prevent T1D in NOD/SCID mice, which 
were derived from transfer of highly purified Th17 cells from BDC2.5 transgenic mice (12).  
Supporting our findings, autoreactive CD8
+
 T cells have been shown to play an important role in 
the pathogenesis of T1D (22, 23).  We have also demonstrated that CD4
+
 Th17-stimulated CD8
+
 
T cells were able to kill OVA-expressing target cells both in vitro and in vivo via the perforin-
dependent pathway (24), indicating that CD4
+
 Th17-induces diabetes in RIP-mOVA mice, 
perhaps through OVA-expressing pancreatic beta-cells killing by CD4
+
 Th17-stimulated CD8
+
 
CTLs via perforin-dependent pathway. 
EAE is a model of human multiple sclerosis induced by autoreactive CD4
+
 Th cells that 
mediate tissue inflammation and demyelination in the central nervous system. Although the 
predominant evidence had shown the critical role of CD4
+
 Th17 cells in EAE pathogenesis (25-
29), a potential involvement of CD8
+
 T cells in EAE had also been recognized (30). Whereas 
other studies had demonstrated that both CD4
+
 and CD8
+
 T cells are involved in EAE 
pathogenesis (31), we have assessed whether CD4
+
 or CD8
+
 T cells are involved in the 
pathogenesis of EAE. Our experiments reveal that MOG immunization induced EAE only in 
C57BL/6 and H-2Kb-/- mice, but not in CD4
+
 T-deficient Iab
-/-
 mice, indicating that CD4
+
 T 
cells are likely to play a critical role in MOG immunization-induced EAE in C57BL/6 mice. 
Further, we have addressed the potential relationship between the pathogenic CD4
+
 Th17 and 
CD8
+
 T cells in EAE and the extent of their influence on EAE pathogenesis.  By using two types 
of MOG-specific CD4
+
 Th17 cells, we have showed that the adoptively transferred CD4
+
 Th17 
cells, but not in vivo CD4
+
 Th17-stimulated CD8
+
 CTLs, were responsible for the EAE initiation 
in C57BL/6 mice, indicating that CD4
+
 Th17 cells play a crucial role in the pathogenesis of 
EAE. Our data is consistent with some reports showing that IL-17A significantly contributes to 
the induction of EAE in immunized mice (32), and the adoptive transfer of MOG-specific CD4
+
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Th17 cells induce EAE in C57BL/6 mice leading to the induction of  EAE in wild-type C57BL/6 
mice (25).  
Taken together, our data elucidated a distinct role of CD4
+
 Th17 cells and Th17-
stimulated CD8
+
 T cells in autoimmune diseases: T1D is directly mediated by Th17-stimulated 
CD8
+
 cells, whereas EAE is likely triggered by CD4
+
 Th17 cells. Therefore, this work may have 
great impact on the overall understanding of CD4
+
 Th17 cells in the pathogenesis of autoimmune 
diseases. Understanding the pathogenesis associated with different autoimmune diseases will 
help in designing disease-modifying drugs to treat autoimmunity. We have shown that T1D is 
majorly mediated through CD8
+
 T cells, further studies could be designed to specifically target 
CD8
+
 T cells. IN case of EAE we may have to specifically target Th17 cells to treat MS patients. 
 
5.3 Regulation of CD4
+
 Th2 cells 
Various studies had shown that Th1 and Th2 responses are counter regulated by one 
another (33-35). The majority of the studies dealt with the counter balance of Th1/Th2 responses 
or inhibitory responses of cytokines in counter regulation. In our study, we looked at the direct 
evidence for comparative inhibitory or stimulatory responses of Th1, Th2, and Tr1 cells on 
DCOVA-induced Th1 kind of CD8
+
 T cell-proliferative response. Earlier studies had shown that 
Th2 cells were not affecting vaccine induced antitumor CTL activity (36, 37). We found that, in 
concurrence with earlier studies, Th2 cells were not inhibitory on DCOVA-induced CD8
+
 T cell 
response.  The notion of T-helper cell plasticity (12, 21, 38) suggests that immune response is far 
more adaptable than previously thought and is therefore able to respond more appropriately to 
environmental stimuli. Historically, T-helper cells were deemed terminally differentiated cell 
lineages committed to their paths. Most in vitro differentiation models suggest that such 
commitment of T-helper cells provides simplified experimental models that allow us to 
understand how they are regulated. Emerging evidence suggested that under certain conditions, 
seemingly committed T cells possess plasticity and may convert into other types of effector cells. 
However, how CD4
+
 T helper cells achieve such plasticity was not fully understood, but it was 
very well understood that under different microenvironments even a well differentiated T helper 
cell was ready to re-differentiate into a different T-helper subset.  We speculated that it would be 
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fruitful to harvest this phenomenon to treat immune mediated disease conditions by designing 
effective immune balancing strategies. In our study, we showed that IL-6 and IL-10 gene-
deficient CD4
+
 Th2(IL-6 KO) and Th2(IL-10 KO) cells behave like functional Tr1 and Th1 cells 
by inhibiting and enhancing DCOVA-induced OVA-specific CD8
+
 CTL responses and antitumor 
immunity, respectively. We demonstrated that the inhibition of DCOVA-induced OVA-specific 
CTL responses by CD4
+
 Th2(IL-6 KO) cells was mediated by suppressive IL-10 secretion, 
consistent with previous reports (39-41), since the neutralizing anti-IL-10 Ab treatment 
completely blocked its inhibitory effect. We also demonstrated that the enhancement of DCOVA-
induced OVA-specific CTL responses by CD4
+
 Th2(IL-10 KO) cells was mediated by 
inflammatory IL-6 secretion since the neutralizing anti-IL-6 Ab treatment completely blocked its 
enhancive effect. Our data indicated that the potential immune stimulatory and suppressive 
effects of Th2 cells are balanced by its IL-6 and IL-10 cytokine, and breakage of this balance can 
lead to either immunogenic Th1 or suppressive Tr1-like cells.  Our study provided the first 
evidence for another type of CD4
+
 T cell plasticity through converting one type of functional T 
subset into another one by depletion of one single key signature cytokine gene.  Since the 
persistence of Th2 cytokines is associated with allergy and asthma (42), converting Th2 cell 
lineage commitment with different mechanisms is a key target of allergen-specific 
immunotherapy (43, 44). Therefore, our study may provide another direction for an 
immunotherapeutic approach to allergic diseases by converting pathogenic Th2 cells into 
immune-suppressive Tr1 cells via blocking IL-6 by a neutralizing anti-IL-6 Ab treatment. 
Taken together, our study shows that the deletion of a single cytokine gene IL-6 and IL-
10 converts effector CD4
+
 Th2 cells into functional CD4
+
 Tr1 and Th1 cells, respectively. Our 
data therefore not only provides new evidence for another type of CD4
+
 T cell plasticity, but also 
may have a significant positive impact on the development of a new immunotherapy approach to 
allergy treatment. We speculate that by adaptively transferring single gene deficient naïve CD4
+
 
T cells, they may behave differently when they get the site of allergy. This phenomenon can be 
utilized to get favorable response for our benefit.  
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